CNO Financial (CNO) 10-Q 10 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 25, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-31792
Entity Registrant Name	CNO Financial Group, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	75-3108137
Entity Address, Address Line One	11825 N. Pennsylvania Street
Entity Address, City or Town	Carmel,
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46032
City Area Code	(317)
Local Phone Number	817-6100
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		114,553,509
Entity Central Index Key	0001224608
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, par value $0.01 per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	CNO
Security Exchange Name	NYSE
Rights to purchase Series E Junior Participating Preferred Stock
Document Information [Line Items]
Title of 12(b) Security	Rights to purchase Series E Junior Participating Preferred Stock
Security Exchange Name	NYSE
No Trading Symbol Flag	true
5.125% Subordinated Debentures due 2060
Document Information [Line Items]
Title of 12(b) Security	5.125% Subordinated Debentures due 2060
Trading Symbol	CNOpA
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Investments:
Fixed maturities, available for sale, at fair value (net of allowance for credit losses: March 31, 2023 - $59.1 and December 31, 2022 - $56.0; amortized cost: March 31, 2023 - $23,517.9 and December 31, 2022 - $23,384.2)	$ 21,107.1	$ 20,353.4
Equity securities at fair value	106.1	135.3
Mortgage loans (net of allowance for credit losses: March 31, 2023 - $8.4 and December 31, 2022 - $8.0)	1,676.1	1,411.9
Policy loans	123	121.6
Trading securities	208.1	207.9
Investments held by variable interest entities (net of allowance for credit losses: March 31, 2023 - $3.5 and December 31, 2022 - $5.5; amortized cost: March 31, 2023 - $1,060.3 and December 31, 2022 - $1,134.2)	1,017.9	1,077.6
Other invested assets	1,097.1	1,034.7
Total investments	25,335.4	24,342.4
Cash and cash equivalents - unrestricted	425	575.7
Cash and cash equivalents held by variable interest entities	97.1	69.2
Accrued investment income	241.3	235.6
Present value of future profits	197.6	203.7
Deferred acquisition costs	1,811.3	1,770.9
Reinsurance receivables (net of allowance for credit losses: March 31, 2023 - $2.0 and December 31, 2022 - $2.0)	4,189.6	4,223.4
Market risk benefit asset	57.8	65.3
Income tax assets, net	988.1	1,063.4
Assets held in separate accounts	2.8	2.7
Other assets	669	580.8
Total assets	34,015	33,133.1
Liabilities for insurance products:
Policyholder account balances	15,302.9	15,234.2
Future policy benefits	11,623.3	11,240.2
Market risk benefit liability	17.6	11.3
Liability for life insurance policy claims	67.6	64.1
Unearned and advanced premiums	243.5	235
Liabilities related to separate accounts	2.8	2.7
Other liabilities	681.3	693.9
Investment borrowings	1,839.6	1,639.5
Borrowings related to variable interest entities	1,065.4	1,104.6
Notes payable – direct corporate obligations	1,139.2	1,138.8
Total liabilities	31,983.2	31,364.3
Commitments and Contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: March 31, 2023 – 114,905,172; December 31, 2022 – 114,343,070)	1.1	1.1
Additional paid-in capital	2,021.1	2,033.8
Accumulated other comprehensive loss	(1,664.4)	(1,957.3)
Retained earnings	1,674	1,691.2
Total shareholders' equity	2,031.8	1,768.8
Total liabilities and shareholders' equity	$ 34,015	$ 33,133.1

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Investments:
Fixed maturities, available for sale, allowance for credit losses	$ 59.1	$ 56
Fixed maturities, available for sale, amortized cost	23,517.9	23,384.2
Mortgage loans, allowance for credit losses	8.4	8
Investments held by variable interest entities, allowance for credit losses	3.5	5.5
Investments held by variable interest entities, amortized cost	1,060.3	1,134.2
Reinsurance receivables, allowance for current expected credit losses	$ 2	$ 2
Shareholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	114,905,172	114,343,070
Common stock, shares outstanding (in shares)	114,905,172	114,343,070

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Insurance policy income	$ 625.5	$ 625
Net investment income:
General account assets	292.2	277.5
Policyholder and other special-purpose portfolios	50.8	(69.3)
Investment gains (losses):
Realized investment gains (losses)	(14.6)	18.8
Other investment losses	0	(51.5)
Total investment losses	(14.6)	(32.7)
Fee revenue and other income	52.1	42.4
Total revenues	1,006	842.9
Benefits and expenses:
Insurance policy benefits	609.7	333.9
Liability for future policy benefits remeasurement loss	0.6	7
Change in fair value of market risk benefits	14.8	(32.7)
Interest expense	54.7	23.8
Amortization	55.5	52.3
Other operating costs and expenses	271.7	218.3
Total benefits and expenses	1,007	602.6
Income (loss) before income taxes	(1)	240.3
Income tax expense (benefit) on period income (loss)	(0.2)	56.9
Net income (loss)	$ (0.8)	$ 183.4
Basic:
Weighted average shares outstanding (in shares)	114,545	118,622
Net income (loss) (in dollars per share)	$ (0.01)	$ 1.55
Diluted:
Weighted average shares outstanding (in shares)	114,545	121,002
Net income (loss) (in dollars per share)	$ (0.01)	$ 1.52

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (0.8)	$ 183.4
Other comprehensive loss, before tax:
Unrealized gains (losses) on investments	626.1	(2,435.1)
Adjustment to discount rate for liability for future policy benefits	(263.3)	1,220.4
Adjustment to instrument-specific credit risk for market risk benefits	0.9	6.6
Reclassification adjustments:
For net realized investment (gains) losses included in net income	10.9	7.8
Other comprehensive income (loss) before tax	374.6	(1,200.3)
Income tax (expense) benefit related to items of accumulated other comprehensive income (loss)	(81.7)	265.1
Other comprehensive income (loss), net of tax	292.9	(935.2)
Comprehensive income (loss)	$ 292.1	$ (751.8)

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings
Balance, beginning of period (in shares) at Dec. 31, 2021		120,377,000
Balance, beginning of period at Dec. 31, 2021	$ 3,684.7	$ 1.2	$ 2,184.2	$ 373.7	$ 1,125.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	183.4				183.4
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit (expense)	(935.2)			(935.2)
Common stock repurchased (in shares)		(4,057,000)
Common stock repurchased	(100)		(100)
Dividends on common stock	(16)				(16)
Employee benefit plans, net of shares used to pay tax withholdings (in shares)		921,000
Employee benefit plans, net of shares used to pay tax withholdings	1.5		1.5
Balance, end of period (in shares) at Mar. 31, 2022		117,241,000
Balance, end of period at Mar. 31, 2022	$ 2,818.4	$ 1.2	2,085.7	(561.5)	1,293
Balance, beginning of period (in shares) at Dec. 31, 2022	114,343,070	114,343,000
Balance, beginning of period at Dec. 31, 2022	$ 1,768.8	$ 1.1	2,033.8	(1,957.3)	1,691.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(0.8)				(0.8)
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit (expense)	292.9			292.9
Common stock repurchased (in shares)		(633,000)
Common stock repurchased	(15.1)		(15.1)
Dividends on common stock	(16.4)				(16.4)
Employee benefit plans, net of shares used to pay tax withholdings (in shares)		1,195,000
Employee benefit plans, net of shares used to pay tax withholdings	$ 2.4		2.4
Balance, end of period (in shares) at Mar. 31, 2023	114,905,172	114,905,000
Balance, end of period at Mar. 31, 2023	$ 2,031.8	$ 1.1	$ 2,021.1	$ (1,664.4)	$ 1,674

CONSOLIDATED STATEMENT OF SHA_2

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Change in unrealized appreciation (depreciation) of investments, applicable income tax benefit	$ (81.7)	$ 265.1

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Insurance policy income	$ 582.2	$ 580.8
Net investment income	315	260.5
Fee revenue and other income	50.4	49.8
Insurance policy benefits	(410.9)	(416.8)
Interest expense	(38.6)	(9.7)
Deferrable policy acquisition costs	(89.8)	(83.7)
Other operating costs	(320.2)	(309.9)
Income taxes	(6.2)	(14.6)
Net cash from operating activities	81.9	56.4
Cash flows from investing activities:
Sales of investments	486.5	1,520.6
Maturities and redemptions of investments	276.8	494.9
Purchases of investments	(1,147.7)	(2,995.2)
Net purchases of trading securities	(8.4)	(17.3)
Other	(13.9)	(13.3)
Net cash used by investing activities	(406.7)	(1,010.3)
Cash flows from financing activities:
Issuance of common stock	8.1	4
Payments to repurchase common stock	(25.8)	(109.8)
Common stock dividends paid	(17.1)	(16.1)
Amounts received for deposit products	498.3	1,392.6
Withdrawals from deposit products	(422.1)	(364.2)
Issuance of investment borrowings:
Federal Home Loan Bank	620.5	0
Payments on investment borrowings:
Federal Home Loan Bank	(420.4)	(75.3)
Related to variable interest entities	(39.5)	(15)
Net cash provided by financing activities	202	816.2
Net decrease in cash and cash equivalents	(122.8)	(137.7)
Cash and cash equivalents - unrestricted and held by variable interest entities, beginning of period	644.9	731.7
Cash and cash equivalents - unrestricted and held by variable interest entities, end of period	$ 522.1	$ 594

BUSINESS AND BASIS OF PRESENTAT

BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND BASIS OF PRESENTATION	BUSINESS AND BASIS OF PRESENTATION CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products. The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in these financial statements refer to CNO and its subsidiaries. Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries. We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets. We sell our products through exclusive agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. Our unaudited consolidated financial statements reflect normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position, results of operations and cash flows for the periods presented. As permitted by rules and regulations of the Securities and Exchange Commission (the "SEC") applicable to quarterly reports on Form 10-Q, we have condensed or omitted certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Results for interim periods are not necessarily indicative of the results that may be expected for a full year. Effective January 1, 2023, we adopted Accounting Standards Update 2018-12 ("ASU 2018-12") related to targeted improvements to the accounting for long-duration insurance contracts, with a transition date of January 1, 2021 (the "Transition Date"). The adoption of ASU 2018-12 impacted accounting and presentation related to long-duration insurance contracts and certain related balances for the years ended December 31, 2022 and 2021. Amounts within these interim financial statements, which were previously presented, have been recast to conform with the current accounting and presentation under ASU 2018-12. Disclosures of the impacts of ASU 2018-12 as of the Transition Date are included within the tables in the note to the consolidated financial statements entitled "Recently Adopted Accounting Standards." Except for balances affected by the adoption of ASU 2018-12, the December 31, 2022 consolidated balance sheet data was derived from the audited consolidated financial statements included in our 2022 Annual Report on Form 10-K. Accordingly, these interim consolidated financial statements should be read together with the consolidated financial statements included in our 2022 Annual Report on Form 10-K. When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods. For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), allowance for credit losses and other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals. If our future experience differs from these estimates and assumptions, our financial statements could be materially affected. The accompanying financial statements are unaudited and include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summarizes the significant accounting policies that have been added or updated as a result of the adoption of ASU 2018-12: Deferred acquisition costs, present value of future profits and sales inducements Deferred acquisition costs represent policy acquisition costs that have been capitalized and are subject to amortization. Capitalized costs are incremental costs directly related to the successful acquisition of new or renewal insurance contracts. Such costs consist primarily of commissions, underwriting, sales and contract issuance and processing expenses. Contracts are grouped by contract type and issue year into cohorts consistent with the grouping used in estimating the associated liability. Deferred acquisition costs are amortized on a constant level basis for the grouped contracts over the expected term of the related contracts to approximate straight-line amortization. For life and health insurance products, the constant level basis used is policy counts. For all annuity products, the constant level basis used is the initial deposit in force. The constant level bases used for amortization are projected using mortality and lapse assumptions that are based on our experience, industry data, and other factors and are consistent with those used for the liability for future policy benefits. If those projected assumptions change in future periods, they will be reflected in the cohort level amortization basis at the time. Unexpected lapses, due to higher mortality and lapse experience than expected, are recognized in the current period as a reduction of the capitalized balances. Changes in future estimates are recognized prospectively over the remaining expected contract term. The carrying amount of deferred acquisition costs is not subject to recovery testing upon the adoption of ASU 2018-12. The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the effective date of the bankruptcy reorganization of our Predecessor). The present value of future profits is amortized in the same manner as described above for deferred acquisition costs, although such balances are subject to periodic recovery testing. Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract. Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time. These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP. Such amounts are deferred and amortized in the same manner as deferred acquisition costs (and are classified as deferred acquisition costs in the consolidated balance sheet). Unlike deferred acquisition costs, such amounts are considered contractual cash flows and, as a result, are subject to periodic recovery testing. Market risk benefits Market risk benefits ("MRBs") are contracts or contract features that both provide protection to the contract holder from other-than-nominal capital market risk and expose the Company to other-than-nominal capital market risk. Many of our fixed indexed annuity products include a guaranteed living withdrawal benefit ("GLWB") that is considered a MRB. MRBs are measured at fair value using an option-based valuation model based on amount of exposure, market data, Company experience and other factors. Changes in fair value are recognized in earnings each period with the exception of the portion of the change in fair value due to a change in the instrument-specific credit risk, which is recognized in accumulated other comprehensive income (loss). MRBs in an asset position are presented separately from those in a liability position as there is no legal right of offset between contracts. Policyholder account balances Policyholder account balances represent the contract value that has accrued to the benefit of the policyholder as of the balance sheet date. It includes the accumulated account deposits, plus interest credited, less policyholder withdrawals and, if applicable, charges assessed. This balance also includes liabilities for the funding agreement-backed notes ("FABN"). Liability for future policy benefits The liability for future policy benefits is the present value of estimated future policy benefits to be paid to or on behalf of policyholders and certain related expenses (where the timing and amount of payment depends on policyholder mortality or morbidity), less the present value of estimated future net premiums to be collected from policyholders (where net premiums are gross premiums multiplied by the net-to-gross ratio discussed below). The liability for future policy benefits is accrued over time as premium revenue is recognized. The liability is estimated using current assumptions that include discount rates, mortality, morbidity, lapse/withdrawal rates and expenses. Such assumptions are based on our historical experience, industry data, and other factors that are inherently uncertain. This liability also includes the amount of total reserves above (below) policyholder account balances for our fixed indexed annuity products due to the valuation of the related embedded derivative. The liability for future policy benefits is established using a net premium ratio approach where net premiums (the portion of gross premiums required to fund expected insurance benefits and claims settlement expenses) under the contract are accrued each period as the liability for future policy benefits. The net premium ratio used to accrue the liability for future policy benefits in each period is determined by using the historical and present value of expected future benefits and claim adjustment expenses for the cohort divided by the historical and present value of expected future gross premiums for the cohort. Our long duration insurance contracts are grouped into annual calendar-year cohorts primarily based on the contractual issue date, marketing distribution channel, legal entity and product type. Single premium contracts are grouped into separate cohorts from other traditional products. Riders are generally combined with the base policy. Insurance contracts which were issued prior to September 10, 2003 (the effective date of the bankruptcy reorganization of Conseco, Inc. (the "Predecessor")) are grouped by marketing distribution channel, legal entity and product type in a single issue year cohort. The liability is adjusted for differences between actual and expected experience. We review our historical and future cash flow assumptions quarterly and update the net premium ratio used to calculate the liability each time the assumptions are changed. Each quarter, we update our estimates of cash flows expected over the entire life of a group of contracts using actual historical experience and current future cash flow assumptions. These updated cash flows are used to calculate the revised net premiums and net premium ratio, which are used to derive an updated liability for future policy benefits as of the beginning of the current reporting period, discounted at the original contract issuance discount rate. This amount is then compared to the carrying amount of the liability as of that same date, before the updating of cash flow assumptions, to determine the current period change in liability estimate. This current period change in the liability is the liability remeasurement gain or loss and is presented as a separate component of benefit expense in the consolidated statement of operations. In subsequent periods, the revised net premiums are used to measure the liability for future policy benefits, subject to future revisions. If a cohort is in a loss position where the liability for future policy benefits plus the present value of expected future gross premiums is determined to be insufficient to provide for expected future policy benefits and claim settlement costs, the net to gross ratio is capped at 100 percent. When this occurs, all changes in expected benefits resulting from both actual experience deviations and changes in future assumptions are recognized immediately. The locked-in discount rate is generally based on expected investment returns at contract inception for contracts issued prior to January 1, 2021 and the upper medium grade fixed income corporate instrument yield ("A" credit rated corporate bond yield) at contract inception for contracts issued after January 1, 2021. The contract inception date for contracts issued by the Predecessor is September 10, 2003. The discount rate in effect at contract inception is locked-in for the calculation of the net to gross ratio and accretion of interest cost on the liability is recorded through net income. However, for balance sheet remeasurement purposes, the discount rate is updated using the current rate at each reporting period with the impact resulting from such updates recorded in other comprehensive income. We develop discount rate curves for discounting cash flows to calculate the liability for future policy benefits based on the duration characteristics of the underlying liabilities. For liability cash flows that are projected beyond the duration of market-observable A-credit-rated fixed-income instruments, we use the last market-observable yield level and use linear interpolation to determine yield assumptions for durations that do not have market-observable yields. Liability for life insurance policy claims The liability for life insurance policy claims include life policy and contract claims, including incurred but not reported claims. The liability for these claims is based on our estimated ultimate cost to settle all claims that have been incurred as of the reporting date. Such amounts are estimated based on an analysis of historical patterns of claims, which are continually reviewed and updated. Adjustments resulting from differences between our estimates and actual payments are recognized in the period the estimates are made or claims are paid. Deferred profit liability For limited-payment products, gross premiums received in excess of net premiums are deferred at initial recognition as a deferred profit liability ("DPL"). Gross premiums are measured using assumptions consistent with those used in the measurement of the liability for future policy benefits, including discount rate, mortality, lapses and expenses. The DPL is amortized and recognized in insurance policy benefits in proportion to insurance in force for life insurance contracts and expected future benefit payments for annuity contracts. Interest is accreted on the balance of the DPL using the discount rate determined at contract issuance. We review and update the estimate of cash flows for the DPL at the same time as the estimate of cash flows for the liability for future policy benefits. When cash flows are updated, the updated estimates are used to recalculate the DPL at contract issuance. The recalculated DPL as of the beginning of the current reporting period is compared to the carrying amount of the DPL as of the beginning of the current reporting period and any difference is recognized as either a charge or credit to insurance policy benefits. On the balance sheet, the DPL is recorded as a component of the liability for future policy benefits and was $57.7 million at March 31, 2023. Reinsurance We have determined that each of our reinsurance agreements provide indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Such reinsurance permits recovery of the reinsured losses from reinsurers, although it does not discharge our primary liability as the direct insurer of the risks reinsured. The reinsurance recoverable for traditional and limited-payment contracts is generally measured using a net premium ratio approach to accrue the projected net gain or loss on reinsurance in proportion to the gross premiums of the underlying reinsured cohorts. Such amount is adjusted on a quarterly basis for actual experience and at least once a year for any changes in cash flow assumptions.

RECENTLY ADOPTED ACCOUNTING STA

RECENTLY ADOPTED ACCOUNTING STANDARDS	3 Months Ended
	Mar. 31, 2023
Accounting Changes and Error Corrections [Abstract]
RECENTLY ADOPTED ACCOUNTING STANDARDS	RECENTLY ADOPTED ACCOUNTING STANDARDS We adopted ASU 2018-12 effective January 1, 2023. The new guidance: (i) improves the timeliness of recognizing changes in the liability for future benefits and modifies the rate used to discount future cash flows; (ii) simplifies and improves the accounting for certain market-based options or guarantees associated with deposit (or account balance) contracts; (iii) simplifies the amortization of deferred acquisition costs; and (iv) requires enhanced disclosures, including disaggregated rollforwards of the liability for future policy benefits, policyholder account liabilities, market risk benefits and deferred acquisition costs. Additionally, qualitative and quantitative information about expected cash flows, estimates and assumptions is required. The new measurement guidance for traditional and limited-payment contract liabilities and the new guidance for the amortization of deferred acquisition costs was adopted on a modified retrospective transition approach. For contracts in-force at the transition date, we continue to use the existing locked-in investment yield interest rate assumption to calculate the net premium ratio, rather than the upper-medium grade fixed-income corporate instrument yield. However, for balance sheet remeasurement purposes, the current upper-medium grade fixed-income corporate instrument yield is used at transition through accumulated other comprehensive income (loss) and subsequently through other comprehensive income. For market risk benefits, we use the required retrospective application and were able to use hindsight to measure fair value components to the extent assumptions in a prior period are unobservable or otherwise unavailable. We selected the modified retrospective transition method, except for market risk benefits where we are required to use the full retrospective approach. Pursuant to ASU 2018-12, the account balances subject to the guidance were recast on the Transition Date. The following summarizes the impact of adoption on the Transition Date (dollars in millions): January 1, 2021 Amounts prior to adoption of Effect of ASU 2018-12 adoption As recast Present value of future profits $ 249.4 $ 10.2 $ 259.6 Deferred acquisition costs 1,027.8 458.0 1,485.8 Reinsurance receivables 4,584.3 144.1 4,728.4 Market risk benefit asset — 2.5 2.5 Income tax assets, net 199.4 607.0 806.4 Total assets 35,339.9 1,221.8 36,561.7 Policyholder account balances 12,540.6 (172.9) 12,367.7 Future policy benefits 11,744.2 3,960.7 15,704.9 Market risk benefit liability — 114.8 114.8 Liability for policy and contract claims 561.8 (470.1) 91.7 Total liabilities 29,855.7 3,432.5 33,288.2 Retained earnings 752.3 (130.9) (a) 621.4 Accumulated other comprehensive income 2,186.1 (2,079.8) 106.3 Total shareholders' equity 5,484.2 (2,210.7) 3,273.5 _____________________ (a) The impact to retained earnings was primarily related to certain long-term care product cohorts where the present value of expected benefits exceeded the reserve at the Transition Date plus the present value of future gross premiums. As a result, the net premium ratio was capped at 100 percent with an immediate increase in the reserve for such cohorts. The following summarizes the impact of adoption on previously reported balances as of December 31, 2022 and as of and for the three months ended March 31, 2022 (dollars in millions): December 31, 2022 As previously Effect of reported adoption As recast Present value of future profits $ 212.2 $ (8.5) $ 203.7 Deferred acquisition costs 1,913.4 (142.5) 1,770.9 Reinsurance receivables 4,241.7 (18.3) 4,223.4 Market risk benefit asset — 65.3 65.3 Income tax assets, net 1,165.5 (102.1) 1,063.4 Total assets 33,339.2 (206.1) 33,133.1 Policyholder account balances 14,858.3 375.9 15,234.2 Future policy benefits 11,809.1 (568.9) 11,240.2 Market risk benefit liability — 11.3 11.3 Liability for policy and contract claims 456.5 (392.4) 64.1 Total liabilities 31,938.4 (574.1) 31,364.3 Retained earnings 1,459.0 232.2 1,691.2 Accumulated other comprehensive income (loss) (2,093.1) 135.8 (1,957.3) Total shareholders' equity 1,400.8 368.0 1,768.8 Three months ended March 31, 2022 As previously Effect of reported adoption As recast Insurance policy benefits $ 346.7 $ (12.8) $ 333.9 Liability for future policy benefits remeasurement loss — 7.0 7.0 Change in fair value of market risk benefits — (32.7) (32.7) Amortization 103.9 (51.6) 52.3 Other operating costs and expenses 219.2 (.9) 218.3 Total benefits and expenses 693.6 (91.0) 602.6 Income before income taxes 149.3 91.0 240.3 Income tax expense 37.0 19.9 56.9 Net income 112.3 71.1 183.4 As of March 31, 2022 As previously Effect of reported adoption As recast Retained earnings $ 1,223.5 $ 69.5 1,293.0 Accumulated other comprehensive income (loss) 380.5 (942.0) (561.5) Total shareholders' equity 3,690.9 (872.5) 2,818.4 The following tables detail the January 1, 2021 transition adjustments by providing a rollforward of the ending reported balances as of December 31, 2020 to the opening balances as of January 1, 2021 for retained earnings, accumulated other comprehensive income and the impacted insurance related balances (dollars in millions): January 1, 2021 Asset accounts Present value of future profits Deferred acquisition costs Reinsurance receivables Market risk benefit asset Income tax assets, net Amounts prior to adoption of ASU 2018-12 $ 249.4 $ 1,027.8 $ 4,584.3 $ — $ 199.4 Unwinding amounts related to unrealized gains (losses) 10.2 458.0 — — — Changes in measurement of assets — — (81.6) — — Change in discount rates — — 225.7 — — Changes in market benefit reserve basis — — — 2.5 — Tax impacts of changes recognized in accumulated other comprehensive income — — — — 570.3 Tax impacts of changes recognized in retained earnings — — — — 36.7 Amounts, as recast $ 259.6 $ 1,485.8 $ 4,728.4 $ 2.5 $ 806.4 January 1, 2021 Liability accounts Policyholder account balances Future policy benefits Market risk benefit liability Liability for policy and contract claims Amounts prior to adoption of ASU 2018-12 $ 12,540.6 $ 11,744.2 $ — $ 561.8 Unwinding amounts related to unrealized gains (losses) — (197.5) — — Changes in remeasurement of future policy benefits — 31.1 — — Changes in classification of liabilities (1) (172.9) 643.0 — (470.1) Reclass to market risk benefit liability — (66.6) 66.6 — Changes in market risk benefit reserve basis — — 48.2 — Change in discount rates — 3,550.7 — — Amounts, as recast $ 12,367.7 $ 15,704.9 $ 114.8 $ 91.7 _____________________ (1) Amount includes certain reclassifications to conform with the revised presentation of ASU 2018-12, such as reclassifying claims and benefits payable on long-duration health contracts to the liability for future policy benefits. January 1, 2021 Shareholders' equity accounts Accumulated other comprehensive income Retained earnings Amounts prior to adoption of ASU 2018-12 $ 2,186.1 $ 752.3 Unwinding amounts related to unrealized gains (losses) 665.7 — Changes in measurement of assets and liabilities — (112.7) Change in market risk benefit reserve basis 9.2 (54.9) Tax impacts of changes recognized in retained earnings — 36.7 Change in discount rates (3,325.0) — Tax impacts of changes recognized in accumulated other comprehensive income 570.3 — Amounts, as recast $ 106.3 $ 621.4

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS We classify our fixed maturity securities into one of two categories: (i) "available for sale" (which we carry at estimated fair value with any unrealized gain or loss, net of tax and related adjustments, recorded as a component of shareholders' equity); or (ii) "trading" (which we carry at estimated fair value with changes in such value recognized as either net investment income (classified as investment income from policyholder and other special-purpose portfolios) or investment gains (losses)). Trading securities include: (i) investments purchased with the intent of selling in the near term to generate income; and (ii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in other investment gains (losses). We review our available for sale fixed maturity securities with unrealized losses to determine whether such impairments are the result of credit losses. We analyze various factors to make such determinations including, but not limited to: (i) actions taken by rating agencies; (ii) default by the issuer; (iii) the significance of the decline; (iv) an assessment of our intent to sell the security before recovering the security's amortized cost; (v) an economic analysis of the issuer's industry; and (vi) the financial strength, liquidity, and recoverability of the issuer. We perform a security by security review each quarter to evaluate whether a credit loss has occurred. In determining the credit loss component, we discount the estimated cash flows on a security by security basis. We consider the impact of macroeconomic conditions on inputs used to measure the amount of credit loss. For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees. For corporate bonds, cash flow estimates are derived by considering asset type, rating, time to maturity, and applying an expected loss rate. If a portion of the decline is due to credit-related factors, we separate the credit loss component of the impairment from the amount related to all other factors. The credit loss component is recorded as an allowance and reported in other investment gains (losses) (limited to the difference between estimated fair value and amortized cost). The impairment related to all other factors (non-credit factors) is reported in accumulated other comprehensive income (loss) along with unrealized gains (losses) related to fixed maturity investments, available for sale, net of tax and related adjustments. The allowance is adjusted for any additional credit losses and subsequent recoveries. When recognizing an allowance associated with a credit loss, the cost basis is not adjusted. When we determine a security is uncollectable, the remaining amortized cost will be written off. If we intend to sell an impaired fixed maturity security, available for sale, or identify an impaired fixed maturity security, available for sale, for which it is more likely than not we will be required to sell before anticipated recovery, the difference between the fair value and the amortized cost is included in other investment gains (losses) and the fair value becomes the new amortized cost. The new cost basis is not adjusted for any subsequent recoveries in fair value. The Company reports accrued investment income separately from fixed maturities, available for sale, and has elected not to measure an allowance for credit losses for accrued investment income. Accrued investment income is written off through net investment income at the time the issuer of the bond defaults or is expected to default on payments. Accumulated other comprehensive income (loss), included in shareholders' equity as of March 31, 2023 and December 31, 2022, is comprised of the following (dollars in millions): March 31, December 31, Net unrealized losses on investments having no allowance for credit losses $ (937.1) $ (1,247.0) Unrealized losses on investments with an allowance for credit losses (1,453.6) (1,780.7) Change in discount rates for liability for future policy benefits 237.4 500.7 Change in instrument-specific credit risk for market risk benefits 13.1 12.2 Deferred income tax assets 475.8 557.5 Accumulated other comprehensive loss $ (1,664.4) $ (1,957.3) At March 31, 2023, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Allowance for credit losses Estimated fair value Corporate securities $ 13,497.0 $ 66.3 $ (1,529.7) $ (57.2) $ 11,976.4 United States Treasury securities and obligations of United States government corporations and agencies 174.7 .1 (4.7) — 170.1 States and political subdivisions 2,789.4 34.1 (360.1) (.8) 2,462.6 Foreign governments 88.8 .2 (9.9) (.5) 78.6 Asset-backed securities 1,458.6 2.4 (120.2) (.6) 1,340.2 Agency residential mortgage-backed securities 213.3 2.8 (.2) — 215.9 Non-agency residential mortgage-backed securities 1,778.2 37.2 (174.9) — 1,640.5 Collateralized loan obligations 954.3 .5 (35.9) — 918.9 Commercial mortgage-backed securities 2,563.6 .1 (259.8) — 2,303.9 Total fixed maturities, available for sale $ 23,517.9 $ 143.7 $ (2,495.4) $ (59.1) $ 21,107.1 At December 31, 2022, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Allowance for credit losses Estimated fair value Corporate securities $ 13,649.1 $ 29.9 $ (1,911.9) $ (54.4) $ 11,712.7 United States Treasury securities and obligations of United States government corporations and agencies 171.7 — (13.0) — 158.7 States and political subdivisions 2,846.9 19.3 (476.8) (.9) 2,388.5 Foreign governments 86.3 .1 (11.3) (.4) 74.7 Asset-backed securities 1,435.7 1.0 (149.4) (.3) 1,287.0 Agency residential mortgage-backed securities 174.3 1.4 (.7) — 175.0 Non-agency residential mortgage-backed securities 1,700.4 40.0 (191.9) — 1,548.5 Collateralized loan obligations 825.2 .3 (39.6) — 785.9 Commercial mortgage-backed securities 2,494.6 .1 (272.3) — 2,222.4 Total fixed maturities, available for sale $ 23,384.2 $ 92.1 $ (3,066.9) $ (56.0) $ 20,353.4 The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at March 31, 2023, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities (such as asset-backed securities, agency residential mortgage-backed securities, non-agency residential mortgage-backed securities, collateralized loan obligations and commercial mortgage-backed securities, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized Estimated (Dollars in millions) Due in one year or less $ 140.1 $ 138.7 Due after one year through five years 2,209.3 2,080.0 Due after five years through ten years 1,871.8 1,742.8 Due after ten years 12,328.7 10,726.2 Subtotal 16,549.9 14,687.7 Structured securities 6,968.0 6,419.4 Total fixed maturities, available for sale $ 23,517.9 $ 21,107.1 The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2022, by contractual maturity. Amortized Estimated (Dollars in millions) Due in one year or less $ 112.0 $ 110.8 Due after one year through five years 1,913.7 1,790.2 Due after five years through ten years 2,098.9 1,910.4 Due after ten years 12,629.4 10,523.2 Subtotal 16,754.0 14,334.6 Structured securities 6,630.2 6,018.8 Total fixed maturities, available for sale $ 23,384.2 $ 20,353.4 Gross Unrealized Investment Losses Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities. The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at March 31, 2023 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair Unrealized Fair Unrealized Fair Unrealized Corporate securities $ 973.1 $ (35.5) $ 1,979.4 $ (322.6) $ 2,952.5 $ (358.1) United States Treasury securities and obligations of United States government corporations and agencies 106.8 (1.2) 33.7 (3.5) 140.5 (4.7) States and political subdivisions 207.5 (11.2) 397.4 (97.1) 604.9 (108.3) Foreign governments 15.2 (.3) 13.3 (1.2) 28.5 (1.5) Asset-backed securities 388.9 (12.9) 775.0 (103.2) 1,163.9 (116.1) Agency residential mortgage-backed securities 33.4 (.2) .6 — 34.0 (.2) Non-agency residential mortgage-backed securities 560.9 (27.1) 718.0 (147.8) 1,278.9 (174.9) Collateralized loan obligations 282.6 (6.5) 551.7 (29.4) 834.3 (35.9) Commercial mortgage-backed securities 520.3 (13.7) 1,738.3 (246.1) 2,258.6 (259.8) Total fixed maturities, available for sale $ 3,088.7 $ (108.6) $ 6,207.4 $ (950.9) $ 9,296.1 $ (1,059.5) The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2022 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair Unrealized Fair Unrealized Fair Unrealized Corporate securities $ 2,830.8 $ (329.4) $ 370.4 $ (129.3) $ 3,201.2 $ (458.7) United States Treasury securities and obligations of United States government corporations and agencies 134.4 (9.6) 21.9 (3.4) 156.3 (13.0) States and political subdivisions 667.0 (124.8) 132.1 (58.5) 799.1 (183.3) Foreign governments 35.0 (3.5) 2.1 (.3) 37.1 (3.8) Asset-backed securities 914.0 (90.1) 258.1 (53.4) 1,172.1 (143.5) Agency residential mortgage-backed securities 59.7 (.7) — — 59.7 (.7) Non-agency residential mortgage-backed securities 861.6 (89.7) 335.4 (102.2) 1,197.0 (191.9) Collateralized loan obligations 553.0 (27.4) 184.2 (12.2) 737.2 (39.6) Commercial mortgage-backed securities 1,581.4 (160.0) 593.3 (112.3) 2,174.7 (272.3) Total fixed maturities, available for sale $ 7,636.9 $ (835.2) $ 1,897.5 $ (471.6) $ 9,534.4 $ (1,306.8) Based on management's current assessment of investments with unrealized losses at March 31, 2023, the Company believes the issuers of the securities will continue to meet their obligations. While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments. In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery. The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2023 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2022 $ 54.4 $ .9 $ .4 $ .3 $ 56.0 Additions for securities for which credit losses were not previously recorded 3.0 — — — 3.0 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded .5 (.1) .1 .3 .8 Reduction for securities sold during the period (.7) — — — (.7) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2023 $ 57.2 $ .8 $ .5 $ .6 $ 59.1 The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2022 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2021 $ 7.4 $ — $ .2 $ — $ 7.6 Additions for securities for which credit losses were not previously recorded 14.0 .3 .1 — 14.4 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded 14.6 .5 (.2) .1 15.0 Reduction for securities sold during the period (.4) — — — (.4) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2022 $ 35.6 $ .8 $ .1 $ .1 $ 36.6 Mortgage Loans Mortgage loans are carried at amortized unpaid balance, net of allowance for estimated credit losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received. The allowance for estimated credit losses is measured using a loss-rate method on an individual asset basis. Inputs used include asset-specific characteristics, current economic conditions, historical loss information and reasonable and supportable forecasts about future economic conditions. At March 31, 2023, the mortgage loan balance was primarily comprised of commercial mortgage loans and there were no commercial mortgage loans in process of foreclosure. At March 31, 2023, we held residential mortgage loan investments with an amortized cost and fair value of $409.4 million and $407.2 million, respectively. At March 31, 2023, there were four residential mortgage loans that were noncurrent with a carrying value of $1.1 million (of which, two loans with a carrying value of $0.5 million were in foreclosure). The following table provides the amortized cost by year of origination and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of March 31, 2023 (dollars in millions): Estimated fair Loan-to-value ratio (a) 2023 2022 2021 2020 2019 Prior Total amortized cost Mortgage loans Collateral Less than 60% $ 73.6 $ 178.7 $ 114.4 $ 37.4 $ 75.1 $ 494.2 $ 973.4 $ 884.3 $ 3,553.3 60% to less than 70% — 87.3 26.2 5.7 — 56.8 176.0 159.7 269.3 70% to less than 80% — 47.8 10.1 — — 43.2 101.1 86.8 138.4 80% to less than 90% — — — — — — — — — 90% or greater — — — — — 24.6 24.6 19.5 26.1 Total $ 73.6 $ 313.8 $ 150.7 $ 43.1 $ 75.1 $ 618.8 $ 1,275.1 $ 1,150.3 $ 3,987.1 ________________ (a) Loan-to-value ratios are calculated as the ratio of: (i) the amortized cost of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral. The following table summarizes changes in the allowance for credit losses related to mortgage loans for the three months ended March 31, 2023 and 2022 (dollars in millions): Three months ended March 31, 2023 2022 Allowance at the beginning of the period $ 8.0 $ 5.6 Current period provision for expected credit losses .4 (.5) Initial allowance recognized for purchased financial assets with credit deterioration — — Write-offs charged against the allowance — — Recoveries of amounts previously written off — — Allowance at the end of the period $ 8.4 $ 5.1 Total Investment Gains (Losses) The following table sets forth the total investment gains (losses) for the periods indicated (dollars in millions): Three months ended March 31, 2023 2022 Realized investment gains (losses): Gross realized gains on sales of fixed maturities, available for sale $ 7.3 $ 54.8 Gross realized losses on sales of fixed maturities, available for sale (14.4) (30.6) Equity securities, net (.2) (4.7) Other, net (7.3) (.7) Total realized investment gains (losses) (14.6) 18.8 Change in allowance for credit losses (a) (1.5) (30.7) Change in fair value of equity securities (b) .4 (1.2) Other changes in fair value (c) 1.1 (19.6) Other investment losses — (51.5) Total investment losses $ (14.6) $ (32.7) _________________ (a) Changes in the allowance for credit losses includes $2.0 million and $(2.2) million in the three months ended March 31, 2023 and 2022, respectively, related to investments held by variable interest entities ("VIEs"). (b) Changes in the estimated fair value of equity securities (that are still held as of the end of the respective periods) were $0.3 million and $(5.2) million for the three months ended March 31, 2023 and 2022, respectively. (c) Changes in the estimated fair value of trading securities that we have elected the fair value option (that are still held as of the end of the respective periods) were $(2.5) million and $(12.8) million in the three months ended March 31, 2023 and 2022, respectively. During the first three months of 2023, we recognized net investment losses of $14.6 million, which were comprised of: (i) $10.8 million of net losses from the sales of investments; (ii) $0.3 million of gains related to equity securities, including the change in fair value; (iii) $4.0 million of losses related to certain fixed maturity investments with embedded derivatives, including the change in fair value; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $1.4 million; and (v) an increase in the allowance for credit losses of $1.5 million. During the first three months of 2022, we recognized net investment losses of $32.7 million, which were comprised of: (i) $23.5 million of net gains from the sales of investments; (ii) $5.9 million of losses related to equity securities, including the change in fair value; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $13.1 million; (iv) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $6.5 million; and (v) an increase in the allowance for credit losses of $30.7 million. Our fixed maturity investments are generally purchased in the context of various long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities. In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities. At March 31, 2023, there were no fixed maturity investments in default. During the first three months of 2023, the $14.4 million of gross realized losses on sales of $288.5 million of fixed maturity securities, available for sale, included: (i) $11.1 million related to various corporate securities; (ii) $2.2 million related to commercial mortgage-backed securities; and (iii) $1.1 million related to various other investments. Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values. These reasons include but are not limited to: (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; (v) better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities; or (vi) changes in expected portfolio cash flows. During the first three months of 2022, the $30.6 million of gross realized losses on sales of $786.6 million of fixed maturity securities, available for sale, included: (i) $14.6 million related to various corporate securities; (ii) $9.8 million related to non-agency residential mortgage-backed securities; (iii) $4.2 million related to states and political subdivisions; and (iv) $2.0 million related to various other investments. Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio. Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

LIABILITIES FOR INSURANCE PRODU

LIABILITIES FOR INSURANCE PRODUCTS	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
LIABILITIES FOR INSURANCE PRODUCTS	LIABILITIES FOR INSURANCE PRODUCTS The liability for future policy benefits is determined based on numerous assumptions. The most significant assumptions for our life and annuity business are mortality and lapse/withdrawal rates which are based on our experience and, in cases of limited experience, industry experience. Mortality and lapse/withdrawal rates also take into consideration future expectations in policyholder behavior that may vary from past experience. For our health business, mortality rates, lapse rates, morbidity assumptions and future rate increases are based on our experience and, in cases of limited experience, industry experience. Such assumptions also consider future expectations in policyholder behavior that may vary from past experience. In the first quarter of 2023, we reviewed the actual mortality, lapse, and morbidity experience for the quarter and determined that no changes to assumptions for future cash flows were necessary. This is consistent with the impact in the "Effect of actual variances from expected experience" line items in the tables below, which indicate our actual experience did not deviate significantly from our expectations. The following tables summarize balances and changes in the liability for future policy benefits for traditional and limited-payment contracts for the three months ended March 31, 2023 (dollars in millions): Three months ended March 31, 2023 Supplemental health Medicare supplement Long-term care Traditional life Other annuities Present value of expected net premiums ("PVENP"), beginning of period $ 2,781.3 $ 2,800.6 $ 1,034.1 $ 2,175.0 $ — Effect of changes in discount rate assumptions, beginning of period 188.4 196.4 23.2 137.1 — Beginning PVENP at original discount rate 2,969.7 2,997.0 1,057.3 2,312.1 — Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience (17.2) 27.0 (3.4) (14.1) — Adjusted beginning of period PVENP 2,952.5 3,024.0 1,053.9 2,298.0 — Issuances 63.7 101.6 15.7 108.3 1.1 Interest accrual 32.0 30.5 12.3 23.0 — Net premiums collected (90.3) (113.4) (40.6) (101.4) (1.1) Ending PVENP at original discount rate 2,957.9 3,042.7 1,041.3 2,327.9 — Effect of changes in discount rate assumptions, end of period (120.4) (139.2) (4.6) (92.5) — PVENP, end of period $ 2,837.5 $ 2,903.5 $ 1,036.7 $ 2,235.4 $ — Present value of expected future policy benefits ("PVEFPB"), beginning of period $ 5,886.8 $ 3,033.1 $ 4,158.1 $ 4,417.9 $ 310.9 Effect of changes in discount rate assumptions, beginning of period 483.3 212.0 28.5 336.6 15.4 Beginning PVEFPB at original discount rate 6,370.1 3,245.1 4,186.6 4,754.5 326.3 Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience (20.5) 32.2 (6.3) (15.2) .7 Adjusted beginning of period PVEFPB 6,349.6 3,277.3 4,180.3 4,739.3 327.0 Issuances 63.7 101.6 15.7 108.3 1.1 Interest accrual 73.8 33.2 55.5 51.0 3.7 Benefit payments (99.5) (125.6) (71.3) (115.0) (8.6) Ending PVEFPB at original discount rate 6,387.6 3,286.5 4,180.2 4,783.6 323.2 Effect of changes in discount rate assumptions, end of period (306.8) (150.0) 86.4 (223.0) (6.9) PVEFPB, end of period $ 6,080.8 $ 3,136.5 $ 4,266.6 $ 4,560.6 $ 316.3 Net liability for future policy benefits $ 3,243.3 $ 233.0 $ 3,229.9 $ 2,325.2 $ 316.3 Flooring impact — .4 — — — Adjusted net liability for future policy benefits 3,243.3 233.4 3,229.9 2,325.2 316.3 Related reinsurance recoverable (2.4) — (357.5) (201.1) — Net liability for future policy benefits, net of reinsurance recoverable $ 3,240.9 $ 233.4 $ 2,872.4 $ 2,124.1 $ 316.3 The following tables summarize balances and changes in the liability for future policy benefits for traditional and limited-payment contracts for the three months ended March 31, 2022 (dollars in millions): Three months ended March 31, 2022 Supplemental health Medicare supplement Long-term care Traditional life Other annuities PVENP, beginning of period $ 3,496.8 $ 3,454.0 $ 1,313.4 $ 2,483.7 $ — Effect of changes in discount rate assumptions, beginning of period (525.6) (341.8) (183.2) (239.4) — Beginning PVENP at original discount rate 2,971.2 3,112.2 1,130.2 2,244.3 — Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience 6.3 21.2 (8.9) (11.8) — Adjusted beginning of period PVENP 2,977.5 3,133.4 1,121.3 2,232.5 — Issuances 80.6 68.0 25.7 149.3 1.6 Interest accrual 31.3 30.4 13.1 20.9 — Net premiums collected (89.5) (119.0) (42.7) (99.9) (1.6) Ending PVENP at original discount rate 2,999.9 3,112.8 1,117.4 2,302.8 — Effect of changes in discount rate assumptions, end of period 213.4 112.1 94.2 72.5 — PVENP, end of period $ 3,213.3 $ 3,224.9 $ 1,211.6 $ 2,375.3 $ — PVEFPB, beginning of period $ 7,688.0 $ 3,750.5 $ 5,501.6 $ 5,395.7 $ 431.9 Effect of changes in discount rate assumptions, beginning of period (1,414.8) (373.8) (1,291.2) (767.3) (88.4) Beginning PVEFPB at original discount rate 6,273.2 3,376.7 4,210.4 4,628.4 343.5 Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience 5.6 21.5 (9.2) (8.5) (1.3) Adjusted beginning of period PVEFPB 6,278.8 3,398.2 4,201.2 4,619.9 342.2 Issuances 80.8 67.3 25.7 149.4 1.9 Interest accrual 72.5 33.2 56.1 48.8 3.9 Benefit payments (99.5) (123.3) (64.2) (128.8) (9.3) Ending PVEFPB at original discount rate 6,332.6 3,375.4 4,218.8 4,689.3 338.7 Effect of changes in discount rate assumptions, end of period 622.3 123.9 747.4 296.2 44.6 PVEFPB, end of period $ 6,954.9 $ 3,499.3 $ 4,966.2 $ 4,985.5 $ 383.3 Net liability for future policy benefits $ 3,741.6 $ 274.4 $ 3,754.6 $ 2,610.2 $ 383.3 Flooring impact 1.5 .2 .6 .4 — Adjusted net liability for future policy benefits 3,743.1 274.6 3,755.2 2,610.6 383.3 Related reinsurance recoverable (3.2) — (407.0) (242.1) — Net liability for future policy benefits, net of reinsurance recoverable $ 3,739.9 $ 274.6 $ 3,348.2 $ 2,368.5 $ 383.3 The following table reconciles the net liability for future policy benefits to the amount presented in the consolidated balance sheet (dollars in millions): March 31, 2023 March 31, 2022 Balances included in the future policy benefits rollforwards: Supplemental health $ 3,243.3 $ 3,743.1 Medicare supplement 233.4 274.6 Long-term care 3,229.9 3,755.2 Traditional life 2,325.2 2,610.6 Other annuities 316.3 383.3 Reserves excluded from rollforward (1) 2,593.3 2,626.5 Deferred profit liability 57.7 51.3 Amount of reserves above (below) policyholder account balances (2) (410.5) (273.1) Future loss reserves (3) 34.7 34.6 Future policy benefits $ 11,623.3 $ 13,206.1 _______________ (1) Primarily comprised of blocks of business that are 100% ceded. (2) Such amount represents the difference between: (i) the total insurance liabilities for our fixed indexed annuities (including the host contract and the related embedded derivative); and (ii) the policyholder account balances for these products. The accounting requirement to bifurcate the embedded derivative and value it at the current estimated fair value results in this amount. (3) In certain instances, the total insurance liabilities for a particular line of business may not be deficient in the aggregate to trigger loss recognition, but the pattern of earnings may be such that profits are expected to be recognized in earlier years followed by losses in later years. In these situations, accounting standards require that an additional liability (the "future loss reserve") be recognized by an amount necessary to sufficiently offset the losses that would be recognized in later years. Many of our fixed indexed annuity products include a GLWB that is considered a MRB. The calculation of MRBs includes market assumptions (interest rate, equity returns, volatility and dividend yields) and nonmarket assumptions (mortality rates, surrender and withdrawal rates, GLWB utilization and spreads). Market assumptions are updated quarterly to reflect current market conditions. During the first quarter of 2023, we reviewed the nonmarket assumptions used to calculate MRBs and determined that such assumptions were appropriate. The following table presents the balance of and changes in market risk benefits associated with our fixed indexed annuities (dollars in millions): March 31, 2023 March 31, 2022 Net liability (asset), beginning of period $ (54.0) $ 86.2 Effect of changes in the instrument-specific credit risk, beginning of period 12.2 12.1 Balance, beginning of period, before effect of changes in the instrument-specific credit risk (41.8) 98.3 Issuances .1 (.8) Interest accrual 5.2 3.4 Attributed fees collected — — Benefit payments — — Effect of changes in interest rates 12.3 (35.3) Effect of changes in equity markets 5.3 (6.8) Effect of changes in equity index volatility (7.4) 4.4 Actual policyholder behavior different from expected behavior .6 .3 Effect of changes in future expected policyholder behavior - other — — Effect of changes in future expected policyholder behavior - risk margin — — Effect of changes in assumptions (1.4) 2.1 Net liability (asset), end of period, before effect of changes in the instrument-specific credit risk (27.1) 65.6 Effect of changes in the instrument-specific credit risk, end of period (13.1) (18.7) Net liability (asset), end of period (40.2) 46.9 Reinsurance recoverable, end of period — — Net liability (asset), end of period, net of reinsurance $ (40.2) $ 46.9 Balance reported as an asset $ 57.8 $ 16.9 Balance reported as a liability 17.6 63.8 Net liability (asset) $ (40.2) $ 46.9 Net amount at risk $ 58.9 $ 107.4 Weighted average attained age of contract holders 68 68 The following table summarizes the amount of revenue and interest related to traditional and limited-payment contracts recognized in the consolidated statement of operations (dollars in millions): Gross premiums (a) Interest accretion (b) Three months ended Three months ended March 31, March 31, 2023 2022 2023 2022 Other annuity $ 1.3 $ 2.2 $ 3.7 $ 3.9 Supplemental health 179.4 175.7 41.8 41.2 Medicare supplement 159.2 167.6 2.7 2.8 Long-term care 82.7 82.4 43.2 43.0 Traditional life 178.8 172.4 28.0 27.9 Total $ 601.4 $ 600.3 $ 119.4 $ 118.8 _____________________ (a) Such amounts are included in insurance policy income in the consolidated statement of operations. (b) Such amounts are included in insurance policy benefits in the consolidated statement of operations. The following table provides the amount of undiscounted and discounted expected gross premiums and expected future benefits and expenses for traditional and limited-payment contracts (dollars in millions): March 31, 2023 March 31, 2022 Undiscounted Discounted (a) Undiscounted Discounted (a) Other annuity Expected future gross premiums $ — $ — $ — $ — Expected future benefits and expenses 396.9 316.3 426.0 383.3 Supplemental health Expected future gross premiums 8,964.4 5,605.7 8,862.2 6,222.2 Expected future benefits and expenses 11,040.9 6,080.8 10,940.4 6,954.9 Medicare supplement Expected future gross premiums 5,645.2 4,031.9 5,680.8 4,490.0 Expected future benefits and expenses 4,417.8 3,136.5 4,446.9 3,499.3 Long-term care Expected future gross premiums 2,954.3 2,152.7 3,012.5 2,389.4 Expected future benefits and expenses 7,445.7 4,266.6 7,606.7 4,966.2 Traditional life Expected future gross premiums 5,435.0 3,953.3 5,384.4 4,260.8 Expected future benefits and expenses 7,382.8 4,560.6 7,180.2 4,985.5 _____________________ (a) Calculated at the discount rates at period end. Loss expense as a result of net premium ratio capping was not material in both the three months ended March 31, 2023 and 2022. The following table provides the weighted average durations (under locked-in rates) of the liability for future policy benefits in years: March 31, March 31, Other annuity 9.7 9.7 Supplemental health 11.8 12.0 Medicare supplement 6.1 5.9 Long-term care 10.5 10.8 Traditional life 10.1 10.4 The following table provides the weighted average interest rates for the liability for future policy benefits: March 31, March 31, Other annuity Interest accretion rate 4.76 % 4.72 % Current discount rate 5.17 % 3.68 % Supplemental health Interest accretion rate 5.04 % 5.09 % Current discount rate 5.14 % 3.66 % Medicare supplement Interest accretion rate 4.26 % 4.23 % Current discount rate 4.94 % 3.41 % Long-term care Interest accretion rate 5.67 % 5.71 % Current discount rate 5.18 % 3.71 % Traditional life Interest accretion rate 4.77 % 4.82 % Current discount rate 5.15 % 3.66 % The following tables present the balances of and changes in the liability for policyholder account balances (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Other annuities Interest-sensitive life Funding agreements Other (a) Balance, beginning of period excluding contracts 100% ceded $ 9,490.4 $ 1,663.1 $ 127.1 $ 1,209.6 $ 1,410.8 $ 395.5 Issuances 323.3 45.3 — 9.5 — — Premiums received .4 .7 7.5 50.3 — 63.0 Policy charges (4.0) (.2) — (46.1) — — Surrenders and withdrawals (178.2) (43.3) (10.5) (8.2) (9.9) (72.6) Benefit payments (59.2) (27.7) (1.7) (6.0) — — Interest credited 6.1 11.3 .6 8.1 7.2 .7 Other 5.5 .1 (.2) — — — Balance, end of period excluding contracts 100% ceded 9,584.3 1,649.3 122.8 1,217.2 1,408.1 386.6 Balance, end of period for contracts 100% ceded 154.4 632.6 26.3 110.7 — 10.6 Balance, end of period $ 9,738.7 $ 2,281.9 $ 149.1 $ 1,327.9 $ 1,408.1 $ 397.2 Balance, end of period, reinsurance ceded (154.4) (632.6) (26.3) (130.5) — (24.8) Balance, end of period, net of reinsurance $ 9,584.3 $ 1,649.3 $ 122.8 $ 1,197.4 $ 1,408.1 $ 372.4 Weighted average crediting rate 1.6 % 2.7 % 1.9 % 3.1 % 2.0 % 0.6 % Net amount at risk (b) $ — $ — $ — $ 26,865.3 $ — $ — Cash surrender value, net of reinsurance $ 8,932.4 $ 1,631.5 $ 122.8 $ 977.1 $ — $ 372.4 _________________ (a) Predominantly consists of retained asset accounts associated with our traditional life and supplemental health blocks. (b) Represents the amount of insurance policy benefit expense that we would incur if death claims were filed on all annuity and interest-sensitive life contracts at the balance sheet date. March 31, 2022 Fixed indexed annuities Fixed interest annuities Other annuities Interest-sensitive life Funding agreements Other (a) Balance, beginning of period excluding contracts 100% ceded $ 8,681.0 $ 1,806.1 $ 131.2 $ 1,163.9 $ 502.0 $ 368.0 Issuances 354.6 10.5 — 10.6 899.0 — Premiums received .1 1.1 9.1 47.6 — 61.7 Policy charges (3.0) (.1) — (44.5) — — Surrenders and withdrawals (133.7) (37.9) (10.2) (5.7) — (56.8) Benefit payments (67.3) (39.6) (1.4) (7.8) — (.1) Interest credited 65.7 11.5 .6 15.7 7.0 .7 Other 4.6 .2 — — — — Balance, end of period excluding contracts 100% ceded 8,902.0 1,751.8 129.3 1,179.8 1,408.0 373.5 Balance, end of period for contracts 100% ceded 166.6 658.8 28.2 115.7 — 11.9 Balance, end of period $ 9,068.6 $ 2,410.6 $ 157.5 $ 1,295.5 $ 1,408.0 $ 385.4 Balance, end of period, reinsurance ceded (166.6) (658.8) (28.2) (136.5) — (26.7) Balance, end of period, net of reinsurance $ 8,902.0 $ 1,751.8 $ 129.3 $ 1,159.0 $ 1,408.0 $ 358.7 Weighted average crediting rate 1.4 % 2.6 % 1.8 % 5.9 % 2.0 % 0.7 % Net amount at risk (b) $ — $ — $ — $ 26,436.6 $ — $ — Cash surrender value, net of reinsurance $ 8,295.5 $ 1,743.3 $ 129.3 $ 938.6 $ — $ 358.7 _________________ (a) Predominantly consists of retained asset accounts associated with our traditional life and supplemental health blocks. (b) Represents the amount of insurance policy benefit expense that we would incur if death claims were filed on all annuity and interest-sensitive life contracts at the balance sheet date. The following table reconciles the liability for policyholder account balances to the amount presented in the consolidated balance sheet (dollars in millions): March 31, 2023 March 31, 2022 Amounts included in the liability for policyholder account balances rollforwards: Fixed indexed annuities $ 9,738.7 $ 9,068.6 Fixed interest annuities 2,281.9 2,410.6 Other annuities 149.1 157.5 Interest-sensitive life 1,327.9 1,295.5 Funding agreements 1,408.1 1,408.0 Other 397.2 385.4 Total $ 15,302.9 $ 14,725.6 The following tables present the account values by range of guaranteed minimum crediting rates and the related range of difference, in basis points, between rates being credited to policyholders and the respective guaranteed minimums (dollars in millions): March 31, 2023 Range of guaranteed minimum crediting rates (a) At guaranteed minimum 1-50 basis points above 51-150 basis points above Greater than 150 basis points above Total Fixed interest annuity 0.00%-2.99% $ 144.9 $ 291.7 $ 78.3 $ 76.9 $ 591.8 3.00%-4.99% 1,572.0 27.7 .1 — 1,599.8 5.00% and greater 90.3 — — — 90.3 Subtotal 1,807.2 319.4 78.4 76.9 2,281.9 Other annuity 0.00%-2.99% 43.6 29.5 — — 73.1 3.00%-4.99% 65.3 — — — 65.3 5.00% and greater 10.7 — — — 10.7 Subtotal 119.6 29.5 — — 149.1 Interest-sensitive life 0.00%-2.99% 66.5 225.8 225.4 — 517.7 3.00%-4.99% 461.5 51.7 146.6 125.0 784.8 5.00% and greater 21.9 .5 2.7 .3 25.4 Subtotal 549.9 278.0 374.7 125.3 1,327.9 Funding agreements 0.00%-2.99% 1,408.1 — — — 1,408.1 3.00%-4.99% — — — — — 5.00% and greater — — — — — Subtotal 1,408.1 — — — 1,408.1 Other 0.00%-2.99% 17.8 355.4 — — 373.2 3.00%-4.99% 23.6 — — — 23.6 5.00% and greater .4 — — — .4 Subtotal 41.8 355.4 — — 397.2 Total 0.00%-2.99% 1,680.9 902.4 303.7 76.9 2,963.9 3.00%-4.99% 2,122.4 79.4 146.7 125.0 2,473.5 5.00% and greater 123.3 .5 2.7 .3 126.8 Total policyholder account balances, excluding fixed indexed annuities $ 3,926.6 $ 982.3 $ 453.1 $ 202.2 5,564.2 Fixed indexed annuity account balances 9,738.7 Total policyholder account balances $ 15,302.9 ____________________ (a) Excludes the account balances related to our fixed indexed annuity contracts which do not have a minimum crediting rate since returns are based on an index. March 31, 2022 Range of guaranteed minimum crediting rates (a) At guaranteed minimum 1-50 basis points above 51-150 basis points above Greater than 150 basis points above Total Fixed interest annuity 0.00%-2.99% $ 171.7 $ 332.2 $ 42.9 $ 11.5 $ 558.3 3.00%-4.99% 1,734.3 23.5 0.1 — 1,757.9 5.00% and greater 94.4 — — — 94.4 Subtotal 2,000.4 355.7 43.0 11.5 2,410.6 Other annuity 0.00%-2.99% 53.1 30.3 — — 83.4 3.00%-4.99% 62.4 — — — 62.4 5.00% and greater 11.7 — — — 11.7 Subtotal 127.2 30.3 — — 157.5 Interest-sensitive life 0.00%-2.99% 7.5 — — — 7.5 3.00%-4.99% 409.3 56.5 178.0 146.4 790.2 5.00% and greater 22.7 0.4 — 474.7 497.8 Subtotal 439.5 56.9 178.0 621.1 1,295.5 Funding agreements 0.00%-2.99% 1,408.0 — — — 1,408.0 3.00%-4.99% — — — — — 5.00% and greater — — — — — Subtotal 1,408.0 — — — 1,408.0 Other 0.00%-2.99% 18.5 341.1 — — 359.6 3.00%-4.99% 24.8 — — — 24.8 5.00% and greater 1.0 — — — 1.0 Subtotal 44.3 341.1 — — 385.4 Total 0.00%-2.99% 1,658.8 703.6 42.9 11.5 2,416.8 3.00%-4.99% 2,230.8 80.0 178.1 146.4 2,635.3 5.00% and greater 129.8 0.4 — 474.7 604.9 Total policyholder account balances, excluding fixed indexed annuities $ 4,019.4 $ 784.0 $ 221.0 $ 632.6 5,657.0 Fixed indexed annuity account balances 9,068.6 Total policyholder account balances $ 14,725.6 ____________________

DEFERRED ACQUISITION COSTS, PRE

DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS	3 Months Ended
	Mar. 31, 2023
Deferred Charges, Insurers [Abstract]
DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS	DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS Changes in deferred acquisition costs were as follows (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Supplemental health Medicare supplement Long-term care Interest-sensitive life Traditional life Funding agreements Total Beginning of period $ 365.6 $ 19.6 $ 378.8 $ 161.2 $ 137.9 $ 212.2 $ 409.1 $ 6.0 $ 1,690.4 Capitalizations 21.6 2.5 14.4 5.8 3.4 8.3 28.2 — 84.2 Amortization expense (11.1) (.9) (7.6) (7.2) (3.8) (3.5) (12.2) (.3) (46.6) End of period $ 376.1 $ 21.2 $ 385.6 $ 159.8 $ 137.5 $ 217.0 $ 425.1 $ 5.7 $ 1,728.0 March 31, 2022 Fixed indexed annuities Fixed interest annuities Supplemental health Medicare supplement Long-term care Interest-sensitive life Traditional life Funding agreements Total Beginning of period $ 313.0 $ 19.0 $ 357.5 $ 170.2 $ 136.4 $ 196.3 $ 357.6 $ 3.3 $ 1,553.3 Capitalizations 22.5 .5 12.0 5.5 4.8 7.8 21.7 4.2 79.0 Amortization expense (9.7) (.9) (7.0) (7.6) (3.9) (3.4) (10.2) (.3) (43.0) End of period $ 325.8 $ 18.6 $ 362.5 $ 168.1 $ 137.3 $ 200.7 $ 369.1 $ 7.2 $ 1,589.3 Changes in the present value of future profits were as follows (dollars in millions): March 31, 2023 Supplemental health Medicare supplement Long-term care Traditional life Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 154.0 $ 27.5 $ 6.2 $ 14.8 $ .8 $ .4 $ 203.7 Amortization expense (3.3) (1.9) (.3) (.5) (.1) — (6.1) End of period $ 150.7 $ 25.6 $ 5.9 $ 14.3 $ .7 $ .4 $ 197.6 March 31, 2022 Supplemental health Medicare supplement Long-term care Traditional life Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 168.1 $ 36.5 $ 7.3 $ 16.9 $ .9 $ .4 $ 230.1 Amortization expense (3.6) (2.5) (.3) (.5) — — (6.9) End of period $ 164.5 $ 34.0 $ 7.0 $ 16.4 $ .9 $ .4 $ 223.2 Changes in sales inducements were as follows (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 76.0 $ 4.5 $ 80.5 Capitalizations 5.4 .2 5.6 Amortization expense (2.6) (.2) (2.8) End of period $ 78.8 $ 4.5 $ 83.3 March 31, 2022 Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 63.0 $ 5.0 $ 68.0 Capitalizations 4.6 .1 4.7 Amortization expense (2.1) (.3) (2.4) End of period $ 65.5 $ 4.8 $ 70.3

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE A reconciliation of net income (loss) and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands): Three months ended March 31, 2023 2022 Net income (loss) for basic and diluted earnings per share $ (.8) $ 183.4 Shares: Weighted average shares outstanding for basic earnings per share 114,545 118,622 Effect of dilutive securities on weighted average shares: Amounts related to employee benefit plans — 2,380 Weighted average shares outstanding for diluted earnings per share 114,545 121,002 In the three months ended March 31, 2023, the equivalent of 2,182 thousand common shares (related to shares issuable pursuant to employee benefit plans) were not included in the diluted weighted average shares outstanding because their inclusion would have been anti-dilutive due to the net loss recognized by the Company in such period.

BUSINESS SEGMENTS

BUSINESS SEGMENTS	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
BUSINESS SEGMENTS	BUSINESS SEGMENTS We view our operations as three insurance product lines (annuity, health and life) and the investment and fee income segments. Our segments are aligned based on their common characteristics, comparability of profit margins and the way management makes operating decisions and assesses the performance of the business. Our insurance product line segments (annuity, health and life) include marketing, underwriting and administration of the policies our insurance subsidiaries sell. The business written in each of the three product categories through all of our insurance subsidiaries is aggregated allowing management and investors to assess the performance of each product category. When analyzing profitability of these segments, we use insurance product margin as the measure of profitability, which is: (i) insurance policy income; and (ii) net investment income allocated to the insurance product lines; less (i) insurance policy benefits and interest credited to policyholders; and (ii) amortization, non-deferred commissions and advertising expense. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average net insurance liabilities for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes insurance product margin and income from insurance products help provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines. We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company. The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. This structure unifies consumer capabilities into a single division and integrates the strength of our agent sales forces with one of the largest direct-to-consumer insurance businesses with proven experience in advertising, web/digital and call center support. The Worksite Division focuses on worksite and group sales for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually. With a separate Worksite Division, we are bringing a sharper focus to this high-growth business while further capitalizing on the strength of our wholly-owned subsidiary, Optavise, LLC ("Optavise"), a national provider of year-round technology-driven employee benefits management services. The Consumer and Worksite Divisions are primarily focused on marketing insurance products, several types of which are sold in both divisions and underwritten in the same manner. Sales of group underwritten policies are currently not significant, but are expected to increase within the Worksite Division. The investment segment involves the management of our capital resources, including investments and the management of corporate debt and liquidity. Our measure of profitability of this segment is the total net investment income not allocated to the insurance products. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable and investment borrowings; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank ("FHLB") investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investments income not allocated to product lines), net of interest expense on corporate debt. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program. Our fee income segment includes the earnings generated from sales of third-party insurance products, services provided by Optavise and the operations of our broker/dealer and registered investment advisor. Expenses not allocated to product lines include the expenses of our corporate operations, excluding interest expense on debt. We measure segment performance by excluding total investment gains (losses), changes in fair value of embedded derivative liabilities and market risk benefits, fair value changes related to the agent deferred compensation plan, income taxes and other non-operating items consisting primarily of earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business. Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Investment gains (losses), changes in fair value of embedded derivative liabilities and market risk benefits, fair value changes related to the agent deferred compensation plan and other non-operating items consisting primarily of earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments. Investment gains (losses) and changes in fair value of embedded derivative liabilities and market risk benefits may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business. Operating information by segment is as follows (dollars in millions): Three months ended March 31, 2023 2022 Revenues: Annuity: Insurance policy income $ 5.1 $ 5.0 Net investment income 125.4 117.5 Total annuity revenues 130.5 122.5 Health: Insurance policy income 401.4 406.7 Net investment income 74.0 73.3 Total health revenues 475.4 480.0 Life: Insurance policy income 219.0 213.3 Net investment income 36.3 35.5 Total life revenues 255.3 248.8 Change in market values of the underlying options supporting the fixed indexed annuity and life products (offset by market value changes credited to policyholder balances) 18.6 (71.9) Investment income not allocated to product lines 67.8 46.6 Fee revenue and other income: Fee income 51.3 40.3 Amounts netted in expenses not allocated to product lines 1.6 2.8 Total segment revenues $ 1,000.5 $ 869.1 (continued on next page) (continued from previous page) Three months ended March 31, 2023 2022 Expenses: Annuity: Insurance policy benefits $ 8.7 $ 9.5 Interest credited 48.1 42.5 Amortization and non-deferred commissions 16.4 14.6 Total annuity expenses 73.2 66.6 Health: Insurance policy benefits 318.1 323.1 Amortization and non-deferred commissions 40.8 41.6 Total health expenses 358.9 364.7 Life: Insurance policy benefits 147.2 153.1 Interest credited 12.1 12.0 Amortization, non-deferred commissions and advertising expense 48.6 47.7 Total life expenses 207.9 212.8 Allocated expenses 157.5 144.8 Expenses not allocated to product lines 19.9 17.6 Market value changes of options credited to fixed indexed annuity and life policyholders 18.6 (71.9) Amounts netted in investment income not allocated to product lines: Interest expense 37.4 18.1 Interest credited 7.2 6.9 Impact of annual option forfeitures related to fixed indexed annuity surrenders — (1.6) Amortization .4 .4 Other expenses 7.3 (4.2) Expenses netted in fee revenue: Commissions and other operating expenses 35.8 30.4 Total segment expenses 924.1 784.6 Pre-tax measure of profitability: Annuity margin 57.3 55.9 Health margin 116.5 115.3 Life margin 47.4 36.0 Total insurance product margin 221.2 207.2 Allocated expenses (157.5) (144.8) Income from insurance products 63.7 62.4 Fee income 15.5 9.9 Investment income not allocated to product lines 15.5 27.0 Expenses not allocated to product lines (18.3) (14.8) Operating earnings before taxes 76.4 84.5 Income tax expense on operating income 17.8 20.0 Net operating income $ 58.6 $ 64.5 A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions): Three months ended March 31, 2023 2022 Total segment revenues $ 1,000.5 $ 869.1 Total investment losses (14.6) (32.7) Revenues related to earnings attributable to VIEs 20.1 6.5 Consolidated revenues 1,006.0 842.9 Total segment expenses 924.1 784.6 Insurance policy benefits - changes in fair value of embedded derivative liabilities and market risk benefits 65.1 (165.4) Expenses attributable to VIEs 17.8 6.1 Fair value changes related to agent deferred compensation plan — (22.7) Consolidated expenses 1,007.0 602.6 Income (loss) before tax (1.0) 240.3 Income tax expense (benefit) on period income (loss) (.2) 56.9 Net income (loss) (.8) $ 183.4

ACCOUNTING FOR DERIVATIVES

ACCOUNTING FOR DERIVATIVES	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
ACCOUNTING FOR DERIVATIVES	ACCOUNTING FOR DERIVATIVES Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions): Fair value March 31, December 31, 2022 Assets: Other invested assets: Fixed indexed call options $ 108.2 $ 56.7 Reinsurance receivables (16.4) (17.8) Total assets $ 91.8 $ 38.9 Liabilities: Future policy benefits: Fixed indexed products $ 1,347.9 $ 1,297.0 Total liabilities $ 1,347.9 $ 1,297.0 We are required to establish an embedded derivative related to a modified coinsurance agreement pursuant to which we assume the risks of a block of health insurance business. The embedded derivative represents the mark-to-market adjustment for approximately $88 million in underlying investments held by the ceding reinsurer at March 31, 2023. Our fixed indexed annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period. We are generally able to change the participation rate at the beginning of each index period (typically on each policy anniversary date), subject to contractual minimums. The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked. The notional amount of these options was $2.7 billion and $2.8 billion at March 31, 2023 and December 31, 2022, respectively. We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value recognized in net income. The following table provides the pre-tax gains (losses) recognized in revenues for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions): Three months ended March 31, 2023 2022 Net investment income (loss) from policyholder and other special-purpose portfolios: Fixed indexed call options $ 18.6 $ (72.9) Total investment gains (losses): Embedded derivative related to modified coinsurance agreement 1.4 (6.5) Total revenues from derivative instruments, not designated as hedges $ 20.0 $ (79.4) Derivative Counterparty Risk If the counterparties to the call options fail to meet their obligations, we may recognize a loss. We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy. At March 31, 2023, all of our counterparties were rated "A-" or higher by S&P Global Ratings ("S&P"). The Company and its subsidiaries are parties to master netting arrangements with its counterparties related to entering into various derivative contracts. The following table summarizes information related to derivatives with master netting arrangements or collateral as of March 31, 2023 and December 31, 2022 (dollars in millions): Gross amounts not offset in the balance sheet Gross amounts recognized Gross amounts offset in the balance sheet Net amounts of assets presented in the balance sheet Financial instruments Cash collateral received Net amount March 31, 2023: Fixed indexed call options $ 108.2 $ — $ 108.2 $ — $ — $ 108.2 December 31, 2022: Fixed indexed call options 56.7 — 56.7 — — 56.7

REINSURANCE

REINSURANCE	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
REINSURANCE	REINSURANCE The cost of reinsurance ceded totaled $48.3 million and $52.0 million in the first quarters of 2023 and 2022, respectively. We deduct this cost from insurance policy income. Reinsurance recoveries netted against insurance policy benefits totaled $134.9 million and $93.9 million in the first quarters of 2023 and 2022, respectively. From time to time, we assume insurance from other companies. Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs. Reinsurance premiums assumed totaled $4.1 million and $4.9 million in the first quarters of 2023 and 2022, respectively. Insurance policy benefits related to reinsurance assumed totaled $4.7 million and $6.1 million in the first quarters of 2023 and 2022, respectively.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company's interim tax expense is based upon the estimated annual effective tax rate for the respective period. Under authoritative guidance, certain items are required to be excluded from the estimated annual effective tax rate calculation. Such items include changes in judgment about the realizability of deferred tax assets resulting from changes in projections of income expected to be available in future years, and items deemed to be unusual, infrequent, or that cannot be reliably estimated. In these cases, the actual tax expense or benefit applicable to that item is treated discretely and is reported in the same period as the related item. The components of income tax expense are as follows (dollars in millions): Three months ended March 31, 2023 2022 Current tax expense $ 14.0 $ 4.4 Deferred tax expense (benefit) (14.2) 52.5 Total income tax expense (benefit) $ (.2) $ 56.9 A reconciliation of the U.S. statutory corporate tax rate to the estimated annual effective rate, reflected in the consolidated statement of operations is as follows: Three months ended March 31, 2023 2022 U.S. statutory corporate rate 21.0 % 21.0 % Non-taxable income and nondeductible benefits, net (.4) — State taxes 2.7 2.7 Effective tax rate 23.3 % 23.7 % The components of the Company's income tax assets and liabilities are summarized below (dollars in millions): March 31, December 31, Deferred tax assets: Net federal operating loss carryforwards $ 149.9 $ 166.0 Net state operating loss carryforwards 2.5 2.5 Insurance liabilities 329.4 298.5 Indirect costs allocable to self-constructed real estate assets 224.4 214.8 Accumulated other comprehensive loss 470.1 552.4 Other — 7.3 Gross deferred tax assets 1,176.3 1,241.5 Deferred tax liabilities: Investments (34.8) (37.2) Present value of future profits and deferred acquisition costs (152.1) (148.9) Other (1.5) — Gross deferred tax liabilities (188.4) (186.1) Net deferred tax assets 987.9 1,055.4 Current income taxes prepaid .2 8.0 Income tax assets, net $ 988.1 $ 1,063.4 Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted. A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, are considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis using a deferred tax valuation model. Our model is adjusted to reflect changes in our projections of future taxable income. Our estimates of future taxable income are based on evidence we consider to be objectively verifiable. At March 31, 2023, our projection of future taxable income for purposes of determining the valuation allowance is based on our estimates of such future taxable income through the date our NOLs expire. Such estimates are subject to numerous risks and uncertainties and the extent to which actual impacts differ from the assumptions used in our deferred tax valuation model. Based on our assessment, we have concluded that it is more likely than not that all our deferred tax assets of $987.9 million will be realized through future taxable earnings. Recovery of our deferred tax asset is dependent on achieving the level of future taxable income projected in our deferred tax valuation model and failure to do so could result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future. The Internal Revenue Code (the "Code") limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of: (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities). There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities). Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when the company undergoes a 50 percent ownership change over a three-year period. Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes. Such transactions may include, but are not limited to, additional repurchases under our securities repurchase program, issuances of common stock and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future five percent or more of our outstanding common stock for their own account. Many of these transactions are beyond our control. If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income. The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (2.92 percent at March 31, 2023), and the annual restriction could limit our ability to use a substantial portion of our NOLs to offset future taxable income. We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of March 31, 2023, we were below the 50 percent ownership change level that could limit our ability to utilize our NOLs. We have $0.7 billion of federal non-life NOLs as of March 31, 2023, as summarized below (dollars in millions): Net operating loss Year of expiration carryforwards 2023 $ 127.4 2025 85.2 2026 149.9 2027 10.8 2028 80.3 2029 213.2 2030 .3 2031 .2 2032 44.4 2033 .6 2034 .9 2035 .8 Total federal non-life NOLs $ 714.0 Our non-life NOLs can be used to offset 35 percent of life insurance company taxable income and 100 percent of non-life company taxable income until all non-life NOLs are utilized or expire. We also had deferred tax assets related to NOLs for state income taxes of $2.5 million and $2.5 million at March 31, 2023 and December 31, 2022, respectively. The related state NOLs are available to offset future state taxable income in certain states and are expected to be fully utilized prior to expiration.

NOTES PAYABLE - DIRECT CORPORAT

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS	NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS The following notes payable were direct corporate obligations of the Company as of March 31, 2023 and December 31, 2022 (dollars in millions): March 31, December 31, 5.250% Senior Notes due May 2025 $ 500.0 $ 500.0 5.250% Senior Notes due May 2029 500.0 500.0 5.125% Subordinated Debentures due November 2060 150.0 150.0 Revolving Credit Agreement (as defined below) — — Unamortized debt issue costs (10.8) (11.2) Direct corporate obligations $ 1,139.2 $ 1,138.8 Revolving Credit Agreement The $250.0 million revolving credit agreement (the "Revolving Credit Agreement"), among other things, (i) requires the Company to maintain (each as calculated in accordance with the Revolving Credit Agreement): (i) a debt to total capitalization ratio (excluding hybrid securities, except to the extent that the aggregate amount outstanding of all such hybrid securities exceeds an amount equal to 15 percent of total capitalization) of not more than 35.0 percent (such ratio was 20.9 percent at March 31, 2023); and (ii) a minimum consolidated net worth of not less than the sum of (x) $2,674 million plus (y) 25.0 percent of the net equity proceeds received by the Company from the issuance and sale of equity interests in the Company (the Company's consolidated net worth was $3,696.2 million at March 31, 2023 compared to the minimum requirement of $2,696.2 million). The maturity date of the Revolving Credit Agreement is July 16, 2026. The Revolving Credit Agreement contains certain other restrictive covenants with which the Company must comply. The interest rate applicable to loans under the Revolving Credit Agreement is calculated as the Secured Overnight Financing Rate ("SOFR") (plus a credit spread adjustment of 0.10 percent for all available interest periods) or the base rate, at the Company’s option, plus a margin based on the Company’s unsecured debt rating. The margins under the Revolving Credit Agreement range from 1.375 percent to 2.125 percent, in the case of loans at the SOFR, and 0.375 percent to 1.125 percent, in the case of loans at the base rate. The commitment fee under the Revolving Credit Agreement is based on the Company's unsecured debt rating and the Revolving Credit Agreement includes updated benchmark interest rate replacement provisions. There were no amounts outstanding under the Revolving Credit Agreement during the three months ended March 31, 2023.

INVESTMENT BORROWINGS

INVESTMENT BORROWINGS	3 Months Ended
	Mar. 31, 2023
Investment Borrowings [Abstract]
INVESTMENT BORROWINGS	INVESTMENT BORROWINGS Three of the Company's insurance subsidiaries (Bankers Life and Casualty Company ("Bankers Life"), Washington National Insurance Company ("Washington National") and Colonial Penn Life Insurance Company ("Colonial Penn")) are members of the FHLB. As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB. We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings. At March 31, 2023, the carrying value of the FHLB common stock was $79.6 million. As of March 31, 2023, collateralized borrowings from the FHLB totaled $1.8 billion and the proceeds were used to purchase matched variable rate fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of $2.4 billion at March 31, 2023, which are maintained in a custodial account for the benefit of the FHLB. Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet. The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions): Amount Maturity Interest rate at borrowed date March 31, 2023 100.0 April 2024 Variable rate – 4.973% 22.0 May 2024 Variable rate – 5.202% 15.5 July 2024 Fixed rate – 1.990% 27.0 August 2024 Fixed rate – .640% 25.0 September 2024 Variable rate – 5.439% 21.7 May 2025 Variable rate – 5.114% 18.4 June 2025 Fixed rate – 2.940% 125.0 September 2025 Variable rate – 5.170% 100.0 October 2025 Variable rate – 5.246% 100.0 October 2025 Variable rate – 5.223% 57.7 October 2025 Variable rate – 5.185% 50.0 November 2025 Variable rate – 5.226% 50.0 January 2026 Variable rate – 5.168% 50.0 January 2026 Variable rate – 5.195% 100.0 January 2026 Variable rate – 5.064% 15.0 January 2026 Variable rate – 5.487% 21.8 May 2026 Variable rate – 4.954% 50.0 May 2026 Variable rate – 5.090% 75.0 December 2026 Variable rate – 5.169% 75.0 January 2027 Variable rate – 5.060% 50.0 January 2027 Variable rate – 5.077% 50.0 January 2027 Variable rate – 5.204% 100.0 February 2027 Variable rate – 5.133% 50.0 April 2027 Variable rate – 5.135% 50.0 May 2027 Variable rate – 5.145% 100.0 June 2027 Variable rate – 5.190% 10.0 June 2027 Variable rate – 5.413% 75.0 January 2028 Variable rate – 5.174% 50.0 January 2028 Variable rate – 5.382% 50.0 January 2028 Variable rate – 5.236% 34.5 February 2028 Variable rate – 5.294% 21.0 February 2028 Variable rate – 5.156% 100.0 February 2028 Variable rate – 5.153% $ 1,839.6 Generally, the variable rate borrowings are pre-payable on each interest reset date without penalty. The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on prevailing market interest rates. At March 31, 2023, the aggregate yield maintenance fee to prepay all fixed rate borrowings was $1.0 million.

CHANGES IN COMMON STOCK

CHANGES IN COMMON STOCK	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
CHANGES IN COMMON STOCK	CHANGES IN COMMON STOCK In the first three months of 2023, we repurchased 0.6 million shares of common stock for $15.1 million under our securities repurchase program. The Company had remaining repurchase authority of $171.8 million as of March 31, 2023. In May 2023, the Company's Board of Directors approved an additional $500.0 million to repurchase the Company's outstanding shares of common stock. In the first three months of 2023, we issued 1.2 million shares of common stock, net of shares withheld to pay tax withholdings, pursuant to employee benefit plans. In the first three months of 2023, dividends declared on common stock totaled $16.4 million ($0.14 per common share). In May 2023, the Company increased its quarterly common stock dividend to $0.15 per share from $0.14 per share.

LITIGATION AND OTHER LEGAL PROC

LITIGATION AND OTHER LEGAL PROCEEDINGS	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
LITIGATION AND OTHER LEGAL PROCEEDINGS	LITIGATION AND OTHER LEGAL PROCEEDINGS Legal Proceedings The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals. On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association , in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary duty claims against Wilmington. The Wilmington Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division. On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties are vigorously contesting the plaintiff's claims. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. After the stay is lifted, the court will address the CNO Parties’ and other defendants’ motions to dismiss the Amended Complaint on numerous other grounds. On June 28, 2019, BCLIC and Washington National commenced an action entitled Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The KPMG Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division. On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana (the "Court"). On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case. Regulatory Examinations and Fines Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending

CONSOLIDATED STATEMENT OF CAS_2

CONSOLIDATED STATEMENT OF CASH FLOWS	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
CONSOLIDATED STATEMENT OF CASH FLOWS	CONSOLIDATED STATEMENT OF CASH FLOWS The following reconciles net income (loss) to net cash from operating activities (dollars in millions): Three months ended March 31, 2023 2022 Cash flows from operating activities: Net income (loss) $ (.8) $ 183.4 Adjustments to reconcile net income (loss) to net cash from operating activities: Amortization and depreciation 65.7 61.1 Income taxes (6.4) 42.3 Insurance liabilities 173.3 (152.4) Accrual, amortization and fair value changes included in investment income (27.9) 52.2 Deferral of policy acquisition costs (89.8) (83.7) Net investment losses 14.6 32.7 Other (a) (46.8) (79.2) Net cash from operating activities $ 81.9 $ 56.4 _____________ (a) Primarily relates to: (i) changes in other assets and liabilities related to the timing of payments and receipts; and (ii) the change in fair value of the deferred compensation plan liability. Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions): Three months ended March 31, 2023 2022 Amounts related to employee benefit plans $ 6.5 $ 7.2

INVESTMENTS IN VARIABLE INTERES

INVESTMENTS IN VARIABLE INTEREST ENTITIES	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
INVESTMENTS IN VARIABLE INTEREST ENTITIES	INVESTMENTS IN VARIABLE INTEREST ENTITIES We have concluded that we are the primary beneficiary with respect to certain VIEs, which are consolidated in our financial statements. In consolidating the VIEs, we consistently use the financial information most recently distributed to investors in the VIE. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments. The assets held by the trusts are legally isolated and not available to the Company. The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company. The Company has no financial obligation to the VIEs beyond its investment in each VIE. Certain of our subsidiaries are noteholders of the VIEs. Another subsidiary of the Company is the investment manager for the VIEs. As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs. The following tables provide supplemental information about the assets and liabilities of the VIEs which have been consolidated in accordance with authoritative guidance (dollars in millions): March 31, 2023 VIEs Eliminations Net effect on Assets: Investments held by variable interest entities $ 1,017.9 $ — $ 1,017.9 Notes receivable of VIEs held by subsidiaries — (113.8) (113.8) Cash and cash equivalents held by variable interest entities 97.1 — 97.1 Accrued investment income 4.0 — 4.0 Income tax assets, net 16.6 — 16.6 Other assets 4.5 (.8) 3.7 Total assets $ 1,140.1 $ (114.6) $ 1,025.5 Liabilities: Other liabilities $ 26.8 $ (3.9) $ 22.9 Borrowings related to variable interest entities 1,065.4 — 1,065.4 Notes payable of VIEs held by subsidiaries 126.1 (126.1) — Total liabilities $ 1,218.3 $ (130.0) $ 1,088.3 December 31, 2022 VIEs Eliminations Net effect on Assets: Investments held by variable interest entities $ 1,077.6 $ — $ 1,077.6 Notes receivable of VIEs held by subsidiaries — (113.8) (113.8) Cash and cash equivalents held by variable interest entities 69.2 — 69.2 Accrued investment income 3.5 — 3.5 Income tax assets, net 19.6 — 19.6 Other assets 2.5 (.8) 1.7 Total assets $ 1,172.4 $ (114.6) $ 1,057.8 Liabilities: Other liabilities $ 29.3 $ (2.4) $ 26.9 Borrowings related to variable interest entities 1,104.6 — 1,104.6 Notes payable of VIEs held by subsidiaries 126.1 (126.1) — Total liabilities $ 1,260.0 $ (128.5) $ 1,131.5 The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade. At March 31, 2023, such loans had an amortized cost of $1,060.3 million; gross unrealized gains of $1.4 million; gross unrealized losses of $40.3 million; allowance for credit losses of $3.5 million; and an estimated fair value of $1,017.9 million. The following table summarizes changes in the allowance for credit losses related to corporate securities held by VIEs for the three months ended March 31, 2023 and 2022 (dollars in millions): Three months ended March 31, 2023 2022 Allowance at the beginning of the period $ 5.5 $ 3.7 Additions for securities for which credit losses were not previously recorded .3 1.5 Additions for purchased securities with deteriorated credit — — Additions (reductions) for securities where an allowance was previously recorded (.7) 1.3 Reduction for securities sold during the period (1.6) (.6) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — Write-offs — — Recoveries of previously written-off amount — — Allowance at the end of the period $ 3.5 $ 5.9 The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at March 31, 2023, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized Estimated (Dollars in millions) Due in one year or less $ 5.4 $ 4.7 Due after one year through five years 782.3 752.8 Due after five years through ten years 272.6 260.4 Total $ 1,060.3 $ 1,017.9 During the first three months of 2023, the VIEs recognized investment losses of $0.6 million which were comprised of: (i) $2.6 million of net losses from the sales of fixed maturities; and (ii) a decrease in the allowance for credit losses of $2.0 million. Such net realized losses included gross realized losses of $2.6 million from the sale of $5.6 million of investments. During the first three months of 2022, the VIEs recognized net investment losses of $3.2 million which were comprised of: (i) $0.8 million of net losses from the sales of fixed maturities; (ii) the change in market value of other investments of $(0.2) million; and (iii) an increase in the allowance for credit losses of $2.2 million. Such net realized losses included gross realized losses of $0.8 million from the sale of $11.7 million of investments. At March 31, 2023, there were no fixed maturity investments held by the VIEs in default. At March 31, 2023, the VIEs held: (i) investments (for which an allowance for credit losses has not been recorded) with a fair value of $214.9 million and gross unrealized losses not deemed to have credit losses of $3.3 million that had been in an unrealized loss position for less than twelve months; and (ii) investments (for which an allowance for credit losses has not been recorded) with a fair value of $571.3 million and gross unrealized losses not deemed to have credit losses of $19.4 million that had been in an unrealized loss position for twelve months or greater. At December 31, 2022, the VIEs held: (i) investments (for which an allowance for credit losses has not been recorded) with a fair value of $392.2 million and gross unrealized losses of $14.2 million that had been in an unrealized loss position for less than twelve months; and (ii) investments (for which an allowance for credit losses has not been recorded) with a fair value of $477.9 million and gross unrealized losses of $17.3 million that had been in an unrealized loss position for twelve months or greater. The investments held by the VIEs are evaluated for impairment in a manner that is consistent with the Company's fixed maturities, available for sale. In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager. These structured securities include asset-backed securities, collateralized loan obligations, commercial mortgage-backed securities, agency residential mortgage-backed securities and non-agency residential mortgage-backed securities. Our maximum exposure to loss on these securities is limited to our cost basis in the investment. We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses. At March 31, 2023, we held investments in various limited partnerships and hedge funds, in which we are not the primary beneficiary, totaling $578.5 million (classified as other invested assets). At March 31, 2023, we had unfunded commitments to these partnerships totaling $431.0 million. Our maximum exposure to loss on these investments is limited to the amount of our investment.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price. We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives. We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products and funding agreements, investment borrowings, notes payable and borrowings related to VIEs. The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value. Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value. Valuation Hierarchy There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable. • Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange-traded securities. • Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; and derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs. • Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities, certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed indexed annuity products and to a modified coinsurance arrangement), and funding agreements since their values include significant unobservable inputs including actuarial assumptions. At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value. This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions. Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. The vast majority of our assets carried at fair value use Level 2 inputs for the determination of fair value. These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value. Our Level 2 assets are valued as follows: • Fixed maturities available for sale, equity securities and trading securities Corporate securities are generally priced using market and income approaches using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity and credit spreads. U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity. States and political subdivisions are generally priced using the market approach using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads. Foreign governments are generally priced using the market approach using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances, benchmark yields, credit spreads and issuer rating. Asset-backed securities, agency and non-agency residential mortgage-backed securities, collateralized loan obligations and commercial mortgage-backed securities are generally priced using market and income approaches using independent pricing services. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates and issue specific information including, but not limited to, collateral type, seniority and vintage. Equity securities are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity and credit spreads. • Investments held by VIEs Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads. • Other invested assets - derivatives The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes, time value and volatility factors underlying options, market interest rates and non-performance risk. Third-party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. If there are no recently reported trades, the third-party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate. The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below. As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes: (i) a review of the methodology used by third-party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties. As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions. In those instances, we may request additional pricing quotes or apply internally developed valuations. However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received. The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes. Such inputs typically include: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data. The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments. For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes. These broker quotes are non-binding and represent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs. Approximately 86 percent of our Level 3 fixed maturity securities and trading securities were valued using unadjusted broker quotes or broker-provided valuation inputs. The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs. For these securities, we use internally developed valuations. Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market. For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate. The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity. In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity. The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at March 31, 2023 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 11,848.6 $ 127.8 $ 11,976.4 United States Treasury securities and obligations of United States government corporations and agencies — 170.1 — 170.1 States and political subdivisions — 2,462.6 — 2,462.6 Foreign governments — 78.6 — 78.6 Asset-backed securities — 1,299.1 41.1 1,340.2 Agency residential mortgage-backed securities — 215.9 — 215.9 Non-agency residential mortgage-backed securities — 1,606.7 33.8 1,640.5 Collateralized loan obligations — 918.9 — 918.9 Commercial mortgage-backed securities — 2,290.1 13.8 2,303.9 Total fixed maturities, available for sale — 20,890.6 216.5 21,107.1 Equity securities - corporate securities 31.1 — 75.0 106.1 Trading securities: Asset-backed securities — 25.5 — 25.5 Agency residential mortgage-backed securities — .3 — .3 Non-agency residential mortgage-backed securities — 58.3 .5 58.8 Commercial mortgage-backed securities — 123.5 — 123.5 Total trading securities — 207.6 .5 208.1 Investments held by variable interest entities - corporate securities — 1,017.9 — 1,017.9 Other invested assets: Derivatives — 108.2 — 108.2 Residual tranches — .9 19.2 20.1 Total other invested assets — 109.1 19.2 128.3 Market risk benefit asset — — 57.8 57.8 Assets held in separate accounts — 2.8 — 2.8 Total assets carried at fair value by category $ 31.1 $ 22,228.0 $ 369.0 $ 22,628.1 Liabilities: Market risk benefit liability $ — $ — $ 17.6 $ 17.6 Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) — — 1,347.9 1,347.9 Total liabilities carried at fair value by category $ — $ — $ 1,365.5 $ 1,365.5 The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2022 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 11,584.9 $ 127.8 $ 11,712.7 United States Treasury securities and obligations of United States government corporations and agencies — 158.7 — 158.7 States and political subdivisions — 2,388.5 — 2,388.5 Foreign governments — 74.7 — 74.7 Asset-backed securities — 1,230.0 57.0 1,287.0 Agency residential mortgage-backed securities — 175.0 — 175.0 Non-agency residential mortgage-backed securities — 1,492.3 56.2 1,548.5 Collateralized loan obligations — 782.5 3.4 785.9 Commercial mortgage-backed securities — 2,207.9 14.5 2,222.4 Total fixed maturities, available for sale — 20,094.5 258.9 20,353.4 Equity securities - corporate securities 59.6 — 75.7 135.3 Trading securities: Asset-backed securities — 15.1 — 15.1 Agency residential mortgage-backed securities — .3 — .3 Non-agency residential mortgage-backed securities — 60.2 .5 60.7 Commercial mortgage-backed securities — 131.8 — 131.8 Total trading securities — 207.4 .5 207.9 Investments held by variable interest entities - corporate securities — 1,077.6 — 1,077.6 Other invested assets: Derivatives — 56.7 — 56.7 Residual tranches — — 18.3 18.3 Total other invested assets — 56.7 18.3 75.0 Market risk benefit asset — — 65.3 65.3 Assets held in separate accounts — 2.7 — 2.7 Total assets carried at fair value by category $ 59.6 $ 21,438.9 $ 418.7 $ 21,917.2 Liabilities: Market risk benefit liability $ — $ — $ 11.3 $ 11.3 Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) — — 1,297.0 1,297.0 Total liabilities carried at fair value by category $ — $ — $ 1,308.3 $ 1,308.3 The fair value of our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions): March 31, 2023 Quoted prices in active markets for identical assets or liabilities Significant other observable inputs Significant unobservable inputs Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,557.5 $ 1,557.5 $ 1,676.1 Policy loans — — 123.0 123.0 123.0 Other invested assets: Company-owned life insurance — 201.3 — 201.3 201.3 Cash and cash equivalents: Unrestricted 425.0 — — 425.0 425.0 Held by variable interest entities 97.1 — — 97.1 97.1 Liabilities: Policyholder account liabilities — — 15,302.9 15,302.9 15,302.9 Investment borrowings — 1,840.6 — 1,840.6 1,839.6 Borrowings related to variable interest entities — 1,034.8 — 1,034.8 1,065.4 Notes payable – direct corporate obligations — 1,079.5 — 1,079.5 1,139.2 December 31, 2022 Quoted prices in active markets for identical assets or liabilities Significant other observable inputs Significant unobservable inputs Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,273.6 $ 1,273.6 $ 1,411.9 Policy loans — — 121.6 121.6 121.6 Other invested assets: Company-owned life insurance — 199.1 — 199.1 199.1 Cash and cash equivalents: Unrestricted 575.7 — — 575.7 575.7 Held by variable interest entities 69.2 — — 69.2 69.2 Liabilities: Policyholder account liabilities — — 15,234.2 15,234.2 15,234.2 Investment borrowings — 1,640.5 — 1,640.5 1,639.5 Borrowings related to variable interest entities — 1,066.3 — 1,066.3 1,104.6 Notes payable – direct corporate obligations — 1,077.0 — 1,077.0 1,138.8 The following table presents additional information about assets measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended March 31, 2023 (dollars in millions): March 31, 2023 Beginning balance as of December 31, 2022 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Ending balance as of March 31, 2023 Amount of total gains (losses) for the three months ended March 31, 2023 included in our net income relating to assets still held as of the reporting date Amount of total gains (losses) for the three months ended March 31, 2023 included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 127.8 $ (.5) $ .1 $ .9 $ 5.9 $ (6.4) $ 127.8 $ .1 $ .1 Asset-backed securities 57.0 (5.1) (.2) (.2) — (10.4) 41.1 — (.5) Non-agency residential mortgage-backed securities 56.2 (.2) — 2.3 — (24.5) 33.8 — 2.4 Collateralized loan obligations 3.4 — — — — (3.4) — — — Commercial mortgage-backed securities 14.5 — — (.7) — — 13.8 — (.7) Total fixed maturities, available for sale 258.9 (5.8) (.1) 2.3 5.9 (44.7) 216.5 .1 1.3 Equity securities - corporate securities 75.7 — (.7) — — — 75.0 (.7) — Trading securities - non-agency residential mortgage-backed securities .5 — — — — — .5 — — Other invested assets - residual tranches 18.3 .5 .4 — — — 19.2 .4 — _________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities. The following summarizes such activity for the three months ended March 31, 2023 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ .9 $ (1.4) $ — $ — $ (.5) Asset-backed securities 2.3 (7.4) — — (5.1) Non-agency residential mortgage-backed securities — (.2) — — (.2) Total fixed maturities, available for sale 3.2 (9.0) — — (5.8) Other invested assets - residual tranches .7 (.2) — — .5 The following table presents additional information about assets measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended March 31, 2022 (dollars in millions): March 31, 2022 Beginning balance as of December 31, 2021 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of March 31, 2022 Amount of total gains (losses) for the three months ended March 31, 2022 included in our net income relating to assets still held as of the reporting date Amount of total gains (losses) for the three months ended March 31, 2022 included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 89.7 $ — $ (1.4) $ (6.5) $ 36.2 $ — $ 118.0 $ (2.1) $ (6.5) Asset-backed securities 26.6 15.9 — (1.3) — — 41.2 — (1.3) Non-agency residential mortgage-backed securities — — — (.6) 5.0 — 4.4 — (.6) Collateralized loan obligations 5.0 10.0 — (.2) — (5.0) 9.8 — (.2) Commercial mortgage-backed securities 19.0 — — (1.5) — — 17.5 — (1.5) Total fixed maturities, available for sale 140.3 25.9 (1.4) (10.1) 41.2 (5.0) 190.9 (2.1) (10.1) Equity securities - corporate securities 11.5 (2.9) (.2) — — — 8.4 (.2) — Trading securities: Non-agency residential mortgage-backed securities 3.5 — — — — (3.5) — — — Commercial mortgage-backed securities 12.9 — (.4) .2 — — 12.7 (.4) — Total trading securities 16.4 — (.4) .2 — (3.5) 12.7 (.4) — Investments held by variable interest entities - corporate securities 2.2 (2.1) (.1) — — — — — — ____________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities. The following summarizes such activity for the three months ended March 31, 2022 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 9.4 $ (9.4) $ — $ — $ — Asset-backed securities 16.0 (.1) — — 15.9 Collateralized loan obligations 10.0 — — — 10.0 Total fixed maturities, available for sale 35.4 (9.5) — — 25.9 Equity securities - corporate securities .3 (3.2) — — (2.9) Investments held by variable interest entities - corporate securities — (2.1) — — (2.1) Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3. Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios or investment gains (losses) within the consolidated statement of operations; or accumulated other comprehensive income (loss) within shareholders' equity based on the appropriate accounting treatment for the instrument. The amount presented for gains (losses) included in our net income for assets still held as of the reporting date primarily represents: (i) the change in allowance for credit losses for fixed maturities, available for sale; and (ii) changes in fair value of equity securities and trading securities that are held as of the reporting date. The amount presented for gains (losses) included in accumulated other comprehensive income (loss) for assets still held as of the reporting date primarily represents changes in the fair value of fixed maturities, available for sale, that are held as of the reporting date. At March 31, 2023, 87 percent of our Level 3 fixed maturities, available for sale, were investment grade and 59 percent of our Level 3 fixed maturities, available for sale, consisted of corporate securities. The following table summarizes changes in the value of our embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) which are measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value (dollars in millions): Three months ended March 31, 2023 2022 Balance at beginning of the period $ 1,297.0 $ 1,724.1 Premiums less benefits (14.0) 21.1 Change in fair value, net 64.9 (201.7) Balance at end of the period $ 1,347.9 $ 1,543.5 The change in fair value, net for each period in our embedded derivatives is included in the consolidated statement of operations. The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at March 31, 2023 (dollars in millions): Fair value at March 31, 2023 Valuation techniques Unobservable inputs Range (weighted average) (a) Assets: Corporate securities (b) $ 2.9 Discounted cash flow analysis Discount margins 2.41% Corporate securities (c) 3.5 Recovery method Percent of recovery expected 0.00% - 35.00% (35.00%) Corporate securities (d) .5 Unadjusted purchase price Not applicable Not applicable Asset-backed securities (e) 23.1 Discounted cash flow analysis Discount margins 1.99% - 4.02% (3.20%) Equity securities (f) 63.6 Market comparables EBITDA multiples 8.8X Equity securities (g) .1 Recovery method Percent of recovery expected 0.00% - 100.00% (100.00%) Equity securities (h) 11.4 Unadjusted purchase price Not applicable Not applicable Other assets categorized as Level 3 (i) 206.1 Unadjusted third-party price source Not applicable Not applicable Market risk benefit asset (k) 57.8 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.45%) Utilization rates 5.92% - 47.62% (22.54%) Total 369.0 Liabilities: Market risk benefit liability (k) 17.6 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.45%) Utilization rates 5.92% - 47.62% (22.54%) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) (j) 1,347.9 Discounted projected embedded derivatives Projected portfolio yields 4.30% - 4.63% (4.31%) Discount rates 3.47% - 5.33% (4.13%) Surrender rates 1.90% - 27.70% (9.20%) ________________________________ (a) The weighted average is based on the relative fair value of the related assets or liabilities. (b) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (c) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (d) Corporate securities - For these assets, there were no adjustments to the purchase price. (e) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (f) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements. (g) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (h) Equity securities - For these assets, there were no adjustments to the purchase price. (i) Other assets categorized as Level 3 - For these assets, there were no adjustments to non-binding quoted market prices obtained from third-party pricing sources. (j) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed indexed annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would have resulted in a higher (lower) fair value measurement. The discount rate is based on risk free rates (U.S. Treasury rates for similar durations) adjusted for our non-performance risk and risk margins for non-capital market inputs. Increases (decreases) in the discount rates would have resulted in a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative. (k) Market risk benefits – Many of our fixed indexed annuity products include a GLWB that is considered a MRB. The calculation of the value of MRBs are based on significant unobservable inputs including assumptions related to surrenders and utilization of policy benefits. These assumptions are based on actuarial estimates and past experience. Increases in assumed surrender rates would generally increase the value of a MRB asset or decrease the value of a MRB liability (with decreases in assumed surrender rates having the opposite impacts). Increases in utilization rates would generally decrease the value of a MRB asset or increase the value of a MRB liability (with decreases in utilization rates having the opposite impacts). The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2022 (dollars in millions): Fair value at December 31, 2022 Valuation techniques Unobservable inputs Range (weighted average) (a) Assets: Corporate securities (b) $ 2.9 Discounted cash flow analysis Discount margins 2.23% - 3.94% (2.25%) Corporate securities (c) 3.5 Recovery method Percent of recovery expected 0.00% - 35.00% (35.00%) Corporate securities (d) .5 Unadjusted purchase price Not applicable Not applicable Asset-backed securities (e) 21.8 Discounted cash flow analysis Discount margins 2.50% - 3.86% (3.30%) Equity securities (f) 63.9 Market comparables EBITDA multiples 8.5X Equity securities (g) .1 Recovery method Percent of recovery expected 0.00% - 100.00% (100.00%) Equity securities (h) 11.7 Unadjusted purchase price Not applicable Not applicable Other assets categorized as Level 3 (i) 249.0 Unadjusted third-party price source Not applicable Not applicable Market risk benefit asset (k) 65.3 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.68%) Utilization rates 6.78% - 63.16% (20.09%) Total 418.7 Liabilities: Market risk benefit liability (k) 11.3 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.68%) Utilization rates 6.78% - 63.16% (20.09%) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) (j) 1,297.0 Discount

BUSINESS AND BASIS OF PRESENT_2

BUSINESS AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), allowance for credit losses and other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements could be materially affected.
Consolidation	The accompanying financial statements are unaudited and include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.
Deferred acquisition costs, present value of future profits and sales inducements	Deferred acquisition costs, present value of future profits and sales inducements Deferred acquisition costs represent policy acquisition costs that have been capitalized and are subject to amortization. Capitalized costs are incremental costs directly related to the successful acquisition of new or renewal insurance contracts. Such costs consist primarily of commissions, underwriting, sales and contract issuance and processing expenses. Contracts are grouped by contract type and issue year into cohorts consistent with the grouping used in estimating the associated liability. Deferred acquisition costs are amortized on a constant level basis for the grouped contracts over the expected term of the related contracts to approximate straight-line amortization. For life and health insurance products, the constant level basis used is policy counts. For all annuity products, the constant level basis used is the initial deposit in force. The constant level bases used for amortization are projected using mortality and lapse assumptions that are based on our experience, industry data, and other factors and are consistent with those used for the liability for future policy benefits. If those projected assumptions change in future periods, they will be reflected in the cohort level amortization basis at the time. Unexpected lapses, due to higher mortality and lapse experience than expected, are recognized in the current period as a reduction of the capitalized balances. Changes in future estimates are recognized prospectively over the remaining expected contract term. The carrying amount of deferred acquisition costs is not subject to recovery testing upon the adoption of ASU 2018-12. The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the effective date of the bankruptcy reorganization of our Predecessor). The present value of future profits is amortized in the same manner as described above for deferred acquisition costs, although such balances are subject to periodic recovery testing.
Market risk benefits	Market risk benefits Market risk benefits ("MRBs") are contracts or contract features that both provide protection to the contract holder from other-than-nominal capital market risk and expose the Company to other-than-nominal capital market risk. Many of our fixed indexed annuity products include a guaranteed living withdrawal benefit ("GLWB") that is considered a MRB. MRBs are measured at fair value using an option-based valuation model based on amount of exposure, market data, Company experience and other factors. Changes in fair value are recognized in earnings each period with the exception of the portion of the change in fair value due to a change in the instrument-specific credit risk, which is recognized in accumulated other comprehensive income (loss). MRBs in an asset position are presented separately from those in a liability position as there is no legal right of offset between contracts.
Policyholder account balances	Policyholder account balances Policyholder account balances represent the contract value that has accrued to the benefit of the policyholder as of the balance sheet date. It includes the accumulated account deposits, plus interest credited, less policyholder withdrawals and, if applicable, charges assessed. This balance also includes liabilities for the funding agreement-backed notes ("FABN").
Liability for future policy benefits	Liability for future policy benefits The liability for future policy benefits is the present value of estimated future policy benefits to be paid to or on behalf of policyholders and certain related expenses (where the timing and amount of payment depends on policyholder mortality or morbidity), less the present value of estimated future net premiums to be collected from policyholders (where net premiums are gross premiums multiplied by the net-to-gross ratio discussed below). The liability for future policy benefits is accrued over time as premium revenue is recognized. The liability is estimated using current assumptions that include discount rates, mortality, morbidity, lapse/withdrawal rates and expenses. Such assumptions are based on our historical experience, industry data, and other factors that are inherently uncertain. This liability also includes the amount of total reserves above (below) policyholder account balances for our fixed indexed annuity products due to the valuation of the related embedded derivative. The liability for future policy benefits is established using a net premium ratio approach where net premiums (the portion of gross premiums required to fund expected insurance benefits and claims settlement expenses) under the contract are accrued each period as the liability for future policy benefits. The net premium ratio used to accrue the liability for future policy benefits in each period is determined by using the historical and present value of expected future benefits and claim adjustment expenses for the cohort divided by the historical and present value of expected future gross premiums for the cohort. Our long duration insurance contracts are grouped into annual calendar-year cohorts primarily based on the contractual issue date, marketing distribution channel, legal entity and product type. Single premium contracts are grouped into separate cohorts from other traditional products. Riders are generally combined with the base policy. Insurance contracts which were issued prior to September 10, 2003 (the effective date of the bankruptcy reorganization of Conseco, Inc. (the "Predecessor")) are grouped by marketing distribution channel, legal entity and product type in a single issue year cohort. The liability is adjusted for differences between actual and expected experience. We review our historical and future cash flow assumptions quarterly and update the net premium ratio used to calculate the liability each time the assumptions are changed. Each quarter, we update our estimates of cash flows expected over the entire life of a group of contracts using actual historical experience and current future cash flow assumptions. These updated cash flows are used to calculate the revised net premiums and net premium ratio, which are used to derive an updated liability for future policy benefits as of the beginning of the current reporting period, discounted at the original contract issuance discount rate. This amount is then compared to the carrying amount of the liability as of that same date, before the updating of cash flow assumptions, to determine the current period change in liability estimate. This current period change in the liability is the liability remeasurement gain or loss and is presented as a separate component of benefit expense in the consolidated statement of operations. In subsequent periods, the revised net premiums are used to measure the liability for future policy benefits, subject to future revisions. If a cohort is in a loss position where the liability for future policy benefits plus the present value of expected future gross premiums is determined to be insufficient to provide for expected future policy benefits and claim settlement costs, the net to gross ratio is capped at 100 percent. When this occurs, all changes in expected benefits resulting from both actual experience deviations and changes in future assumptions are recognized immediately. The locked-in discount rate is generally based on expected investment returns at contract inception for contracts issued prior to January 1, 2021 and the upper medium grade fixed income corporate instrument yield ("A" credit rated corporate bond yield) at contract inception for contracts issued after January 1, 2021. The contract inception date for contracts issued by the Predecessor is September 10, 2003. The discount rate in effect at contract inception is locked-in for the calculation of the net to gross ratio and accretion of interest cost on the liability is recorded through net income. However, for balance sheet remeasurement purposes, the discount rate is updated using the current rate at each reporting period with the impact resulting from such updates recorded in other comprehensive income. We develop discount rate curves for discounting cash flows to calculate the liability for future policy benefits based on the duration characteristics of the underlying liabilities. For liability cash flows that are projected beyond the duration of market-observable A-credit-rated fixed-income instruments, we use the last market-observable yield level and use linear interpolation to determine yield assumptions for durations that do not have market-observable yields.
Liability for life insurance policy claims	Liability for life insurance policy claims The liability for life insurance policy claims include life policy and contract claims, including incurred but not reported claims. The liability for these claims is based on our estimated ultimate cost to settle all claims that have been incurred as of the reporting date. Such amounts are estimated based on an analysis of historical patterns of claims, which are continually reviewed and updated. Adjustments resulting from differences between our estimates and actual payments are recognized in the period the estimates are made or claims are paid.
Deferred profit liability	Deferred profit liability For limited-payment products, gross premiums received in excess of net premiums are deferred at initial recognition as a deferred profit liability ("DPL"). Gross premiums are measured using assumptions consistent with those used in the measurement of the liability for future policy benefits, including discount rate, mortality, lapses and expenses. The DPL is amortized and recognized in insurance policy benefits in proportion to insurance in force for life insurance contracts and expected future benefit payments for annuity contracts. Interest is accreted on the balance of the DPL using the discount rate determined at contract issuance. We review and update the estimate of cash flows for the DPL at the same time as the estimate of cash flows for the liability for future policy benefits. When cash flows are updated, the updated estimates are used to recalculate the DPL at contract issuance. The recalculated DPL as of the beginning of the current reporting period is compared to the carrying amount of the DPL as of the beginning of the current reporting period and any difference is recognized as either a charge or credit to insurance policy benefits. On the balance sheet, the DPL is recorded as a component of the liability for future policy benefits and was $57.7 million at March 31, 2023.
Reinsurance	Reinsurance We have determined that each of our reinsurance agreements provide indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Such reinsurance permits recovery of the reinsured losses from reinsurers, although it does not discharge our primary liability as the direct insurer of the risks reinsured. The reinsurance recoverable for traditional and limited-payment contracts is generally measured using a net premium ratio approach to accrue the projected net gain or loss on reinsurance in proportion to the gross premiums of the underlying reinsured cohorts. Such amount is adjusted on a quarterly basis for actual experience and at least once a year for any changes in cash flow assumptions.
Recently Adopted Accounting Standards and Adopted Accounting Standards	RECENTLY ADOPTED ACCOUNTING STANDARDS We adopted ASU 2018-12 effective January 1, 2023. The new guidance: (i) improves the timeliness of recognizing changes in the liability for future benefits and modifies the rate used to discount future cash flows; (ii) simplifies and improves the accounting for certain market-based options or guarantees associated with deposit (or account balance) contracts; (iii) simplifies the amortization of deferred acquisition costs; and (iv) requires enhanced disclosures, including disaggregated rollforwards of the liability for future policy benefits, policyholder account liabilities, market risk benefits and deferred acquisition costs. Additionally, qualitative and quantitative information about expected cash flows, estimates and assumptions is required. The new measurement guidance for traditional and limited-payment contract liabilities and the new guidance for the amortization of deferred acquisition costs was adopted on a modified retrospective transition approach. For contracts in-force at the transition date, we continue to use the existing locked-in investment yield interest rate assumption to calculate the net premium ratio, rather than the upper-medium grade fixed-income corporate instrument yield. However, for balance sheet remeasurement purposes, the current upper-medium grade fixed-income corporate instrument yield is used at transition through accumulated other comprehensive income (loss) and subsequently through other comprehensive income. For market risk benefits, we use the required retrospective application and were able to use hindsight to measure fair value components to the extent assumptions in a prior period are unobservable or otherwise unavailable.
Investments	We classify our fixed maturity securities into one of two categories: (i) "available for sale" (which we carry at estimated fair value with any unrealized gain or loss, net of tax and related adjustments, recorded as a component of shareholders' equity); or (ii) "trading" (which we carry at estimated fair value with changes in such value recognized as either net investment income (classified as investment income from policyholder and other special-purpose portfolios) or investment gains (losses)). Trading securities include: (i) investments purchased with the intent of selling in the near term to generate income; and (ii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in other investment gains (losses). We review our available for sale fixed maturity securities with unrealized losses to determine whether such impairments are the result of credit losses. We analyze various factors to make such determinations including, but not limited to: (i) actions taken by rating agencies; (ii) default by the issuer; (iii) the significance of the decline; (iv) an assessment of our intent to sell the security before recovering the security's amortized cost; (v) an economic analysis of the issuer's industry; and (vi) the financial strength, liquidity, and recoverability of the issuer. We perform a security by security review each quarter to evaluate whether a credit loss has occurred. In determining the credit loss component, we discount the estimated cash flows on a security by security basis. We consider the impact of macroeconomic conditions on inputs used to measure the amount of credit loss. For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees. For corporate bonds, cash flow estimates are derived by considering asset type, rating, time to maturity, and applying an expected loss rate. If a portion of the decline is due to credit-related factors, we separate the credit loss component of the impairment from the amount related to all other factors. The credit loss component is recorded as an allowance and reported in other investment gains (losses) (limited to the difference between estimated fair value and amortized cost). The impairment related to all other factors (non-credit factors) is reported in accumulated other comprehensive income (loss) along with unrealized gains (losses) related to fixed maturity investments, available for sale, net of tax and related adjustments. The allowance is adjusted for any additional credit losses and subsequent recoveries. When recognizing an allowance associated with a credit loss, the cost basis is not adjusted. When we determine a security is uncollectable, the remaining amortized cost will be written off. If we intend to sell an impaired fixed maturity security, available for sale, or identify an impaired fixed maturity security, available for sale, for which it is more likely than not we will be required to sell before anticipated recovery, the difference between the fair value and the amortized cost is included in other investment gains (losses) and the fair value becomes the new amortized cost. The new cost basis is not adjusted for any subsequent recoveries in fair value. The Company reports accrued investment income separately from fixed maturities, available for sale, and has elected not to measure an allowance for credit losses for accrued investment income. Accrued investment income is written off through net investment income at the time the issuer of the bond defaults or is expected to default on payments.
Earnings Per Share	Basic earnings per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period.  Restricted shares (including our performance units) are not included in basic earnings per share until vested.  Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options were exercised and restricted stock was vested.  The dilution from options and restricted shares is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options (or the vesting of the restricted stock and performance units).
Business Segments	We view our operations as three insurance product lines (annuity, health and life) and the investment and fee income segments. Our segments are aligned based on their common characteristics, comparability of profit margins and the way management makes operating decisions and assesses the performance of the business. Our insurance product line segments (annuity, health and life) include marketing, underwriting and administration of the policies our insurance subsidiaries sell. The business written in each of the three product categories through all of our insurance subsidiaries is aggregated allowing management and investors to assess the performance of each product category. When analyzing profitability of these segments, we use insurance product margin as the measure of profitability, which is: (i) insurance policy income; and (ii) net investment income allocated to the insurance product lines; less (i) insurance policy benefits and interest credited to policyholders; and (ii) amortization, non-deferred commissions and advertising expense. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average net insurance liabilities for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes insurance product margin and income from insurance products help provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines. We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company. The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. This structure unifies consumer capabilities into a single division and integrates the strength of our agent sales forces with one of the largest direct-to-consumer insurance businesses with proven experience in advertising, web/digital and call center support. The Worksite Division focuses on worksite and group sales for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually. With a separate Worksite Division, we are bringing a sharper focus to this high-growth business while further capitalizing on the strength of our wholly-owned subsidiary, Optavise, LLC ("Optavise"), a national provider of year-round technology-driven employee benefits management services. The Consumer and Worksite Divisions are primarily focused on marketing insurance products, several types of which are sold in both divisions and underwritten in the same manner. Sales of group underwritten policies are currently not significant, but are expected to increase within the Worksite Division. The investment segment involves the management of our capital resources, including investments and the management of corporate debt and liquidity. Our measure of profitability of this segment is the total net investment income not allocated to the insurance products. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable and investment borrowings; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank ("FHLB") investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investments income not allocated to product lines), net of interest expense on corporate debt. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program. Our fee income segment includes the earnings generated from sales of third-party insurance products, services provided by Optavise and the operations of our broker/dealer and registered investment advisor. Expenses not allocated to product lines include the expenses of our corporate operations, excluding interest expense on debt. We measure segment performance by excluding total investment gains (losses), changes in fair value of embedded derivative liabilities and market risk benefits, fair value changes related to the agent deferred compensation plan, income taxes and other non-operating items consisting primarily of earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business. Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Investment gains (losses), changes in fair value of embedded derivative liabilities and market risk benefits, fair value changes related to the agent deferred compensation plan and other non-operating items consisting primarily of earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments. Investment gains (losses) and changes in fair value of embedded derivative liabilities and market risk benefits may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business.
Fair Value Measurements	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price. We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives. We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products and funding agreements, investment borrowings, notes payable and borrowings related to VIEs. The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value. Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value. Valuation Hierarchy There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable. • Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange-traded securities. • Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; and derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs. • Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities, certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed indexed annuity products and to a modified coinsurance arrangement), and funding agreements since their values include significant unobservable inputs including actuarial assumptions. At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value. This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions. Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. The vast majority of our assets carried at fair value use Level 2 inputs for the determination of fair value. These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value. Our Level 2 assets are valued as follows: • Fixed maturities available for sale, equity securities and trading securities Corporate securities are generally priced using market and income approaches using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity and credit spreads. U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity. States and political subdivisions are generally priced using the market approach using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads. Foreign governments are generally priced using the market approach using independent pricing services. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances, benchmark yields, credit spreads and issuer rating. Asset-backed securities, agency and non-agency residential mortgage-backed securities, collateralized loan obligations and commercial mortgage-backed securities are generally priced using market and income approaches using independent pricing services. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates and issue specific information including, but not limited to, collateral type, seniority and vintage. Equity securities are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity and credit spreads. • Investments held by VIEs Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads. • Other invested assets - derivatives The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes, time value and volatility factors underlying options, market interest rates and non-performance risk. Third-party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. If there are no recently reported trades, the third-party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate. The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below. As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes: (i) a review of the methodology used by third-party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties. As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions. In those instances, we may request additional pricing quotes or apply internally developed valuations. However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received. The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes. Such inputs typically include: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data. The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments. For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes. These broker quotes are non-binding and represent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs. Approximately 86 percent of our Level 3 fixed maturity securities and trading securities were valued using unadjusted broker quotes or broker-provided valuation inputs. The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs. For these securities, we use internally developed valuations. Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market. For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate. The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity. In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

RECENTLY ADOPTED ACCOUNTING S_2

RECENTLY ADOPTED ACCOUNTING STANDARDS (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Impact of Adoption	The following summarizes the impact of adoption on the Transition Date (dollars in millions): January 1, 2021 Amounts prior to adoption of Effect of ASU 2018-12 adoption As recast Present value of future profits $ 249.4 $ 10.2 $ 259.6 Deferred acquisition costs 1,027.8 458.0 1,485.8 Reinsurance receivables 4,584.3 144.1 4,728.4 Market risk benefit asset — 2.5 2.5 Income tax assets, net 199.4 607.0 806.4 Total assets 35,339.9 1,221.8 36,561.7 Policyholder account balances 12,540.6 (172.9) 12,367.7 Future policy benefits 11,744.2 3,960.7 15,704.9 Market risk benefit liability — 114.8 114.8 Liability for policy and contract claims 561.8 (470.1) 91.7 Total liabilities 29,855.7 3,432.5 33,288.2 Retained earnings 752.3 (130.9) (a) 621.4 Accumulated other comprehensive income 2,186.1 (2,079.8) 106.3 Total shareholders' equity 5,484.2 (2,210.7) 3,273.5 _____________________ (a) The impact to retained earnings was primarily related to certain long-term care product cohorts where the present value of expected benefits exceeded the reserve at the Transition Date plus the present value of future gross premiums. As a result, the net premium ratio was capped at 100 percent with an immediate increase in the reserve for such cohorts. The following summarizes the impact of adoption on previously reported balances as of December 31, 2022 and as of and for the three months ended March 31, 2022 (dollars in millions): December 31, 2022 As previously Effect of reported adoption As recast Present value of future profits $ 212.2 $ (8.5) $ 203.7 Deferred acquisition costs 1,913.4 (142.5) 1,770.9 Reinsurance receivables 4,241.7 (18.3) 4,223.4 Market risk benefit asset — 65.3 65.3 Income tax assets, net 1,165.5 (102.1) 1,063.4 Total assets 33,339.2 (206.1) 33,133.1 Policyholder account balances 14,858.3 375.9 15,234.2 Future policy benefits 11,809.1 (568.9) 11,240.2 Market risk benefit liability — 11.3 11.3 Liability for policy and contract claims 456.5 (392.4) 64.1 Total liabilities 31,938.4 (574.1) 31,364.3 Retained earnings 1,459.0 232.2 1,691.2 Accumulated other comprehensive income (loss) (2,093.1) 135.8 (1,957.3) Total shareholders' equity 1,400.8 368.0 1,768.8 Three months ended March 31, 2022 As previously Effect of reported adoption As recast Insurance policy benefits $ 346.7 $ (12.8) $ 333.9 Liability for future policy benefits remeasurement loss — 7.0 7.0 Change in fair value of market risk benefits — (32.7) (32.7) Amortization 103.9 (51.6) 52.3 Other operating costs and expenses 219.2 (.9) 218.3 Total benefits and expenses 693.6 (91.0) 602.6 Income before income taxes 149.3 91.0 240.3 Income tax expense 37.0 19.9 56.9 Net income 112.3 71.1 183.4 As of March 31, 2022 As previously Effect of reported adoption As recast Retained earnings $ 1,223.5 $ 69.5 1,293.0 Accumulated other comprehensive income (loss) 380.5 (942.0) (561.5) Total shareholders' equity 3,690.9 (872.5) 2,818.4 The following tables detail the January 1, 2021 transition adjustments by providing a rollforward of the ending reported balances as of December 31, 2020 to the opening balances as of January 1, 2021 for retained earnings, accumulated other comprehensive income and the impacted insurance related balances (dollars in millions): January 1, 2021 Asset accounts Present value of future profits Deferred acquisition costs Reinsurance receivables Market risk benefit asset Income tax assets, net Amounts prior to adoption of ASU 2018-12 $ 249.4 $ 1,027.8 $ 4,584.3 $ — $ 199.4 Unwinding amounts related to unrealized gains (losses) 10.2 458.0 — — — Changes in measurement of assets — — (81.6) — — Change in discount rates — — 225.7 — — Changes in market benefit reserve basis — — — 2.5 — Tax impacts of changes recognized in accumulated other comprehensive income — — — — 570.3 Tax impacts of changes recognized in retained earnings — — — — 36.7 Amounts, as recast $ 259.6 $ 1,485.8 $ 4,728.4 $ 2.5 $ 806.4 January 1, 2021 Liability accounts Policyholder account balances Future policy benefits Market risk benefit liability Liability for policy and contract claims Amounts prior to adoption of ASU 2018-12 $ 12,540.6 $ 11,744.2 $ — $ 561.8 Unwinding amounts related to unrealized gains (losses) — (197.5) — — Changes in remeasurement of future policy benefits — 31.1 — — Changes in classification of liabilities (1) (172.9) 643.0 — (470.1) Reclass to market risk benefit liability — (66.6) 66.6 — Changes in market risk benefit reserve basis — — 48.2 — Change in discount rates — 3,550.7 — — Amounts, as recast $ 12,367.7 $ 15,704.9 $ 114.8 $ 91.7 _____________________ (1) Amount includes certain reclassifications to conform with the revised presentation of ASU 2018-12, such as reclassifying claims and benefits payable on long-duration health contracts to the liability for future policy benefits. January 1, 2021 Shareholders' equity accounts Accumulated other comprehensive income Retained earnings Amounts prior to adoption of ASU 2018-12 $ 2,186.1 $ 752.3 Unwinding amounts related to unrealized gains (losses) 665.7 — Changes in measurement of assets and liabilities — (112.7) Change in market risk benefit reserve basis 9.2 (54.9) Tax impacts of changes recognized in retained earnings — 36.7 Change in discount rates (3,325.0) — Tax impacts of changes recognized in accumulated other comprehensive income 570.3 — Amounts, as recast $ 106.3 $ 621.4

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income (loss), included in shareholders' equity as of March 31, 2023 and December 31, 2022, is comprised of the following (dollars in millions): March 31, December 31, Net unrealized losses on investments having no allowance for credit losses $ (937.1) $ (1,247.0) Unrealized losses on investments with an allowance for credit losses (1,453.6) (1,780.7) Change in discount rates for liability for future policy benefits 237.4 500.7 Change in instrument-specific credit risk for market risk benefits 13.1 12.2 Deferred income tax assets 475.8 557.5 Accumulated other comprehensive loss $ (1,664.4) $ (1,957.3)
Schedule of Fixed Maturities for Available for Sale Securities	At March 31, 2023, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Allowance for credit losses Estimated fair value Corporate securities $ 13,497.0 $ 66.3 $ (1,529.7) $ (57.2) $ 11,976.4 United States Treasury securities and obligations of United States government corporations and agencies 174.7 .1 (4.7) — 170.1 States and political subdivisions 2,789.4 34.1 (360.1) (.8) 2,462.6 Foreign governments 88.8 .2 (9.9) (.5) 78.6 Asset-backed securities 1,458.6 2.4 (120.2) (.6) 1,340.2 Agency residential mortgage-backed securities 213.3 2.8 (.2) — 215.9 Non-agency residential mortgage-backed securities 1,778.2 37.2 (174.9) — 1,640.5 Collateralized loan obligations 954.3 .5 (35.9) — 918.9 Commercial mortgage-backed securities 2,563.6 .1 (259.8) — 2,303.9 Total fixed maturities, available for sale $ 23,517.9 $ 143.7 $ (2,495.4) $ (59.1) $ 21,107.1 At December 31, 2022, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions): Amortized cost Gross unrealized gains Gross unrealized losses Allowance for credit losses Estimated fair value Corporate securities $ 13,649.1 $ 29.9 $ (1,911.9) $ (54.4) $ 11,712.7 United States Treasury securities and obligations of United States government corporations and agencies 171.7 — (13.0) — 158.7 States and political subdivisions 2,846.9 19.3 (476.8) (.9) 2,388.5 Foreign governments 86.3 .1 (11.3) (.4) 74.7 Asset-backed securities 1,435.7 1.0 (149.4) (.3) 1,287.0 Agency residential mortgage-backed securities 174.3 1.4 (.7) — 175.0 Non-agency residential mortgage-backed securities 1,700.4 40.0 (191.9) — 1,548.5 Collateralized loan obligations 825.2 .3 (39.6) — 785.9 Commercial mortgage-backed securities 2,494.6 .1 (272.3) — 2,222.4 Total fixed maturities, available for sale $ 23,384.2 $ 92.1 $ (3,066.9) $ (56.0) $ 20,353.4
Schedule of Investments Classified by Contractual Maturity Date	The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at March 31, 2023, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities (such as asset-backed securities, agency residential mortgage-backed securities, non-agency residential mortgage-backed securities, collateralized loan obligations and commercial mortgage-backed securities, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments. Amortized Estimated (Dollars in millions) Due in one year or less $ 140.1 $ 138.7 Due after one year through five years 2,209.3 2,080.0 Due after five years through ten years 1,871.8 1,742.8 Due after ten years 12,328.7 10,726.2 Subtotal 16,549.9 14,687.7 Structured securities 6,968.0 6,419.4 Total fixed maturities, available for sale $ 23,517.9 $ 21,107.1 The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2022, by contractual maturity. Amortized Estimated (Dollars in millions) Due in one year or less $ 112.0 $ 110.8 Due after one year through five years 1,913.7 1,790.2 Due after five years through ten years 2,098.9 1,910.4 Due after ten years 12,629.4 10,523.2 Subtotal 16,754.0 14,334.6 Structured securities 6,630.2 6,018.8 Total fixed maturities, available for sale $ 23,384.2 $ 20,353.4
Schedule of Unrealized Loss on Investments	The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at March 31, 2023 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair Unrealized Fair Unrealized Fair Unrealized Corporate securities $ 973.1 $ (35.5) $ 1,979.4 $ (322.6) $ 2,952.5 $ (358.1) United States Treasury securities and obligations of United States government corporations and agencies 106.8 (1.2) 33.7 (3.5) 140.5 (4.7) States and political subdivisions 207.5 (11.2) 397.4 (97.1) 604.9 (108.3) Foreign governments 15.2 (.3) 13.3 (1.2) 28.5 (1.5) Asset-backed securities 388.9 (12.9) 775.0 (103.2) 1,163.9 (116.1) Agency residential mortgage-backed securities 33.4 (.2) .6 — 34.0 (.2) Non-agency residential mortgage-backed securities 560.9 (27.1) 718.0 (147.8) 1,278.9 (174.9) Collateralized loan obligations 282.6 (6.5) 551.7 (29.4) 834.3 (35.9) Commercial mortgage-backed securities 520.3 (13.7) 1,738.3 (246.1) 2,258.6 (259.8) Total fixed maturities, available for sale $ 3,088.7 $ (108.6) $ 6,207.4 $ (950.9) $ 9,296.1 $ (1,059.5) The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2022 (dollars in millions): Less than 12 months 12 months or greater Total Description of securities Fair Unrealized Fair Unrealized Fair Unrealized Corporate securities $ 2,830.8 $ (329.4) $ 370.4 $ (129.3) $ 3,201.2 $ (458.7) United States Treasury securities and obligations of United States government corporations and agencies 134.4 (9.6) 21.9 (3.4) 156.3 (13.0) States and political subdivisions 667.0 (124.8) 132.1 (58.5) 799.1 (183.3) Foreign governments 35.0 (3.5) 2.1 (.3) 37.1 (3.8) Asset-backed securities 914.0 (90.1) 258.1 (53.4) 1,172.1 (143.5) Agency residential mortgage-backed securities 59.7 (.7) — — 59.7 (.7) Non-agency residential mortgage-backed securities 861.6 (89.7) 335.4 (102.2) 1,197.0 (191.9) Collateralized loan obligations 553.0 (27.4) 184.2 (12.2) 737.2 (39.6) Commercial mortgage-backed securities 1,581.4 (160.0) 593.3 (112.3) 2,174.7 (272.3) Total fixed maturities, available for sale $ 7,636.9 $ (835.2) $ 1,897.5 $ (471.6) $ 9,534.4 $ (1,306.8)
Schedule of Changes in the Allowance for Current Expected Credit Losses	The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2023 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2022 $ 54.4 $ .9 $ .4 $ .3 $ 56.0 Additions for securities for which credit losses were not previously recorded 3.0 — — — 3.0 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded .5 (.1) .1 .3 .8 Reduction for securities sold during the period (.7) — — — (.7) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2023 $ 57.2 $ .8 $ .5 $ .6 $ 59.1 The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2022 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2021 $ 7.4 $ — $ .2 $ — $ 7.6 Additions for securities for which credit losses were not previously recorded 14.0 .3 .1 — 14.4 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded 14.6 .5 (.2) .1 15.0 Reduction for securities sold during the period (.4) — — — (.4) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2022 $ 35.6 $ .8 $ .1 $ .1 $ 36.6 The following table summarizes changes in the allowance for credit losses related to corporate securities held by VIEs for the three months ended March 31, 2023 and 2022 (dollars in millions): Three months ended March 31, 2023 2022 Allowance at the beginning of the period $ 5.5 $ 3.7 Additions for securities for which credit losses were not previously recorded .3 1.5 Additions for purchased securities with deteriorated credit — — Additions (reductions) for securities where an allowance was previously recorded (.7) 1.3 Reduction for securities sold during the period (1.6) (.6) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — Write-offs — — Recoveries of previously written-off amount — — Allowance at the end of the period $ 3.5 $ 5.9
Schedule of Carrying Value and Estimated Fair Value of Outstanding Commercial Mortgage Loans and Underlying Collateral	The following table provides the amortized cost by year of origination and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of March 31, 2023 (dollars in millions): Estimated fair Loan-to-value ratio (a) 2023 2022 2021 2020 2019 Prior Total amortized cost Mortgage loans Collateral Less than 60% $ 73.6 $ 178.7 $ 114.4 $ 37.4 $ 75.1 $ 494.2 $ 973.4 $ 884.3 $ 3,553.3 60% to less than 70% — 87.3 26.2 5.7 — 56.8 176.0 159.7 269.3 70% to less than 80% — 47.8 10.1 — — 43.2 101.1 86.8 138.4 80% to less than 90% — — — — — — — — — 90% or greater — — — — — 24.6 24.6 19.5 26.1 Total $ 73.6 $ 313.8 $ 150.7 $ 43.1 $ 75.1 $ 618.8 $ 1,275.1 $ 1,150.3 $ 3,987.1 ________________
Schedule of Changes in the Allowance for Current Expected Credit Losses Related to Mortgage Loans	The following table summarizes changes in the allowance for credit losses related to mortgage loans for the three months ended March 31, 2023 and 2022 (dollars in millions): Three months ended March 31, 2023 2022 Allowance at the beginning of the period $ 8.0 $ 5.6 Current period provision for expected credit losses .4 (.5) Initial allowance recognized for purchased financial assets with credit deterioration — — Write-offs charged against the allowance — — Recoveries of amounts previously written off — — Allowance at the end of the period $ 8.4 $ 5.1
Schedule of Realized Gain (Loss) on Investments	The following table sets forth the total investment gains (losses) for the periods indicated (dollars in millions): Three months ended March 31, 2023 2022 Realized investment gains (losses): Gross realized gains on sales of fixed maturities, available for sale $ 7.3 $ 54.8 Gross realized losses on sales of fixed maturities, available for sale (14.4) (30.6) Equity securities, net (.2) (4.7) Other, net (7.3) (.7) Total realized investment gains (losses) (14.6) 18.8 Change in allowance for credit losses (a) (1.5) (30.7) Change in fair value of equity securities (b) .4 (1.2) Other changes in fair value (c) 1.1 (19.6) Other investment losses — (51.5) Total investment losses $ (14.6) $ (32.7) _________________ (a) Changes in the allowance for credit losses includes $2.0 million and $(2.2) million in the three months ended March 31, 2023 and 2022, respectively, related to investments held by variable interest entities ("VIEs"). (b) Changes in the estimated fair value of equity securities (that are still held as of the end of the respective periods) were $0.3 million and $(5.2) million for the three months ended March 31, 2023 and 2022, respectively.

LIABILITIES FOR INSURANCE PRO_2

LIABILITIES FOR INSURANCE PRODUCTS (Tables)	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
Schedule of Balances and Changes in the Liability for Future Policy Benefits	The following tables summarize balances and changes in the liability for future policy benefits for traditional and limited-payment contracts for the three months ended March 31, 2023 (dollars in millions): Three months ended March 31, 2023 Supplemental health Medicare supplement Long-term care Traditional life Other annuities Present value of expected net premiums ("PVENP"), beginning of period $ 2,781.3 $ 2,800.6 $ 1,034.1 $ 2,175.0 $ — Effect of changes in discount rate assumptions, beginning of period 188.4 196.4 23.2 137.1 — Beginning PVENP at original discount rate 2,969.7 2,997.0 1,057.3 2,312.1 — Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience (17.2) 27.0 (3.4) (14.1) — Adjusted beginning of period PVENP 2,952.5 3,024.0 1,053.9 2,298.0 — Issuances 63.7 101.6 15.7 108.3 1.1 Interest accrual 32.0 30.5 12.3 23.0 — Net premiums collected (90.3) (113.4) (40.6) (101.4) (1.1) Ending PVENP at original discount rate 2,957.9 3,042.7 1,041.3 2,327.9 — Effect of changes in discount rate assumptions, end of period (120.4) (139.2) (4.6) (92.5) — PVENP, end of period $ 2,837.5 $ 2,903.5 $ 1,036.7 $ 2,235.4 $ — Present value of expected future policy benefits ("PVEFPB"), beginning of period $ 5,886.8 $ 3,033.1 $ 4,158.1 $ 4,417.9 $ 310.9 Effect of changes in discount rate assumptions, beginning of period 483.3 212.0 28.5 336.6 15.4 Beginning PVEFPB at original discount rate 6,370.1 3,245.1 4,186.6 4,754.5 326.3 Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience (20.5) 32.2 (6.3) (15.2) .7 Adjusted beginning of period PVEFPB 6,349.6 3,277.3 4,180.3 4,739.3 327.0 Issuances 63.7 101.6 15.7 108.3 1.1 Interest accrual 73.8 33.2 55.5 51.0 3.7 Benefit payments (99.5) (125.6) (71.3) (115.0) (8.6) Ending PVEFPB at original discount rate 6,387.6 3,286.5 4,180.2 4,783.6 323.2 Effect of changes in discount rate assumptions, end of period (306.8) (150.0) 86.4 (223.0) (6.9) PVEFPB, end of period $ 6,080.8 $ 3,136.5 $ 4,266.6 $ 4,560.6 $ 316.3 Net liability for future policy benefits $ 3,243.3 $ 233.0 $ 3,229.9 $ 2,325.2 $ 316.3 Flooring impact — .4 — — — Adjusted net liability for future policy benefits 3,243.3 233.4 3,229.9 2,325.2 316.3 Related reinsurance recoverable (2.4) — (357.5) (201.1) — Net liability for future policy benefits, net of reinsurance recoverable $ 3,240.9 $ 233.4 $ 2,872.4 $ 2,124.1 $ 316.3 The following tables summarize balances and changes in the liability for future policy benefits for traditional and limited-payment contracts for the three months ended March 31, 2022 (dollars in millions): Three months ended March 31, 2022 Supplemental health Medicare supplement Long-term care Traditional life Other annuities PVENP, beginning of period $ 3,496.8 $ 3,454.0 $ 1,313.4 $ 2,483.7 $ — Effect of changes in discount rate assumptions, beginning of period (525.6) (341.8) (183.2) (239.4) — Beginning PVENP at original discount rate 2,971.2 3,112.2 1,130.2 2,244.3 — Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience 6.3 21.2 (8.9) (11.8) — Adjusted beginning of period PVENP 2,977.5 3,133.4 1,121.3 2,232.5 — Issuances 80.6 68.0 25.7 149.3 1.6 Interest accrual 31.3 30.4 13.1 20.9 — Net premiums collected (89.5) (119.0) (42.7) (99.9) (1.6) Ending PVENP at original discount rate 2,999.9 3,112.8 1,117.4 2,302.8 — Effect of changes in discount rate assumptions, end of period 213.4 112.1 94.2 72.5 — PVENP, end of period $ 3,213.3 $ 3,224.9 $ 1,211.6 $ 2,375.3 $ — PVEFPB, beginning of period $ 7,688.0 $ 3,750.5 $ 5,501.6 $ 5,395.7 $ 431.9 Effect of changes in discount rate assumptions, beginning of period (1,414.8) (373.8) (1,291.2) (767.3) (88.4) Beginning PVEFPB at original discount rate 6,273.2 3,376.7 4,210.4 4,628.4 343.5 Effect of changes in cash flow assumptions — — — — — Effect of actual variances from expected experience 5.6 21.5 (9.2) (8.5) (1.3) Adjusted beginning of period PVEFPB 6,278.8 3,398.2 4,201.2 4,619.9 342.2 Issuances 80.8 67.3 25.7 149.4 1.9 Interest accrual 72.5 33.2 56.1 48.8 3.9 Benefit payments (99.5) (123.3) (64.2) (128.8) (9.3) Ending PVEFPB at original discount rate 6,332.6 3,375.4 4,218.8 4,689.3 338.7 Effect of changes in discount rate assumptions, end of period 622.3 123.9 747.4 296.2 44.6 PVEFPB, end of period $ 6,954.9 $ 3,499.3 $ 4,966.2 $ 4,985.5 $ 383.3 Net liability for future policy benefits $ 3,741.6 $ 274.4 $ 3,754.6 $ 2,610.2 $ 383.3 Flooring impact 1.5 .2 .6 .4 — Adjusted net liability for future policy benefits 3,743.1 274.6 3,755.2 2,610.6 383.3 Related reinsurance recoverable (3.2) — (407.0) (242.1) — Net liability for future policy benefits, net of reinsurance recoverable $ 3,739.9 $ 274.6 $ 3,348.2 $ 2,368.5 $ 383.3 The following table reconciles the net liability for future policy benefits to the amount presented in the consolidated balance sheet (dollars in millions): March 31, 2023 March 31, 2022 Balances included in the future policy benefits rollforwards: Supplemental health $ 3,243.3 $ 3,743.1 Medicare supplement 233.4 274.6 Long-term care 3,229.9 3,755.2 Traditional life 2,325.2 2,610.6 Other annuities 316.3 383.3 Reserves excluded from rollforward (1) 2,593.3 2,626.5 Deferred profit liability 57.7 51.3 Amount of reserves above (below) policyholder account balances (2) (410.5) (273.1) Future loss reserves (3) 34.7 34.6 Future policy benefits $ 11,623.3 $ 13,206.1 _______________ (1) Primarily comprised of blocks of business that are 100% ceded. (2) Such amount represents the difference between: (i) the total insurance liabilities for our fixed indexed annuities (including the host contract and the related embedded derivative); and (ii) the policyholder account balances for these products. The accounting requirement to bifurcate the embedded derivative and value it at the current estimated fair value results in this amount. (3) In certain instances, the total insurance liabilities for a particular line of business may not be deficient in the aggregate to trigger loss recognition, but the pattern of earnings may be such that profits are expected to be recognized in earlier years followed by losses in later years. In these situations, accounting standards require that an additional liability (the "future loss reserve") be recognized by an amount necessary to sufficiently offset the losses that would be recognized in later years. The following table summarizes the amount of revenue and interest related to traditional and limited-payment contracts recognized in the consolidated statement of operations (dollars in millions): Gross premiums (a) Interest accretion (b) Three months ended Three months ended March 31, March 31, 2023 2022 2023 2022 Other annuity $ 1.3 $ 2.2 $ 3.7 $ 3.9 Supplemental health 179.4 175.7 41.8 41.2 Medicare supplement 159.2 167.6 2.7 2.8 Long-term care 82.7 82.4 43.2 43.0 Traditional life 178.8 172.4 28.0 27.9 Total $ 601.4 $ 600.3 $ 119.4 $ 118.8 _____________________ (a) Such amounts are included in insurance policy income in the consolidated statement of operations. (b) Such amounts are included in insurance policy benefits in the consolidated statement of operations. The following table provides the amount of undiscounted and discounted expected gross premiums and expected future benefits and expenses for traditional and limited-payment contracts (dollars in millions): March 31, 2023 March 31, 2022 Undiscounted Discounted (a) Undiscounted Discounted (a) Other annuity Expected future gross premiums $ — $ — $ — $ — Expected future benefits and expenses 396.9 316.3 426.0 383.3 Supplemental health Expected future gross premiums 8,964.4 5,605.7 8,862.2 6,222.2 Expected future benefits and expenses 11,040.9 6,080.8 10,940.4 6,954.9 Medicare supplement Expected future gross premiums 5,645.2 4,031.9 5,680.8 4,490.0 Expected future benefits and expenses 4,417.8 3,136.5 4,446.9 3,499.3 Long-term care Expected future gross premiums 2,954.3 2,152.7 3,012.5 2,389.4 Expected future benefits and expenses 7,445.7 4,266.6 7,606.7 4,966.2 Traditional life Expected future gross premiums 5,435.0 3,953.3 5,384.4 4,260.8 Expected future benefits and expenses 7,382.8 4,560.6 7,180.2 4,985.5 _____________________ (a) Calculated at the discount rates at period end. The following table provides the weighted average durations (under locked-in rates) of the liability for future policy benefits in years: March 31, March 31, Other annuity 9.7 9.7 Supplemental health 11.8 12.0 Medicare supplement 6.1 5.9 Long-term care 10.5 10.8 Traditional life 10.1 10.4 The following table provides the weighted average interest rates for the liability for future policy benefits: March 31, March 31, Other annuity Interest accretion rate 4.76 % 4.72 % Current discount rate 5.17 % 3.68 % Supplemental health Interest accretion rate 5.04 % 5.09 % Current discount rate 5.14 % 3.66 % Medicare supplement Interest accretion rate 4.26 % 4.23 % Current discount rate 4.94 % 3.41 % Long-term care Interest accretion rate 5.67 % 5.71 % Current discount rate 5.18 % 3.71 % Traditional life Interest accretion rate 4.77 % 4.82 % Current discount rate 5.15 % 3.66 %
Schedule of Policyholder Account Balance	The following tables present the balances of and changes in the liability for policyholder account balances (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Other annuities Interest-sensitive life Funding agreements Other (a) Balance, beginning of period excluding contracts 100% ceded $ 9,490.4 $ 1,663.1 $ 127.1 $ 1,209.6 $ 1,410.8 $ 395.5 Issuances 323.3 45.3 — 9.5 — — Premiums received .4 .7 7.5 50.3 — 63.0 Policy charges (4.0) (.2) — (46.1) — — Surrenders and withdrawals (178.2) (43.3) (10.5) (8.2) (9.9) (72.6) Benefit payments (59.2) (27.7) (1.7) (6.0) — — Interest credited 6.1 11.3 .6 8.1 7.2 .7 Other 5.5 .1 (.2) — — — Balance, end of period excluding contracts 100% ceded 9,584.3 1,649.3 122.8 1,217.2 1,408.1 386.6 Balance, end of period for contracts 100% ceded 154.4 632.6 26.3 110.7 — 10.6 Balance, end of period $ 9,738.7 $ 2,281.9 $ 149.1 $ 1,327.9 $ 1,408.1 $ 397.2 Balance, end of period, reinsurance ceded (154.4) (632.6) (26.3) (130.5) — (24.8) Balance, end of period, net of reinsurance $ 9,584.3 $ 1,649.3 $ 122.8 $ 1,197.4 $ 1,408.1 $ 372.4 Weighted average crediting rate 1.6 % 2.7 % 1.9 % 3.1 % 2.0 % 0.6 % Net amount at risk (b) $ — $ — $ — $ 26,865.3 $ — $ — Cash surrender value, net of reinsurance $ 8,932.4 $ 1,631.5 $ 122.8 $ 977.1 $ — $ 372.4 _________________ (a) Predominantly consists of retained asset accounts associated with our traditional life and supplemental health blocks. (b) Represents the amount of insurance policy benefit expense that we would incur if death claims were filed on all annuity and interest-sensitive life contracts at the balance sheet date. March 31, 2022 Fixed indexed annuities Fixed interest annuities Other annuities Interest-sensitive life Funding agreements Other (a) Balance, beginning of period excluding contracts 100% ceded $ 8,681.0 $ 1,806.1 $ 131.2 $ 1,163.9 $ 502.0 $ 368.0 Issuances 354.6 10.5 — 10.6 899.0 — Premiums received .1 1.1 9.1 47.6 — 61.7 Policy charges (3.0) (.1) — (44.5) — — Surrenders and withdrawals (133.7) (37.9) (10.2) (5.7) — (56.8) Benefit payments (67.3) (39.6) (1.4) (7.8) — (.1) Interest credited 65.7 11.5 .6 15.7 7.0 .7 Other 4.6 .2 — — — — Balance, end of period excluding contracts 100% ceded 8,902.0 1,751.8 129.3 1,179.8 1,408.0 373.5 Balance, end of period for contracts 100% ceded 166.6 658.8 28.2 115.7 — 11.9 Balance, end of period $ 9,068.6 $ 2,410.6 $ 157.5 $ 1,295.5 $ 1,408.0 $ 385.4 Balance, end of period, reinsurance ceded (166.6) (658.8) (28.2) (136.5) — (26.7) Balance, end of period, net of reinsurance $ 8,902.0 $ 1,751.8 $ 129.3 $ 1,159.0 $ 1,408.0 $ 358.7 Weighted average crediting rate 1.4 % 2.6 % 1.8 % 5.9 % 2.0 % 0.7 % Net amount at risk (b) $ — $ — $ — $ 26,436.6 $ — $ — Cash surrender value, net of reinsurance $ 8,295.5 $ 1,743.3 $ 129.3 $ 938.6 $ — $ 358.7 _________________ (a) Predominantly consists of retained asset accounts associated with our traditional life and supplemental health blocks. (b) Represents the amount of insurance policy benefit expense that we would incur if death claims were filed on all annuity and interest-sensitive life contracts at the balance sheet date. The following table reconciles the liability for policyholder account balances to the amount presented in the consolidated balance sheet (dollars in millions): March 31, 2023 March 31, 2022 Amounts included in the liability for policyholder account balances rollforwards: Fixed indexed annuities $ 9,738.7 $ 9,068.6 Fixed interest annuities 2,281.9 2,410.6 Other annuities 149.1 157.5 Interest-sensitive life 1,327.9 1,295.5 Funding agreements 1,408.1 1,408.0 Other 397.2 385.4 Total $ 15,302.9 $ 14,725.6
Schedule of Changes in Market Risk Benefits	The following table presents the balance of and changes in market risk benefits associated with our fixed indexed annuities (dollars in millions): March 31, 2023 March 31, 2022 Net liability (asset), beginning of period $ (54.0) $ 86.2 Effect of changes in the instrument-specific credit risk, beginning of period 12.2 12.1 Balance, beginning of period, before effect of changes in the instrument-specific credit risk (41.8) 98.3 Issuances .1 (.8) Interest accrual 5.2 3.4 Attributed fees collected — — Benefit payments — — Effect of changes in interest rates 12.3 (35.3) Effect of changes in equity markets 5.3 (6.8) Effect of changes in equity index volatility (7.4) 4.4 Actual policyholder behavior different from expected behavior .6 .3 Effect of changes in future expected policyholder behavior - other — — Effect of changes in future expected policyholder behavior - risk margin — — Effect of changes in assumptions (1.4) 2.1 Net liability (asset), end of period, before effect of changes in the instrument-specific credit risk (27.1) 65.6 Effect of changes in the instrument-specific credit risk, end of period (13.1) (18.7) Net liability (asset), end of period (40.2) 46.9 Reinsurance recoverable, end of period — — Net liability (asset), end of period, net of reinsurance $ (40.2) $ 46.9 Balance reported as an asset $ 57.8 $ 16.9 Balance reported as a liability 17.6 63.8 Net liability (asset) $ (40.2) $ 46.9 Net amount at risk $ 58.9 $ 107.4 Weighted average attained age of contract holders 68 68
Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate	The following tables present the account values by range of guaranteed minimum crediting rates and the related range of difference, in basis points, between rates being credited to policyholders and the respective guaranteed minimums (dollars in millions): March 31, 2023 Range of guaranteed minimum crediting rates (a) At guaranteed minimum 1-50 basis points above 51-150 basis points above Greater than 150 basis points above Total Fixed interest annuity 0.00%-2.99% $ 144.9 $ 291.7 $ 78.3 $ 76.9 $ 591.8 3.00%-4.99% 1,572.0 27.7 .1 — 1,599.8 5.00% and greater 90.3 — — — 90.3 Subtotal 1,807.2 319.4 78.4 76.9 2,281.9 Other annuity 0.00%-2.99% 43.6 29.5 — — 73.1 3.00%-4.99% 65.3 — — — 65.3 5.00% and greater 10.7 — — — 10.7 Subtotal 119.6 29.5 — — 149.1 Interest-sensitive life 0.00%-2.99% 66.5 225.8 225.4 — 517.7 3.00%-4.99% 461.5 51.7 146.6 125.0 784.8 5.00% and greater 21.9 .5 2.7 .3 25.4 Subtotal 549.9 278.0 374.7 125.3 1,327.9 Funding agreements 0.00%-2.99% 1,408.1 — — — 1,408.1 3.00%-4.99% — — — — — 5.00% and greater — — — — — Subtotal 1,408.1 — — — 1,408.1 Other 0.00%-2.99% 17.8 355.4 — — 373.2 3.00%-4.99% 23.6 — — — 23.6 5.00% and greater .4 — — — .4 Subtotal 41.8 355.4 — — 397.2 Total 0.00%-2.99% 1,680.9 902.4 303.7 76.9 2,963.9 3.00%-4.99% 2,122.4 79.4 146.7 125.0 2,473.5 5.00% and greater 123.3 .5 2.7 .3 126.8 Total policyholder account balances, excluding fixed indexed annuities $ 3,926.6 $ 982.3 $ 453.1 $ 202.2 5,564.2 Fixed indexed annuity account balances 9,738.7 Total policyholder account balances $ 15,302.9 ____________________ (a) Excludes the account balances related to our fixed indexed annuity contracts which do not have a minimum crediting rate since returns are based on an index. March 31, 2022 Range of guaranteed minimum crediting rates (a) At guaranteed minimum 1-50 basis points above 51-150 basis points above Greater than 150 basis points above Total Fixed interest annuity 0.00%-2.99% $ 171.7 $ 332.2 $ 42.9 $ 11.5 $ 558.3 3.00%-4.99% 1,734.3 23.5 0.1 — 1,757.9 5.00% and greater 94.4 — — — 94.4 Subtotal 2,000.4 355.7 43.0 11.5 2,410.6 Other annuity 0.00%-2.99% 53.1 30.3 — — 83.4 3.00%-4.99% 62.4 — — — 62.4 5.00% and greater 11.7 — — — 11.7 Subtotal 127.2 30.3 — — 157.5 Interest-sensitive life 0.00%-2.99% 7.5 — — — 7.5 3.00%-4.99% 409.3 56.5 178.0 146.4 790.2 5.00% and greater 22.7 0.4 — 474.7 497.8 Subtotal 439.5 56.9 178.0 621.1 1,295.5 Funding agreements 0.00%-2.99% 1,408.0 — — — 1,408.0 3.00%-4.99% — — — — — 5.00% and greater — — — — — Subtotal 1,408.0 — — — 1,408.0 Other 0.00%-2.99% 18.5 341.1 — — 359.6 3.00%-4.99% 24.8 — — — 24.8 5.00% and greater 1.0 — — — 1.0 Subtotal 44.3 341.1 — — 385.4 Total 0.00%-2.99% 1,658.8 703.6 42.9 11.5 2,416.8 3.00%-4.99% 2,230.8 80.0 178.1 146.4 2,635.3 5.00% and greater 129.8 0.4 — 474.7 604.9 Total policyholder account balances, excluding fixed indexed annuities $ 4,019.4 $ 784.0 $ 221.0 $ 632.6 5,657.0 Fixed indexed annuity account balances 9,068.6 Total policyholder account balances $ 14,725.6 ____________________ (a) Excludes the account balances related to our fixed indexed annuity contracts which do not have a minimum crediting rate since returns are based on an index.

DEFERRED ACQUISITION COSTS, P_2

DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Charges, Insurers [Abstract]
Schedule of Deferred Policy Acquisition Costs	Changes in deferred acquisition costs were as follows (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Supplemental health Medicare supplement Long-term care Interest-sensitive life Traditional life Funding agreements Total Beginning of period $ 365.6 $ 19.6 $ 378.8 $ 161.2 $ 137.9 $ 212.2 $ 409.1 $ 6.0 $ 1,690.4 Capitalizations 21.6 2.5 14.4 5.8 3.4 8.3 28.2 — 84.2 Amortization expense (11.1) (.9) (7.6) (7.2) (3.8) (3.5) (12.2) (.3) (46.6) End of period $ 376.1 $ 21.2 $ 385.6 $ 159.8 $ 137.5 $ 217.0 $ 425.1 $ 5.7 $ 1,728.0 March 31, 2022 Fixed indexed annuities Fixed interest annuities Supplemental health Medicare supplement Long-term care Interest-sensitive life Traditional life Funding agreements Total Beginning of period $ 313.0 $ 19.0 $ 357.5 $ 170.2 $ 136.4 $ 196.3 $ 357.6 $ 3.3 $ 1,553.3 Capitalizations 22.5 .5 12.0 5.5 4.8 7.8 21.7 4.2 79.0 Amortization expense (9.7) (.9) (7.0) (7.6) (3.9) (3.4) (10.2) (.3) (43.0) End of period $ 325.8 $ 18.6 $ 362.5 $ 168.1 $ 137.3 $ 200.7 $ 369.1 $ 7.2 $ 1,589.3
Schedule of Present Value of Future Insurance Profits	Changes in the present value of future profits were as follows (dollars in millions): March 31, 2023 Supplemental health Medicare supplement Long-term care Traditional life Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 154.0 $ 27.5 $ 6.2 $ 14.8 $ .8 $ .4 $ 203.7 Amortization expense (3.3) (1.9) (.3) (.5) (.1) — (6.1) End of period $ 150.7 $ 25.6 $ 5.9 $ 14.3 $ .7 $ .4 $ 197.6 March 31, 2022 Supplemental health Medicare supplement Long-term care Traditional life Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 168.1 $ 36.5 $ 7.3 $ 16.9 $ .9 $ .4 $ 230.1 Amortization expense (3.6) (2.5) (.3) (.5) — — (6.9) End of period $ 164.5 $ 34.0 $ 7.0 $ 16.4 $ .9 $ .4 $ 223.2
Schedule of Deferred Sale Inducement Cost	Changes in sales inducements were as follows (dollars in millions): March 31, 2023 Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 76.0 $ 4.5 $ 80.5 Capitalizations 5.4 .2 5.6 Amortization expense (2.6) (.2) (2.8) End of period $ 78.8 $ 4.5 $ 83.3 March 31, 2022 Fixed indexed annuities Fixed interest annuities Total Beginning of period $ 63.0 $ 5.0 $ 68.0 Capitalizations 4.6 .1 4.7 Amortization expense (2.1) (.3) (2.4) End of period $ 65.5 $ 4.8 $ 70.3

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	A reconciliation of net income (loss) and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands): Three months ended March 31, 2023 2022 Net income (loss) for basic and diluted earnings per share $ (.8) $ 183.4 Shares: Weighted average shares outstanding for basic earnings per share 114,545 118,622 Effect of dilutive securities on weighted average shares: Amounts related to employee benefit plans — 2,380 Weighted average shares outstanding for diluted earnings per share 114,545 121,002

BUSINESS SEGMENTS (Tables)

BUSINESS SEGMENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Operating Information by Segment	Operating information by segment is as follows (dollars in millions): Three months ended March 31, 2023 2022 Revenues: Annuity: Insurance policy income $ 5.1 $ 5.0 Net investment income 125.4 117.5 Total annuity revenues 130.5 122.5 Health: Insurance policy income 401.4 406.7 Net investment income 74.0 73.3 Total health revenues 475.4 480.0 Life: Insurance policy income 219.0 213.3 Net investment income 36.3 35.5 Total life revenues 255.3 248.8 Change in market values of the underlying options supporting the fixed indexed annuity and life products (offset by market value changes credited to policyholder balances) 18.6 (71.9) Investment income not allocated to product lines 67.8 46.6 Fee revenue and other income: Fee income 51.3 40.3 Amounts netted in expenses not allocated to product lines 1.6 2.8 Total segment revenues $ 1,000.5 $ 869.1 (continued on next page) (continued from previous page) Three months ended March 31, 2023 2022 Expenses: Annuity: Insurance policy benefits $ 8.7 $ 9.5 Interest credited 48.1 42.5 Amortization and non-deferred commissions 16.4 14.6 Total annuity expenses 73.2 66.6 Health: Insurance policy benefits 318.1 323.1 Amortization and non-deferred commissions 40.8 41.6 Total health expenses 358.9 364.7 Life: Insurance policy benefits 147.2 153.1 Interest credited 12.1 12.0 Amortization, non-deferred commissions and advertising expense 48.6 47.7 Total life expenses 207.9 212.8 Allocated expenses 157.5 144.8 Expenses not allocated to product lines 19.9 17.6 Market value changes of options credited to fixed indexed annuity and life policyholders 18.6 (71.9) Amounts netted in investment income not allocated to product lines: Interest expense 37.4 18.1 Interest credited 7.2 6.9 Impact of annual option forfeitures related to fixed indexed annuity surrenders — (1.6) Amortization .4 .4 Other expenses 7.3 (4.2) Expenses netted in fee revenue: Commissions and other operating expenses 35.8 30.4 Total segment expenses 924.1 784.6 Pre-tax measure of profitability: Annuity margin 57.3 55.9 Health margin 116.5 115.3 Life margin 47.4 36.0 Total insurance product margin 221.2 207.2 Allocated expenses (157.5) (144.8) Income from insurance products 63.7 62.4 Fee income 15.5 9.9 Investment income not allocated to product lines 15.5 27.0 Expenses not allocated to product lines (18.3) (14.8) Operating earnings before taxes 76.4 84.5 Income tax expense on operating income 17.8 20.0 Net operating income $ 58.6 $ 64.5
Schedule of Reconciliation of Segment Revenues and Expenses to Consolidated Revenues and Expenses and Net Income	A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions): Three months ended March 31, 2023 2022 Total segment revenues $ 1,000.5 $ 869.1 Total investment losses (14.6) (32.7) Revenues related to earnings attributable to VIEs 20.1 6.5 Consolidated revenues 1,006.0 842.9 Total segment expenses 924.1 784.6 Insurance policy benefits - changes in fair value of embedded derivative liabilities and market risk benefits 65.1 (165.4) Expenses attributable to VIEs 17.8 6.1 Fair value changes related to agent deferred compensation plan — (22.7) Consolidated expenses 1,007.0 602.6 Income (loss) before tax (1.0) 240.3 Income tax expense (benefit) on period income (loss) (.2) 56.9 Net income (loss) (.8) $ 183.4

ACCOUNTING FOR DERIVATIVES (Tab

ACCOUNTING FOR DERIVATIVES (Tables)	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value by Balance Sheet Location	Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions): Fair value March 31, December 31, 2022 Assets: Other invested assets: Fixed indexed call options $ 108.2 $ 56.7 Reinsurance receivables (16.4) (17.8) Total assets $ 91.8 $ 38.9 Liabilities: Future policy benefits: Fixed indexed products $ 1,347.9 $ 1,297.0 Total liabilities $ 1,347.9 $ 1,297.0
Schedule Pre-Tax Gains (Losses) Recognized in Net Income for Derivative Instruments	The following table provides the pre-tax gains (losses) recognized in revenues for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions): Three months ended March 31, 2023 2022 Net investment income (loss) from policyholder and other special-purpose portfolios: Fixed indexed call options $ 18.6 $ (72.9) Total investment gains (losses): Embedded derivative related to modified coinsurance agreement 1.4 (6.5) Total revenues from derivative instruments, not designated as hedges $ 20.0 $ (79.4)
Schedule of Derivatives with Master Netting Arrangements	The following table summarizes information related to derivatives with master netting arrangements or collateral as of March 31, 2023 and December 31, 2022 (dollars in millions): Gross amounts not offset in the balance sheet Gross amounts recognized Gross amounts offset in the balance sheet Net amounts of assets presented in the balance sheet Financial instruments Cash collateral received Net amount March 31, 2023: Fixed indexed call options $ 108.2 $ — $ 108.2 $ — $ — $ 108.2 December 31, 2022: Fixed indexed call options 56.7 — 56.7 — — 56.7

INCOME TAXES (Tables)

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The components of income tax expense are as follows (dollars in millions): Three months ended March 31, 2023 2022 Current tax expense $ 14.0 $ 4.4 Deferred tax expense (benefit) (14.2) 52.5 Total income tax expense (benefit) $ (.2) $ 56.9
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the U.S. statutory corporate tax rate to the estimated annual effective rate, reflected in the consolidated statement of operations is as follows: Three months ended March 31, 2023 2022 U.S. statutory corporate rate 21.0 % 21.0 % Non-taxable income and nondeductible benefits, net (.4) — State taxes 2.7 2.7 Effective tax rate 23.3 % 23.7 %
Schedule of Deferred Tax Assets and Liabilities	The components of the Company's income tax assets and liabilities are summarized below (dollars in millions): March 31, December 31, Deferred tax assets: Net federal operating loss carryforwards $ 149.9 $ 166.0 Net state operating loss carryforwards 2.5 2.5 Insurance liabilities 329.4 298.5 Indirect costs allocable to self-constructed real estate assets 224.4 214.8 Accumulated other comprehensive loss 470.1 552.4 Other — 7.3 Gross deferred tax assets 1,176.3 1,241.5 Deferred tax liabilities: Investments (34.8) (37.2) Present value of future profits and deferred acquisition costs (152.1) (148.9) Other (1.5) — Gross deferred tax liabilities (188.4) (186.1) Net deferred tax assets 987.9 1,055.4 Current income taxes prepaid .2 8.0 Income tax assets, net $ 988.1 $ 1,063.4
Schedule of Operating Loss Carryforwards	We have $0.7 billion of federal non-life NOLs as of March 31, 2023, as summarized below (dollars in millions): Net operating loss Year of expiration carryforwards 2023 $ 127.4 2025 85.2 2026 149.9 2027 10.8 2028 80.3 2029 213.2 2030 .3 2031 .2 2032 44.4 2033 .6 2034 .9 2035 .8 Total federal non-life NOLs $ 714.0

NOTES PAYABLE - DIRECT CORPOR_2

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	The following notes payable were direct corporate obligations of the Company as of March 31, 2023 and December 31, 2022 (dollars in millions): March 31, December 31, 5.250% Senior Notes due May 2025 $ 500.0 $ 500.0 5.250% Senior Notes due May 2029 500.0 500.0 5.125% Subordinated Debentures due November 2060 150.0 150.0 Revolving Credit Agreement (as defined below) — — Unamortized debt issue costs (10.8) (11.2) Direct corporate obligations $ 1,139.2 $ 1,138.8

INVESTMENT BORROWINGS (Tables)

INVESTMENT BORROWINGS (Tables)	3 Months Ended
	Mar. 31, 2023
Investment Borrowings [Abstract]
Schedule of Terms of Federal Home Loan Bank Borrowing	The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions): Amount Maturity Interest rate at borrowed date March 31, 2023 100.0 April 2024 Variable rate – 4.973% 22.0 May 2024 Variable rate – 5.202% 15.5 July 2024 Fixed rate – 1.990% 27.0 August 2024 Fixed rate – .640% 25.0 September 2024 Variable rate – 5.439% 21.7 May 2025 Variable rate – 5.114% 18.4 June 2025 Fixed rate – 2.940% 125.0 September 2025 Variable rate – 5.170% 100.0 October 2025 Variable rate – 5.246% 100.0 October 2025 Variable rate – 5.223% 57.7 October 2025 Variable rate – 5.185% 50.0 November 2025 Variable rate – 5.226% 50.0 January 2026 Variable rate – 5.168% 50.0 January 2026 Variable rate – 5.195% 100.0 January 2026 Variable rate – 5.064% 15.0 January 2026 Variable rate – 5.487% 21.8 May 2026 Variable rate – 4.954% 50.0 May 2026 Variable rate – 5.090% 75.0 December 2026 Variable rate – 5.169% 75.0 January 2027 Variable rate – 5.060% 50.0 January 2027 Variable rate – 5.077% 50.0 January 2027 Variable rate – 5.204% 100.0 February 2027 Variable rate – 5.133% 50.0 April 2027 Variable rate – 5.135% 50.0 May 2027 Variable rate – 5.145% 100.0 June 2027 Variable rate – 5.190% 10.0 June 2027 Variable rate – 5.413% 75.0 January 2028 Variable rate – 5.174% 50.0 January 2028 Variable rate – 5.382% 50.0 January 2028 Variable rate – 5.236% 34.5 February 2028 Variable rate – 5.294% 21.0 February 2028 Variable rate – 5.156% 100.0 February 2028 Variable rate – 5.153% $ 1,839.6

CONSOLIDATED STATEMENT OF CAS_3

CONSOLIDATED STATEMENT OF CASH FLOWS (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of the Reconciliation for Net Income Provided by Operating Activities	The following reconciles net income (loss) to net cash from operating activities (dollars in millions): Three months ended March 31, 2023 2022 Cash flows from operating activities: Net income (loss) $ (.8) $ 183.4 Adjustments to reconcile net income (loss) to net cash from operating activities: Amortization and depreciation 65.7 61.1 Income taxes (6.4) 42.3 Insurance liabilities 173.3 (152.4) Accrual, amortization and fair value changes included in investment income (27.9) 52.2 Deferral of policy acquisition costs (89.8) (83.7) Net investment losses 14.6 32.7 Other (a) (46.8) (79.2) Net cash from operating activities $ 81.9 $ 56.4 _____________ (a) Primarily relates to: (i) changes in other assets and liabilities related to the timing of payments and receipts; and (ii) the change in fair value of the deferred compensation plan liability.
Schedule of Other Significant Noncash Transactions	Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions): Three months ended March 31, 2023 2022 Amounts related to employee benefit plans $ 6.5 $ 7.2

INVESTMENTS IN VARIABLE INTER_2

INVESTMENTS IN VARIABLE INTEREST ENTITIES (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Impact on Balance Sheet of Consolidating Variable Interest Entities	The following tables provide supplemental information about the assets and liabilities of the VIEs which have been consolidated in accordance with authoritative guidance (dollars in millions): March 31, 2023 VIEs Eliminations Net effect on Assets: Investments held by variable interest entities $ 1,017.9 $ — $ 1,017.9 Notes receivable of VIEs held by subsidiaries — (113.8) (113.8) Cash and cash equivalents held by variable interest entities 97.1 — 97.1 Accrued investment income 4.0 — 4.0 Income tax assets, net 16.6 — 16.6 Other assets 4.5 (.8) 3.7 Total assets $ 1,140.1 $ (114.6) $ 1,025.5 Liabilities: Other liabilities $ 26.8 $ (3.9) $ 22.9 Borrowings related to variable interest entities 1,065.4 — 1,065.4 Notes payable of VIEs held by subsidiaries 126.1 (126.1) — Total liabilities $ 1,218.3 $ (130.0) $ 1,088.3 December 31, 2022 VIEs Eliminations Net effect on Assets: Investments held by variable interest entities $ 1,077.6 $ — $ 1,077.6 Notes receivable of VIEs held by subsidiaries — (113.8) (113.8) Cash and cash equivalents held by variable interest entities 69.2 — 69.2 Accrued investment income 3.5 — 3.5 Income tax assets, net 19.6 — 19.6 Other assets 2.5 (.8) 1.7 Total assets $ 1,172.4 $ (114.6) $ 1,057.8 Liabilities: Other liabilities $ 29.3 $ (2.4) $ 26.9 Borrowings related to variable interest entities 1,104.6 — 1,104.6 Notes payable of VIEs held by subsidiaries 126.1 (126.1) — Total liabilities $ 1,260.0 $ (128.5) $ 1,131.5
Schedule of Changes in the Allowance for Current Expected Credit Losses Related to Investments Held by VIEs	The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2023 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2022 $ 54.4 $ .9 $ .4 $ .3 $ 56.0 Additions for securities for which credit losses were not previously recorded 3.0 — — — 3.0 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded .5 (.1) .1 .3 .8 Reduction for securities sold during the period (.7) — — — (.7) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2023 $ 57.2 $ .8 $ .5 $ .6 $ 59.1 The following table summarizes changes in the allowance for credit losses related to fixed maturities, available for sale, for the three months ended March 31, 2022 (dollars in millions): Corporate securities States and political subdivisions Foreign governments Asset-backed securities Total Allowance at December 31, 2021 $ 7.4 $ — $ .2 $ — $ 7.6 Additions for securities for which credit losses were not previously recorded 14.0 .3 .1 — 14.4 Additions for purchased securities with deteriorated credit — — — — — Additions (reductions) for securities where an allowance was previously recorded 14.6 .5 (.2) .1 15.0 Reduction for securities sold during the period (.4) — — — (.4) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — — — — Write-offs — — — — — Recoveries of previously written-off amount — — — — — Allowance at March 31, 2022 $ 35.6 $ .8 $ .1 $ .1 $ 36.6 The following table summarizes changes in the allowance for credit losses related to corporate securities held by VIEs for the three months ended March 31, 2023 and 2022 (dollars in millions): Three months ended March 31, 2023 2022 Allowance at the beginning of the period $ 5.5 $ 3.7 Additions for securities for which credit losses were not previously recorded .3 1.5 Additions for purchased securities with deteriorated credit — — Additions (reductions) for securities where an allowance was previously recorded (.7) 1.3 Reduction for securities sold during the period (1.6) (.6) Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded — — Write-offs — — Recoveries of previously written-off amount — — Allowance at the end of the period $ 3.5 $ 5.9
Schedule of Variable Interest Entities by Contractual Maturity	The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at March 31, 2023, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Amortized Estimated (Dollars in millions) Due in one year or less $ 5.4 $ 4.7 Due after one year through five years 782.3 752.8 Due after five years through ten years 272.6 260.4 Total $ 1,060.3 $ 1,017.9

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Instruments Carried at Fair Value Categorized by Input Level	The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at March 31, 2023 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 11,848.6 $ 127.8 $ 11,976.4 United States Treasury securities and obligations of United States government corporations and agencies — 170.1 — 170.1 States and political subdivisions — 2,462.6 — 2,462.6 Foreign governments — 78.6 — 78.6 Asset-backed securities — 1,299.1 41.1 1,340.2 Agency residential mortgage-backed securities — 215.9 — 215.9 Non-agency residential mortgage-backed securities — 1,606.7 33.8 1,640.5 Collateralized loan obligations — 918.9 — 918.9 Commercial mortgage-backed securities — 2,290.1 13.8 2,303.9 Total fixed maturities, available for sale — 20,890.6 216.5 21,107.1 Equity securities - corporate securities 31.1 — 75.0 106.1 Trading securities: Asset-backed securities — 25.5 — 25.5 Agency residential mortgage-backed securities — .3 — .3 Non-agency residential mortgage-backed securities — 58.3 .5 58.8 Commercial mortgage-backed securities — 123.5 — 123.5 Total trading securities — 207.6 .5 208.1 Investments held by variable interest entities - corporate securities — 1,017.9 — 1,017.9 Other invested assets: Derivatives — 108.2 — 108.2 Residual tranches — .9 19.2 20.1 Total other invested assets — 109.1 19.2 128.3 Market risk benefit asset — — 57.8 57.8 Assets held in separate accounts — 2.8 — 2.8 Total assets carried at fair value by category $ 31.1 $ 22,228.0 $ 369.0 $ 22,628.1 Liabilities: Market risk benefit liability $ — $ — $ 17.6 $ 17.6 Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) — — 1,347.9 1,347.9 Total liabilities carried at fair value by category $ — $ — $ 1,365.5 $ 1,365.5 The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2022 is as follows (dollars in millions): Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Total Assets: Fixed maturities, available for sale: Corporate securities $ — $ 11,584.9 $ 127.8 $ 11,712.7 United States Treasury securities and obligations of United States government corporations and agencies — 158.7 — 158.7 States and political subdivisions — 2,388.5 — 2,388.5 Foreign governments — 74.7 — 74.7 Asset-backed securities — 1,230.0 57.0 1,287.0 Agency residential mortgage-backed securities — 175.0 — 175.0 Non-agency residential mortgage-backed securities — 1,492.3 56.2 1,548.5 Collateralized loan obligations — 782.5 3.4 785.9 Commercial mortgage-backed securities — 2,207.9 14.5 2,222.4 Total fixed maturities, available for sale — 20,094.5 258.9 20,353.4 Equity securities - corporate securities 59.6 — 75.7 135.3 Trading securities: Asset-backed securities — 15.1 — 15.1 Agency residential mortgage-backed securities — .3 — .3 Non-agency residential mortgage-backed securities — 60.2 .5 60.7 Commercial mortgage-backed securities — 131.8 — 131.8 Total trading securities — 207.4 .5 207.9 Investments held by variable interest entities - corporate securities — 1,077.6 — 1,077.6 Other invested assets: Derivatives — 56.7 — 56.7 Residual tranches — — 18.3 18.3 Total other invested assets — 56.7 18.3 75.0 Market risk benefit asset — — 65.3 65.3 Assets held in separate accounts — 2.7 — 2.7 Total assets carried at fair value by category $ 59.6 $ 21,438.9 $ 418.7 $ 21,917.2 Liabilities: Market risk benefit liability $ — $ — $ 11.3 $ 11.3 Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) — — 1,297.0 1,297.0 Total liabilities carried at fair value by category $ — $ — $ 1,308.3 $ 1,308.3 The fair value of our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions): March 31, 2023 Quoted prices in active markets for identical assets or liabilities Significant other observable inputs Significant unobservable inputs Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,557.5 $ 1,557.5 $ 1,676.1 Policy loans — — 123.0 123.0 123.0 Other invested assets: Company-owned life insurance — 201.3 — 201.3 201.3 Cash and cash equivalents: Unrestricted 425.0 — — 425.0 425.0 Held by variable interest entities 97.1 — — 97.1 97.1 Liabilities: Policyholder account liabilities — — 15,302.9 15,302.9 15,302.9 Investment borrowings — 1,840.6 — 1,840.6 1,839.6 Borrowings related to variable interest entities — 1,034.8 — 1,034.8 1,065.4 Notes payable – direct corporate obligations — 1,079.5 — 1,079.5 1,139.2 December 31, 2022 Quoted prices in active markets for identical assets or liabilities Significant other observable inputs Significant unobservable inputs Total estimated fair value Total carrying amount Assets: Mortgage loans $ — $ — $ 1,273.6 $ 1,273.6 $ 1,411.9 Policy loans — — 121.6 121.6 121.6 Other invested assets: Company-owned life insurance — 199.1 — 199.1 199.1 Cash and cash equivalents: Unrestricted 575.7 — — 575.7 575.7 Held by variable interest entities 69.2 — — 69.2 69.2 Liabilities: Policyholder account liabilities — — 15,234.2 15,234.2 15,234.2 Investment borrowings — 1,640.5 — 1,640.5 1,639.5 Borrowings related to variable interest entities — 1,066.3 — 1,066.3 1,104.6 Notes payable – direct corporate obligations — 1,077.0 — 1,077.0 1,138.8 The following table presents additional information about assets measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended March 31, 2023 (dollars in millions): March 31, 2023 Beginning balance as of December 31, 2022 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Ending balance as of March 31, 2023 Amount of total gains (losses) for the three months ended March 31, 2023 included in our net income relating to assets still held as of the reporting date Amount of total gains (losses) for the three months ended March 31, 2023 included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 127.8 $ (.5) $ .1 $ .9 $ 5.9 $ (6.4) $ 127.8 $ .1 $ .1 Asset-backed securities 57.0 (5.1) (.2) (.2) — (10.4) 41.1 — (.5) Non-agency residential mortgage-backed securities 56.2 (.2) — 2.3 — (24.5) 33.8 — 2.4 Collateralized loan obligations 3.4 — — — — (3.4) — — — Commercial mortgage-backed securities 14.5 — — (.7) — — 13.8 — (.7) Total fixed maturities, available for sale 258.9 (5.8) (.1) 2.3 5.9 (44.7) 216.5 .1 1.3 Equity securities - corporate securities 75.7 — (.7) — — — 75.0 (.7) — Trading securities - non-agency residential mortgage-backed securities .5 — — — — — .5 — — Other invested assets - residual tranches 18.3 .5 .4 — — — 19.2 .4 — _________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities. The following summarizes such activity for the three months ended March 31, 2023 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ .9 $ (1.4) $ — $ — $ (.5) Asset-backed securities 2.3 (7.4) — — (5.1) Non-agency residential mortgage-backed securities — (.2) — — (.2) Total fixed maturities, available for sale 3.2 (9.0) — — (5.8) Other invested assets - residual tranches .7 (.2) — — .5 The following table presents additional information about assets measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended March 31, 2022 (dollars in millions): March 31, 2022 Beginning balance as of December 31, 2021 Purchases, sales, issuances and settlements, net (b) Total realized and unrealized gains (losses) included in net income Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss) Transfers into Level 3 (a) Transfers out of Level 3 (a) Ending balance as of March 31, 2022 Amount of total gains (losses) for the three months ended March 31, 2022 included in our net income relating to assets still held as of the reporting date Amount of total gains (losses) for the three months ended March 31, 2022 included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date Assets: Fixed maturities, available for sale: Corporate securities $ 89.7 $ — $ (1.4) $ (6.5) $ 36.2 $ — $ 118.0 $ (2.1) $ (6.5) Asset-backed securities 26.6 15.9 — (1.3) — — 41.2 — (1.3) Non-agency residential mortgage-backed securities — — — (.6) 5.0 — 4.4 — (.6) Collateralized loan obligations 5.0 10.0 — (.2) — (5.0) 9.8 — (.2) Commercial mortgage-backed securities 19.0 — — (1.5) — — 17.5 — (1.5) Total fixed maturities, available for sale 140.3 25.9 (1.4) (10.1) 41.2 (5.0) 190.9 (2.1) (10.1) Equity securities - corporate securities 11.5 (2.9) (.2) — — — 8.4 (.2) — Trading securities: Non-agency residential mortgage-backed securities 3.5 — — — — (3.5) — — — Commercial mortgage-backed securities 12.9 — (.4) .2 — — 12.7 (.4) — Total trading securities 16.4 — (.4) .2 — (3.5) 12.7 (.4) — Investments held by variable interest entities - corporate securities 2.2 (2.1) (.1) — — — — — — ____________ (a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate. (b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities. The following summarizes such activity for the three months ended March 31, 2022 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, net Assets: Fixed maturities, available for sale: Corporate securities $ 9.4 $ (9.4) $ — $ — $ — Asset-backed securities 16.0 (.1) — — 15.9 Collateralized loan obligations 10.0 — — — 10.0 Total fixed maturities, available for sale 35.4 (9.5) — — 25.9 Equity securities - corporate securities .3 (3.2) — — (2.9) Investments held by variable interest entities - corporate securities — (2.1) — — (2.1) The following table summarizes changes in the value of our embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities) which are measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value (dollars in millions): Three months ended March 31, 2023 2022 Balance at beginning of the period $ 1,297.0 $ 1,724.1 Premiums less benefits (14.0) 21.1 Change in fair value, net 64.9 (201.7) Balance at end of the period $ 1,347.9 $ 1,543.5
Schedule of Fair Value Measurement Inputs	The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at March 31, 2023 (dollars in millions): Fair value at March 31, 2023 Valuation techniques Unobservable inputs Range (weighted average) (a) Assets: Corporate securities (b) $ 2.9 Discounted cash flow analysis Discount margins 2.41% Corporate securities (c) 3.5 Recovery method Percent of recovery expected 0.00% - 35.00% (35.00%) Corporate securities (d) .5 Unadjusted purchase price Not applicable Not applicable Asset-backed securities (e) 23.1 Discounted cash flow analysis Discount margins 1.99% - 4.02% (3.20%) Equity securities (f) 63.6 Market comparables EBITDA multiples 8.8X Equity securities (g) .1 Recovery method Percent of recovery expected 0.00% - 100.00% (100.00%) Equity securities (h) 11.4 Unadjusted purchase price Not applicable Not applicable Other assets categorized as Level 3 (i) 206.1 Unadjusted third-party price source Not applicable Not applicable Market risk benefit asset (k) 57.8 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.45%) Utilization rates 5.92% - 47.62% (22.54%) Total 369.0 Liabilities: Market risk benefit liability (k) 17.6 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.45%) Utilization rates 5.92% - 47.62% (22.54%) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) (j) 1,347.9 Discounted projected embedded derivatives Projected portfolio yields 4.30% - 4.63% (4.31%) Discount rates 3.47% - 5.33% (4.13%) Surrender rates 1.90% - 27.70% (9.20%) ________________________________ (a) The weighted average is based on the relative fair value of the related assets or liabilities. (b) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (c) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (d) Corporate securities - For these assets, there were no adjustments to the purchase price. (e) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (f) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements. (g) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (h) Equity securities - For these assets, there were no adjustments to the purchase price. (i) Other assets categorized as Level 3 - For these assets, there were no adjustments to non-binding quoted market prices obtained from third-party pricing sources. (j) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed indexed annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would have resulted in a higher (lower) fair value measurement. The discount rate is based on risk free rates (U.S. Treasury rates for similar durations) adjusted for our non-performance risk and risk margins for non-capital market inputs. Increases (decreases) in the discount rates would have resulted in a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative. (k) Market risk benefits – Many of our fixed indexed annuity products include a GLWB that is considered a MRB. The calculation of the value of MRBs are based on significant unobservable inputs including assumptions related to surrenders and utilization of policy benefits. These assumptions are based on actuarial estimates and past experience. Increases in assumed surrender rates would generally increase the value of a MRB asset or decrease the value of a MRB liability (with decreases in assumed surrender rates having the opposite impacts). Increases in utilization rates would generally decrease the value of a MRB asset or increase the value of a MRB liability (with decreases in utilization rates having the opposite impacts). The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2022 (dollars in millions): Fair value at December 31, 2022 Valuation techniques Unobservable inputs Range (weighted average) (a) Assets: Corporate securities (b) $ 2.9 Discounted cash flow analysis Discount margins 2.23% - 3.94% (2.25%) Corporate securities (c) 3.5 Recovery method Percent of recovery expected 0.00% - 35.00% (35.00%) Corporate securities (d) .5 Unadjusted purchase price Not applicable Not applicable Asset-backed securities (e) 21.8 Discounted cash flow analysis Discount margins 2.50% - 3.86% (3.30%) Equity securities (f) 63.9 Market comparables EBITDA multiples 8.5X Equity securities (g) .1 Recovery method Percent of recovery expected 0.00% - 100.00% (100.00%) Equity securities (h) 11.7 Unadjusted purchase price Not applicable Not applicable Other assets categorized as Level 3 (i) 249.0 Unadjusted third-party price source Not applicable Not applicable Market risk benefit asset (k) 65.3 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.68%) Utilization rates 6.78% - 63.16% (20.09%) Total 418.7 Liabilities: Market risk benefit liability (k) 11.3 Discounted cash flow analysis Surrender rates 1.28% - 11.05% (3.68%) Utilization rates 6.78% - 63.16% (20.09%) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) (j) 1,297.0 Discounted projected embedded derivatives Projected portfolio yields 4.30% - 4.63% (4.31%) Discount rates 3.77% - 5.48% (4.47%) Surrender rates 1.90% - 27.70% (9.20%) ________________________________ (a) The weighted average is based on the relative fair value of the related assets or liabilities. (b) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (c) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (d) Corporate securities - For these assets, there were no adjustments to the purchase price. (e) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would have resulted in a significantly lower (higher) fair value measurement. (f) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before EBITDA. Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements. (g) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would have resulted in a significantly higher (lower) fair value measurement. (h) Equity securities - For these assets, there were no adjustments to the purchase price. (i) Other assets categorized as Level 3 - For these assets, there were no adjustments to non-binding quoted market prices obtained from third-party pricing sources. (j) Embedded derivatives related to fixed indexed annuity products (classified as policyholder account liabilities) - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed indexed annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would have resulted in a higher (lower) fair value measurement. The discount rate is based on risk free rates (U.S. Treasury rates for similar durations) adjusted for our non-performance risk and risk margins for non-capital market inputs. Increases (decreases) in the discount rates would have resulted in a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Millions	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Deferred profit liability	$ 57.7

RECENTLY ADOPTED ACCOUNTING S_3

RECENTLY ADOPTED ACCOUNTING STANDARDS - Impact of Adoption Transition (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of future profits	$ 197.6	$ 223.2	$ 203.7	$ 230.1	$ 259.6	$ 249.4
Deferred acquisition costs	1,811.3		1,770.9		1,485.8	1,027.8
Reinsurance receivables	4,189.6		4,223.4			4,584.3
Market risk benefit asset	57.8	16.9	65.3		2.5	0
Income tax assets, net	988.1		1,063.4		806.4	199.4
Total assets	34,015		33,133.1			35,339.9
Policyholder account balances	15,302.9	14,725.6	15,234.2		12,367.7	12,540.6
Future policy benefits	11,623.3		11,240.2		15,704.9	11,744.2
Market risk benefit liability	17.6	63.8	11.3		114.8	0
Liability for life insurance policy claims	67.6		64.1			561.8
Total liabilities	31,983.2		31,364.3			29,855.7
Retained earnings	1,674	1,293	1,691.2			752.3
Accumulated other comprehensive income	(1,664.4)	(561.5)	(1,957.3)			2,186.1
Total shareholders' equity	2,031.8	2,818.4	1,768.8	$ 3,684.7		$ 5,484.2
Insurance policy benefits	609.7	333.9
Liability for future policy benefits remeasurement loss	(0.6)	(7)
Change in fair value of market risk benefits	14.8	(32.7)
Amortization	55.5	52.3
Other operating costs and expenses	271.7	218.3
Total benefits and expenses	1,007	602.6
Income before income taxes	(1)	240.3
Income tax expense (benefit) on period income (loss)	(0.2)	56.9
Net income (loss)	$ (0.8)	183.4
Amount prior to adoption of ASU 2018-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of future profits			212.2		249.4
Deferred acquisition costs			1,913.4		1,027.8
Reinsurance receivables			4,241.7
Market risk benefit asset			0		0
Income tax assets, net			1,165.5		199.4
Total assets			33,339.2
Policyholder account balances			14,858.3		12,540.6
Future policy benefits			11,809.1		11,744.2
Market risk benefit liability			0		0
Liability for life insurance policy claims			456.5
Total liabilities			31,938.4
Retained earnings		1,223.5	1,459
Accumulated other comprehensive income		380.5	(2,093.1)
Total shareholders' equity		3,690.9	1,400.8
Insurance policy benefits		346.7
Liability for future policy benefits remeasurement loss		0
Change in fair value of market risk benefits		0
Amortization		103.9
Other operating costs and expenses		219.2
Total benefits and expenses		693.6
Income before income taxes		149.3
Income tax expense (benefit) on period income (loss)		37
Net income (loss)		112.3
Effect of adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of future profits			(8.5)
Deferred acquisition costs			(142.5)
Reinsurance receivables			(18.3)
Market risk benefit asset			65.3
Income tax assets, net			(102.1)
Total assets			(206.1)
Policyholder account balances			375.9
Future policy benefits			(568.9)
Market risk benefit liability			11.3
Liability for life insurance policy claims			(392.4)
Total liabilities			(574.1)
Retained earnings		69.5	232.2
Accumulated other comprehensive income		(942)	135.8
Total shareholders' equity		(872.5)	368
Insurance policy benefits		(12.8)
Liability for future policy benefits remeasurement loss		7
Change in fair value of market risk benefits		(32.7)
Amortization		(51.6)
Other operating costs and expenses		(0.9)
Total benefits and expenses		(91)
Income before income taxes		91
Income tax expense (benefit) on period income (loss)		19.9
Net income (loss)		71.1
Effect of adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of future profits					10.2
Deferred acquisition costs					458
Reinsurance receivables					144.1
Market risk benefit asset					2.5
Income tax assets, net					607
Total assets					1,221.8
Policyholder account balances					(172.9)
Future policy benefits					3,960.7
Market risk benefit liability					114.8
Liability for life insurance policy claims					(470.1)
Total liabilities					3,432.5
Retained earnings					(130.9)
Accumulated other comprehensive income					(2,079.8)
Total shareholders' equity					(2,210.7)
As recast
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of future profits			203.7		259.6
Deferred acquisition costs			1,770.9		1,485.8
Reinsurance receivables			4,223.4		4,728.4
Market risk benefit asset			65.3		2.5
Income tax assets, net			1,063.4		806.4
Total assets			33,133.1		36,561.7
Policyholder account balances			15,234.2		12,367.7
Future policy benefits			11,240.2		15,704.9
Market risk benefit liability			11.3		114.8
Liability for life insurance policy claims			64.1		91.7
Total liabilities			31,364.3		33,288.2
Retained earnings			1,691.2		621.4
Accumulated other comprehensive income			(1,957.3)		106.3
Total shareholders' equity			$ 1,768.8		$ 3,273.5
Insurance policy benefits		333.9
Liability for future policy benefits remeasurement loss		7
Change in fair value of market risk benefits		(32.7)
Amortization		52.3
Other operating costs and expenses		218.3
Total benefits and expenses		602.6
Income before income taxes		240.3
Income tax expense (benefit) on period income (loss)		56.9
Net income (loss)		$ 183.4

RECENTLY ADOPTED ACCOUNTING S_4

RECENTLY ADOPTED ACCOUNTING STANDARDS - Transition Adjustments (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Present value of future profits
Balance	$ 197.6	$ 203.7	$ 223.2	$ 230.1	$ 259.6	$ 249.4
Deferred acquisition costs
Balance	1,811.3	1,770.9			1,485.8	1,027.8
Reinsurance receivables
Balance					4,728.4
Market risk benefit asset
Market risk benefit asset	57.8	65.3	16.9		2.5	0
Income tax assets, net
Balance	988.1	1,063.4			806.4	199.4
Policyholder Account Balance [Abstract]
Balance	15,302.9	15,234.2	14,725.6		12,367.7	12,540.6
Future policy benefits
Future policy benefits	11,623.3	11,240.2			15,704.9	11,744.2
Market risk benefit liability
Market risk benefit liability	17.6	11.3	63.8		114.8	0
Liability for policy and contract claims
Balance					91.7
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity	2,031.8	1,768.8	2,818.4	3,684.7		$ 5,484.2
Accumulated other comprehensive income (loss)
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity	(1,664.4)	(1,957.3)	(561.5)	373.7	106.3
Retained earnings
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity	$ 1,674	1,691.2	1,293	$ 1,125.6	621.4
Amount prior to adoption of ASU 2018-12
Present value of future profits
Balance		212.2			249.4
Deferred acquisition costs
Balance		1,913.4			1,027.8
Reinsurance receivables
Balance					4,584.3
Market risk benefit asset
Market risk benefit asset		0			0
Income tax assets, net
Balance		1,165.5			199.4
Policyholder Account Balance [Abstract]
Balance		14,858.3			12,540.6
Future policy benefits
Future policy benefits		11,809.1			11,744.2
Market risk benefit liability
Market risk benefit liability		0			0
Liability for policy and contract claims
Balance					561.8
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity		1,400.8	3,690.9
Amount prior to adoption of ASU 2018-12 | Accumulated other comprehensive income (loss)
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity					2,186.1
Amount prior to adoption of ASU 2018-12 | Retained earnings
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity					752.3
Effect of adoption
Present value of future profits
Balance		(8.5)
Unwinding amounts related to unrealized gains (losses)					10.2
Deferred acquisition costs
Balance		(142.5)
Unwinding amounts related to unrealized gains (losses)					458
Reinsurance receivables
Changes in measurement of assets					(81.6)
Change in discount rates					225.7
Market risk benefit asset
Market risk benefit asset		65.3
Changes in market benefit reserve basis					2.5
Income tax assets, net
Balance		(102.1)
Tax impacts of changes recognized in accumulated other comprehensive income					570.3
Tax impacts of changes recognized in retained earnings					36.7
Policyholder Account Balance [Abstract]
Balance		375.9
Changes in classification of liabilities					(172.9)
Future policy benefits
Future policy benefits		(568.9)
Unwinding amounts related to unrealized gains (losses)					(197.5)
Changes in remeasurement of future policy benefits					31.1
Changes in classification of liabilities					643
Reclass to market risk benefit liability					(66.6)
Change in discount rates					3,550.7
Market risk benefit liability
Market risk benefit liability		11.3
Reclass to market risk benefit liability					66.6
Changes in market risk benefit reserve basis					48.2
Liability for policy and contract claims
Changes in classification of liabilities					(470.1)
Statement of Stockholders' Equity [Abstract]
Total shareholders' equity		$ 368	$ (872.5)
Effect of adoption | Accumulated other comprehensive income (loss)
Statement of Stockholders' Equity [Abstract]
Unwinding amounts related to unrealized gains (losses)					665.7
Changes in measurement of assets and liabilities					0
Change in market risk benefit reserve basis					9.2
Tax impacts of changes recognized in retained earnings					0
Change in discount rates					(3,325)
Tax impacts of changes recognized in accumulated other comprehensive income					570.3
Effect of adoption | Retained earnings
Statement of Stockholders' Equity [Abstract]
Unwinding amounts related to unrealized gains (losses)					0
Changes in measurement of assets and liabilities					(112.7)
Change in market risk benefit reserve basis					(54.9)
Tax impacts of changes recognized in retained earnings					36.7
Change in discount rates					0
Tax impacts of changes recognized in accumulated other comprehensive income					$ 0

INVESTMENTS - SCHEDULE OF UNREA

INVESTMENTS - SCHEDULE OF UNREALIZED APPRECIATION (DEPRECIATION) ON INVESTMENTS INCLUDED IN ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Net unrealized losses on investments having no allowance for credit losses	$ (937.1)	$ (1,247)
Unrealized losses on investments with an allowance for credit losses	(1,453.6)	(1,780.7)
Change in discount rates for liability for future policy benefits	237.4	500.7
Change in instrument-specific credit risk for market risk benefits	13.1	12.2
Deferred income tax assets	475.8	557.5
Accumulated other comprehensive loss	$ (1,664.4)	$ (1,957.3)	$ (561.5)	$ 2,186.1

INVESTMENTS - SCHEDULE OF AMORT

INVESTMENTS - SCHEDULE OF AMORTIZED COST, GROSS UNREALIZED GAINS AND LOSSES, ESTIMATED FAIR VALUE, AND ALLOWANCE FOR CREDIT LOSSES (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 23,517.9	$ 23,384.2
Allowance for credit losses	(59.1)	(56)	$ (36.6)	$ (7.6)
Estimated fair value	21,107.1	20,353.4
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	13,497	13,649.1
Gross unrealized gains	66.3	29.9
Gross unrealized losses	(1,529.7)	(1,911.9)
Allowance for credit losses	(57.2)	(54.4)	(35.6)	(7.4)
Estimated fair value	11,976.4	11,712.7
United States Treasury securities and obligations of United States government corporations and agencies
Debt Securities, Available-for-sale [Line Items]
Amortized cost	174.7	171.7
Gross unrealized gains	0.1	0
Gross unrealized losses	(4.7)	(13)
Allowance for credit losses	0	0
Estimated fair value	170.1	158.7
States and political subdivisions
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,789.4	2,846.9
Gross unrealized gains	34.1	19.3
Gross unrealized losses	(360.1)	(476.8)
Allowance for credit losses	(0.8)	(0.9)	(0.8)	0
Estimated fair value	2,462.6	2,388.5
Foreign governments
Debt Securities, Available-for-sale [Line Items]
Amortized cost	88.8	86.3
Gross unrealized gains	0.2	0.1
Gross unrealized losses	(9.9)	(11.3)
Allowance for credit losses	(0.5)	(0.4)	(0.1)	(0.2)
Estimated fair value	78.6	74.7
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	1,458.6	1,435.7
Gross unrealized gains	2.4	1
Gross unrealized losses	(120.2)	(149.4)
Allowance for credit losses	(0.6)	(0.3)	$ (0.1)	$ 0
Estimated fair value	1,340.2	1,287
Agency residential mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	213.3	174.3
Gross unrealized gains	2.8	1.4
Gross unrealized losses	(0.2)	(0.7)
Allowance for credit losses	0	0
Estimated fair value	215.9	175
Non-agency residential mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	1,778.2	1,700.4
Gross unrealized gains	37.2	40
Gross unrealized losses	(174.9)	(191.9)
Allowance for credit losses	0	0
Estimated fair value	1,640.5	1,548.5
Collateralized loan obligations
Debt Securities, Available-for-sale [Line Items]
Amortized cost	954.3	825.2
Gross unrealized gains	0.5	0.3
Gross unrealized losses	(35.9)	(39.6)
Allowance for credit losses	0	0
Estimated fair value	918.9	785.9
Commercial mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,563.6	2,494.6
Gross unrealized gains	0.1	0.1
Gross unrealized losses	(259.8)	(272.3)
Allowance for credit losses	0	0
Estimated fair value	2,303.9	2,222.4
Total fixed maturities, available for sale
Debt Securities, Available-for-sale [Line Items]
Amortized cost	23,517.9	23,384.2
Gross unrealized gains	143.7	92.1
Gross unrealized losses	(2,495.4)	(3,066.9)
Allowance for credit losses	(59.1)	(56)
Estimated fair value	$ 21,107.1	$ 20,353.4

INVESTMENTS - SUMMARY OF INVEST

INVESTMENTS - SUMMARY OF INVESTMENTS BY CONTRACTUAL MATURITY (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Amortized cost
Due in one year or less	$ 140.1	$ 112
Due after one year through five years	2,209.3	1,913.7
Due after five years through ten years	1,871.8	2,098.9
Due after ten years	12,328.7	12,629.4
Subtotal	16,549.9	16,754
Structured securities	6,968	6,630.2
Amortized cost	23,517.9	23,384.2
Estimated fair value
Due in one year or less	138.7	110.8
Due after one year through five years	2,080	1,790.2
Due after five years through ten years	1,742.8	1,910.4
Due after ten years	10,726.2	10,523.2
Subtotal	14,687.7	14,334.6
Structured securities	6,419.4	6,018.8
Estimated fair value	$ 21,107.1	$ 20,353.4

INVESTMENTS - SUMMARY OF INVE_2

INVESTMENTS - SUMMARY OF INVESTMENTS WITH UNREALIZED LOSSES BY INVESTMENT CATEGORY (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair value
Less than 12 months	$ 3,088.7	$ 7,636.9
12 months or greater	6,207.4	1,897.5
Total	9,296.1	9,534.4
Unrealized losses
Less than 12 months	(108.6)	(835.2)
12 months or greater	(950.9)	(471.6)
Total	(1,059.5)	(1,306.8)
Corporate securities
Fair value
Less than 12 months	973.1	2,830.8
12 months or greater	1,979.4	370.4
Total	2,952.5	3,201.2
Unrealized losses
Less than 12 months	(35.5)	(329.4)
12 months or greater	(322.6)	(129.3)
Total	(358.1)	(458.7)
United States Treasury securities and obligations of United States government corporations and agencies
Fair value
Less than 12 months	106.8	134.4
12 months or greater	33.7	21.9
Total	140.5	156.3
Unrealized losses
Less than 12 months	(1.2)	(9.6)
12 months or greater	(3.5)	(3.4)
Total	(4.7)	(13)
States and political subdivisions
Fair value
Less than 12 months	207.5	667
12 months or greater	397.4	132.1
Total	604.9	799.1
Unrealized losses
Less than 12 months	(11.2)	(124.8)
12 months or greater	(97.1)	(58.5)
Total	(108.3)	(183.3)
Foreign governments
Fair value
Less than 12 months	15.2	35
12 months or greater	13.3	2.1
Total	28.5	37.1
Unrealized losses
Less than 12 months	(0.3)	(3.5)
12 months or greater	(1.2)	(0.3)
Total	(1.5)	(3.8)
Asset-backed securities
Fair value
Less than 12 months	388.9	914
12 months or greater	775	258.1
Total	1,163.9	1,172.1
Unrealized losses
Less than 12 months	(12.9)	(90.1)
12 months or greater	(103.2)	(53.4)
Total	(116.1)	(143.5)
Agency residential mortgage-backed securities
Fair value
Less than 12 months	33.4	59.7
12 months or greater	0.6	0
Total	34	59.7
Unrealized losses
Less than 12 months	(0.2)	(0.7)
12 months or greater	0	0
Total	(0.2)	(0.7)
Non-agency residential mortgage-backed securities
Fair value
Less than 12 months	560.9	861.6
12 months or greater	718	335.4
Total	1,278.9	1,197
Unrealized losses
Less than 12 months	(27.1)	(89.7)
12 months or greater	(147.8)	(102.2)
Total	(174.9)	(191.9)
Collateralized loan obligations
Fair value
Less than 12 months	282.6	553
12 months or greater	551.7	184.2
Total	834.3	737.2
Unrealized losses
Less than 12 months	(6.5)	(27.4)
12 months or greater	(29.4)	(12.2)
Total	(35.9)	(39.6)
Commercial mortgage-backed securities
Fair value
Less than 12 months	520.3	1,581.4
12 months or greater	1,738.3	593.3
Total	2,258.6	2,174.7
Unrealized losses
Less than 12 months	(13.7)	(160)
12 months or greater	(246.1)	(112.3)
Total	$ (259.8)	$ (272.3)

INVESTMENTS - SUMMARY OF CHANGE

INVESTMENTS - SUMMARY OF CHANGES IN THE ALLOWANCE FOR CURRENT EXPECTED CREDIT LOSSES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	$ 56	$ 7.6
Additions for securities for which credit losses were not previously recorded	3	14.4
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.8	15
Reduction for securities sold during the period	(0.7)	(0.4)
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	59.1	36.6
Corporate securities
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	54.4	7.4
Additions for securities for which credit losses were not previously recorded	3	14
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.5	14.6
Reduction for securities sold during the period	(0.7)	(0.4)
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	57.2	35.6
States and political subdivisions
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	0.9	0
Additions for securities for which credit losses were not previously recorded	0	0.3
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	(0.1)	0.5
Reduction for securities sold during the period	0	0
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	0.8	0.8
Foreign governments
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	0.4	0.2
Additions for securities for which credit losses were not previously recorded	0	0.1
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.1	(0.2)
Reduction for securities sold during the period	0	0
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	0.5	0.1
Asset-backed securities
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	0.3	0
Additions for securities for which credit losses were not previously recorded	0	0
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.3	0.1
Reduction for securities sold during the period	0	0
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	$ 0.6	$ 0.1

INVESTMENTS - NARRATIVE (Detail

INVESTMENTS - NARRATIVE (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) investment loan mortgage_loan	Mar. 31, 2022 USD ($)
Debt Securities, Available-for-sale [Line Items]
Net realized investment gains (losses)	$ (14.6)	$ (32.7)
Change in allowance for credit losses	$ 1.5	30.7
Number of investments in default or considered nonperforming | investment	0
Value of available for sale securities sold	$ 288.5	786.6
Total fixed maturities, available for sale
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale	14.4	30.6
Embedded Derivative Related to Fixed Maturity Securities
Debt Securities, Available-for-sale [Line Items]
Change in fair value of certain investments with embedded derivatives	(4)	(13.1)
Reinsurance Contract | Coinsurance
Debt Securities, Available-for-sale [Line Items]
Change in fair value of certain investments with embedded derivatives	1.4	(6.5)
Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Net realized investment gains (losses)	(10.8)	23.5
Equity Securities - Corporate Securities
Debt Securities, Available-for-sale [Line Items]
Net realized investment gains (losses)	0.3	(5.9)
Commercial mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale	2.2
Corporate Securities
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale	11.1	14.6
Non-agency residential mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale		9.8
States and political subdivisions
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale		4.2
Various Other Investments
Debt Securities, Available-for-sale [Line Items]
Gross realized losses on sale	1.1	$ 2
Carrying Value | Residential Mortgage
Debt Securities, Available-for-sale [Line Items]
Mortgage loans	409.4
Fair Value | Residential Mortgage
Debt Securities, Available-for-sale [Line Items]
Mortgage loans	$ 407.2
Commercial Portfolio Segment
Debt Securities, Available-for-sale [Line Items]
Number of mortgage loans in process of foreclosure | mortgage_loan	0
Carrying value of loans	$ 1,275.1
Residential Portfolio Segment | Financial Asset, Past Due
Debt Securities, Available-for-sale [Line Items]
Number of mortgage loans noncurrent | loan	4
Carrying value of loans	$ 1.1
Residential Portfolio Segment | Foreclosure | Financial Asset, Past Due
Debt Securities, Available-for-sale [Line Items]
Number of mortgage loans noncurrent | loan	2
Carrying value of loans	$ 0.5

INVESTMENTS - SUMMARY OF CARRYI

INVESTMENTS - SUMMARY OF CARRYING VALUE AND ESTIMATED FAIR VALUE OF OUTSTANDING COMMERCIAL MORTGAGE LOANS AND UNDERLYING COLLATERAL (Details) $ in Millions	Mar. 31, 2023 USD ($)
Less than 60% | Maximum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	60%
60% to less than 70% | Maximum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	70%
60% to less than 70% | Minimum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	60%
70% to less than 80% | Maximum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	80%
70% to less than 80% | Minimum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	70%
80% to less than 90% | Maximum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	90%
80% to less than 90% | Minimum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	80%
Debt-To-Value Ratio, Greater Than 90 Percent | Minimum
Financing Receivable, Credit Quality Indicator [Line Items]
Outstanding Mortgage Loans, Loan to Value Ratio	90%
Commercial Portfolio Segment
Financing Receivable, Credit Quality Indicator [Line Items]
2023	$ 73.6
2022	313.8
2021	150.7
2020	43.1
2019	75.1
Prior	618.8
Total amortized cost	1,275.1
Mortgage loans	1,150.3
Collateral	3,987.1
Commercial Portfolio Segment | Less than 60%
Financing Receivable, Credit Quality Indicator [Line Items]
2023	73.6
2022	178.7
2021	114.4
2020	37.4
2019	75.1
Prior	494.2
Total amortized cost	973.4
Mortgage loans	884.3
Collateral	3,553.3
Commercial Portfolio Segment | 60% to less than 70%
Financing Receivable, Credit Quality Indicator [Line Items]
2023	0
2022	87.3
2021	26.2
2020	5.7
2019	0
Prior	56.8
Total amortized cost	176
Mortgage loans	159.7
Collateral	269.3
Commercial Portfolio Segment | 70% to less than 80%
Financing Receivable, Credit Quality Indicator [Line Items]
2023	0
2022	47.8
2021	10.1
2020	0
2019	0
Prior	43.2
Total amortized cost	101.1
Mortgage loans	86.8
Collateral	138.4
Commercial Portfolio Segment | 80% to less than 90%
Financing Receivable, Credit Quality Indicator [Line Items]
2023	0
2022	0
2021	0
2020	0
2019	0
Prior	0
Total amortized cost	0
Mortgage loans	0
Collateral	0
Commercial Portfolio Segment | 90% or greater
Financing Receivable, Credit Quality Indicator [Line Items]
2023	0
2022	0
2021	0
2020	0
2019	0
Prior	24.6
Total amortized cost	24.6
Mortgage loans	19.5
Collateral	$ 26.1

INVESTMENTS - SUMMARY OF CHAN_2

INVESTMENTS - SUMMARY OF CHANGES IN THE ALLOWANCE FOR CURRENT EXPECTED CREDIT LOSSES RELATED TO MORTGAGE LOANS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for credit losses at beginning of period	$ 8	$ 5.6
Current period provision for expected credit losses	0.4	(0.5)
Initial allowance recognized for purchased financial assets with credit deterioration	0	0
Write-offs charged against the allowance	0	0
Recoveries of amounts previously written off	0	0
Allowance for credit losses at end of period	$ 8.4	$ 5.1

INVESTMENTS - TOTAL INVESTMENT

INVESTMENTS - TOTAL INVESTMENT GAINS (LOSSES) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Realized investment gains (losses):
Total realized investment gains (losses)	$ (14.6)	$ 18.8
Change in allowance for credit losses	(1.5)	(30.7)
Change in fair value of equity securities	0.4	(1.2)
Other changes in fair value	1.1	(19.6)
Other investment losses	0	(51.5)
Net realized investment gains (losses)	(14.6)	(32.7)
Variable interest entities, change in allowance for current expected credit losses	2	(2.2)
Increase (decrease) in equity securities, FV-NI, held at end of period	0.3	(5.2)
Change in estimated fair value of trading securities	(2.5)	(12.8)
Total fixed maturities, available for sale
Realized investment gains (losses):
Gross realized gains on sales of fixed maturities, available for sale	7.3	54.8
Gross realized losses on sales of fixed maturities, available for sale	(14.4)	(30.6)
Equity securities, net	(0.2)	(4.7)
Other, net	$ (7.3)	$ (0.7)

LIABILITIES FOR INSURANCE PRO_3

LIABILITIES FOR INSURANCE PRODUCTS - SUMMARY OF CHANGES IN LIABILITY FOR FUTURE POLICY BENEFITS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Net liability for future policy benefits	$ 11,623.3		$ 11,240.2		$ 15,704.9	$ 11,744.2
Supplemental health
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Present value of expected net premiums ("PVENP"), beginning of period	2,781.3	$ 3,496.8
Effect of changes in discount rate assumptions, beginning of period	(188.4)	525.6
Beginning PVENP at original discount rate	2,969.7	2,971.2
Effect of changes in cash flow assumptions			0	$ 0
Effect of actual variances from expected experience			(17.2)	6.3
Adjusted beginning of period PVENP			2,952.5	2,977.5
Issuances	63.7	80.6
Interest accrual	32	31.3
Net premiums collected	(90.3)	(89.5)
Ending PVENP at original discount rate	2,957.9	2,999.9
Effect of changes in discount rate assumptions, end of period	(120.4)	213.4
PVENP, end of period	2,837.5	3,213.3
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Present value of expected future policy benefits ("PVEFPB"), beginning of period	5,886.8	7,688
Effect of changes in discount rate assumptions, beginning of period	483.3	(1,414.8)
Beginning PVEFPB at original discount rate	6,370.1	6,273.2
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			(20.5)	5.6
Adjusted beginning of period PVEFPB			6,349.6	6,278.8
Issuances	63.7	80.8
Interest accrual	73.8	72.5
Benefit payments	(99.5)	(99.5)
Ending PVEFPB at original discount rate	6,387.6	6,332.6
Effect of changes in discount rate assumptions, end of period	306.8	(622.3)
PVEFPB, end of period	6,080.8	6,954.9
Net liability for future policy benefits	3,243.3	3,741.6
Flooring impact	0	1.5
Adjusted net liability for future policy benefits	3,243.3	3,743.1
Related reinsurance recoverable	(2.4)	(3.2)
Net liability for future policy benefits, net of reinsurance recoverable	3,240.9	3,739.9
Medicare supplement
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Present value of expected net premiums ("PVENP"), beginning of period	2,800.6	3,454
Effect of changes in discount rate assumptions, beginning of period	(196.4)	341.8
Beginning PVENP at original discount rate	2,997	3,112.2
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			27	21.2
Adjusted beginning of period PVENP			3,024	3,133.4
Issuances	101.6	68
Interest accrual	30.5	30.4
Net premiums collected	(113.4)	(119)
Ending PVENP at original discount rate	3,042.7	3,112.8
Effect of changes in discount rate assumptions, end of period	(139.2)	112.1
PVENP, end of period	2,903.5	3,224.9
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Present value of expected future policy benefits ("PVEFPB"), beginning of period	3,033.1	3,750.5
Effect of changes in discount rate assumptions, beginning of period	212	(373.8)
Beginning PVEFPB at original discount rate	3,245.1	3,376.7
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			32.2	21.5
Adjusted beginning of period PVEFPB			3,277.3	3,398.2
Issuances	101.6	67.3
Interest accrual	33.2	33.2
Benefit payments	(125.6)	(123.3)
Ending PVEFPB at original discount rate	3,286.5	3,375.4
Effect of changes in discount rate assumptions, end of period	150	(123.9)
PVEFPB, end of period	3,136.5	3,499.3
Net liability for future policy benefits	233	274.4
Flooring impact	0.4	0.2
Adjusted net liability for future policy benefits	233.4	274.6
Related reinsurance recoverable	0	0
Net liability for future policy benefits, net of reinsurance recoverable	233.4	274.6
Long-term care
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Present value of expected net premiums ("PVENP"), beginning of period	1,034.1	1,313.4
Effect of changes in discount rate assumptions, beginning of period	(23.2)	183.2
Beginning PVENP at original discount rate	1,057.3	1,130.2
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			(3.4)	(8.9)
Adjusted beginning of period PVENP			1,053.9	1,121.3
Issuances	15.7	25.7
Interest accrual	12.3	13.1
Net premiums collected	(40.6)	(42.7)
Ending PVENP at original discount rate	1,041.3	1,117.4
Effect of changes in discount rate assumptions, end of period	(4.6)	94.2
PVENP, end of period	1,036.7	1,211.6
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Present value of expected future policy benefits ("PVEFPB"), beginning of period	4,158.1	5,501.6
Effect of changes in discount rate assumptions, beginning of period	28.5	(1,291.2)
Beginning PVEFPB at original discount rate	4,186.6	4,210.4
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			(6.3)	(9.2)
Adjusted beginning of period PVEFPB			4,180.3	4,201.2
Issuances	15.7	25.7
Interest accrual	55.5	56.1
Benefit payments	(71.3)	(64.2)
Ending PVEFPB at original discount rate	4,180.2	4,218.8
Effect of changes in discount rate assumptions, end of period	(86.4)	(747.4)
PVEFPB, end of period	4,266.6	4,966.2
Net liability for future policy benefits	3,229.9	3,754.6
Flooring impact	0	0.6
Adjusted net liability for future policy benefits	3,229.9	3,755.2
Related reinsurance recoverable	(357.5)	(407)
Net liability for future policy benefits, net of reinsurance recoverable	2,872.4	3,348.2
Traditional life
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Present value of expected net premiums ("PVENP"), beginning of period	2,175	2,483.7
Effect of changes in discount rate assumptions, beginning of period	(137.1)	239.4
Beginning PVENP at original discount rate	2,312.1	2,244.3
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			(14.1)	(11.8)
Adjusted beginning of period PVENP			2,298	2,232.5
Issuances	108.3	149.3
Interest accrual	23	20.9
Net premiums collected	(101.4)	(99.9)
Ending PVENP at original discount rate	2,327.9	2,302.8
Effect of changes in discount rate assumptions, end of period	(92.5)	72.5
PVENP, end of period	2,235.4	2,375.3
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Present value of expected future policy benefits ("PVEFPB"), beginning of period	4,417.9	5,395.7
Effect of changes in discount rate assumptions, beginning of period	336.6	(767.3)
Beginning PVEFPB at original discount rate	4,754.5	4,628.4
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			(15.2)	(8.5)
Adjusted beginning of period PVEFPB			4,739.3	4,619.9
Issuances	108.3	149.4
Interest accrual	51	48.8
Benefit payments	(115)	(128.8)
Ending PVEFPB at original discount rate	4,783.6	4,689.3
Effect of changes in discount rate assumptions, end of period	223	(296.2)
PVEFPB, end of period	4,560.6	4,985.5
Net liability for future policy benefits	2,325.2	2,610.2
Flooring impact	0	0.4
Adjusted net liability for future policy benefits	2,325.2	2,610.6
Related reinsurance recoverable	(201.1)	(242.1)
Net liability for future policy benefits, net of reinsurance recoverable	2,124.1	2,368.5
Other annuities
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Present value of expected net premiums ("PVENP"), beginning of period	0	0
Effect of changes in discount rate assumptions, beginning of period	0	0
Beginning PVENP at original discount rate	0	0
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			0	0
Adjusted beginning of period PVENP			0	0
Issuances	1.1	1.6
Interest accrual	0	0
Net premiums collected	(1.1)	(1.6)
Ending PVENP at original discount rate	0	0
Effect of changes in discount rate assumptions, end of period	0	0
PVENP, end of period	0	0
Present value of expected future policy benefits ("PVEFPB"), beginning of period
Present value of expected future policy benefits ("PVEFPB"), beginning of period	310.9	431.9
Effect of changes in discount rate assumptions, beginning of period	15.4	(88.4)
Beginning PVEFPB at original discount rate	326.3	343.5
Effect of changes in cash flow assumptions			0	0
Effect of actual variances from expected experience			0.7	(1.3)
Adjusted beginning of period PVEFPB			$ 327	$ 342.2
Issuances	1.1	1.9
Interest accrual	3.7	3.9
Benefit payments	(8.6)	(9.3)
Ending PVEFPB at original discount rate	323.2	338.7
Effect of changes in discount rate assumptions, end of period	6.9	(44.6)
PVEFPB, end of period	316.3	383.3
Net liability for future policy benefits	316.3	383.3
Flooring impact	0	0
Adjusted net liability for future policy benefits	316.3	383.3
Related reinsurance recoverable	0	0
Net liability for future policy benefits, net of reinsurance recoverable	$ 316.3	$ 383.3

LIABILITIES FOR INSURANCE PRO_4

LIABILITIES FOR INSURANCE PRODUCTS - RECONCILIATION OF NET LIABILITY FOR FUTURE POLICY BENEFITS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022
Liability for Future Policy Benefit, Activity [Line Items]
Reserves excluded from rollforward	$ 2,593.3	$ 2,626.5
Deferred profit liability	57.7	51.3
Amount of reserves above (below) policyholder account balances	(410.5)	(273.1)
Future loss reserves	34.7	34.6
Future policy benefits	11,623.3	13,206.1
Supplemental health
Liability for Future Policy Benefit, Activity [Line Items]
Adjusted net liability for future policy benefits	3,243.3	3,743.1
Medicare supplement
Liability for Future Policy Benefit, Activity [Line Items]
Adjusted net liability for future policy benefits	233.4	274.6
Long-term care
Liability for Future Policy Benefit, Activity [Line Items]
Adjusted net liability for future policy benefits	3,229.9	3,755.2
Traditional life
Liability for Future Policy Benefit, Activity [Line Items]
Adjusted net liability for future policy benefits	2,325.2	2,610.6
Other annuities
Liability for Future Policy Benefit, Activity [Line Items]
Adjusted net liability for future policy benefits	$ 316.3	$ 383.3

LIABILITIES FOR INSURANCE PRO_5

LIABILITIES FOR INSURANCE PRODUCTS - CHANGES IN MARKET RISK BENEFITS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Market Risk Benefit [Roll Forward]
Net liability (asset), beginning of period	$ (54)	$ 86.2
Effect of changes in the instrument-specific credit risk, beginning of period	(13.1)	(18.7)	$ 12.2	$ 12.1
Balance, beginning of period, before effect of changes in the instrument-specific credit risk	(41.8)	98.3
Issuances	0.1	(0.8)
Interest accrual	5.2	3.4
Attributed fees collected	0	0
Benefit payments	0	0
Effect of changes in interest rates	12.3	(35.3)
Effect of changes in equity markets	5.3	(6.8)
Effect of changes in equity index volatility	(7.4)	4.4
Actual policyholder behavior different from expected behavior	0.6	0.3
Effect of changes in future expected policyholder behavior - other	0	0
Effect of changes in future expected policyholder behavior - risk margin	0	0
Effect of changes in assumptions	(1.4)	2.1
Net liability (asset), end of period, before effect of changes in the instrument-specific credit risk	(27.1)	65.6
Net liability (asset), end of period	(40.2)	46.9
Reinsurance recoverable, end of period	0	0
Net liability (asset), end of period, net of reinsurance	(40.2)	46.9
Balance reported as an asset	57.8	16.9	65.3		$ 2.5	$ 0
Balance reported as a liability	17.6	63.8	11.3		$ 114.8	$ 0
Net liability (asset)	(40.2)	46.9	$ (54)	$ 86.2
Net amount at risk	$ 58.9	$ 107.4
Weighted average attained age of contract holders	68 years	68 years

LIABILITIES FOR INSURANCE PRO_6

LIABILITIES FOR INSURANCE PRODUCTS - SUMMARY OF AMOUNT OF REVENUE AND INTEREST, TRADITIONAL AND LIMITED PAYMENT CONTRACTS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	$ 601.4	$ 600.3
Interest accretion	119.4	118.8
Other annuity
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	1.3	2.2
Interest accretion	3.7	3.9
Supplemental health
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	179.4	175.7
Interest accretion	41.8	41.2
Medicare supplement
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	159.2	167.6
Interest accretion	2.7	2.8
Long-term care
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	82.7	82.4
Interest accretion	43.2	43
Traditional life
Liability for Future Policy Benefit, Activity [Line Items]
Gross premiums	178.8	172.4
Interest accretion	$ 28	$ 27.9

LIABILITIES FOR INSURANCE PRO_7

LIABILITIES FOR INSURANCE PRODUCTS - SUMMARY OF AMOUNT OF UNDISCOUNTED AND DISCOUNTED EXPECTED GROSS PREMIUMS AND EXPECTED FUTURE BENEFITS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022
Other annuity
Liability for Future Policy Benefit, Activity [Line Items]
Expected future gross premiums (Undiscounted)	$ 0	$ 0
Expected future gross premiums (Discounted)	0	0
Expected future benefits and expenses (Undiscounted)	396.9	426
Expected future benefits and expenses (Discounted)	316.3	383.3
Supplemental health
Liability for Future Policy Benefit, Activity [Line Items]
Expected future gross premiums (Undiscounted)	8,964.4	8,862.2
Expected future gross premiums (Discounted)	5,605.7	6,222.2
Expected future benefits and expenses (Undiscounted)	11,040.9	10,940.4
Expected future benefits and expenses (Discounted)	6,080.8	6,954.9
Medicare supplement
Liability for Future Policy Benefit, Activity [Line Items]
Expected future gross premiums (Undiscounted)	5,645.2	5,680.8
Expected future gross premiums (Discounted)	4,031.9	4,490
Expected future benefits and expenses (Undiscounted)	4,417.8	4,446.9
Expected future benefits and expenses (Discounted)	3,136.5	3,499.3
Long-term care
Liability for Future Policy Benefit, Activity [Line Items]
Expected future gross premiums (Undiscounted)	2,954.3	3,012.5
Expected future gross premiums (Discounted)	2,152.7	2,389.4
Expected future benefits and expenses (Undiscounted)	7,445.7	7,606.7
Expected future benefits and expenses (Discounted)	4,266.6	4,966.2
Traditional life
Liability for Future Policy Benefit, Activity [Line Items]
Expected future gross premiums (Undiscounted)	5,435	5,384.4
Expected future gross premiums (Discounted)	3,953.3	4,260.8
Expected future benefits and expenses (Undiscounted)	7,382.8	7,180.2
Expected future benefits and expenses (Discounted)	$ 4,560.6	$ 4,985.5

LIABILITIES FOR INSURANCE PRO_8

LIABILITIES FOR INSURANCE PRODUCTS - WEIGHTED AVERAGE DURATIONS OF LIABILITY (Details)	Mar. 31, 2023	Mar. 31, 2022
Other annuity
Liability for Future Policy Benefit, Activity [Line Items]
Weighted average duration	9 years 8 months 12 days	9 years 8 months 12 days
Supplemental health
Liability for Future Policy Benefit, Activity [Line Items]
Weighted average duration	11 years 9 months 18 days	12 years
Medicare supplement
Liability for Future Policy Benefit, Activity [Line Items]
Weighted average duration	6 years 1 month 6 days	5 years 10 months 24 days
Long-term care
Liability for Future Policy Benefit, Activity [Line Items]
Weighted average duration	10 years 6 months	10 years 9 months 18 days
Traditional life
Liability for Future Policy Benefit, Activity [Line Items]
Weighted average duration	10 years 1 month 6 days	10 years 4 months 24 days

LIABILITIES FOR INSURANCE PRO_9

LIABILITIES FOR INSURANCE PRODUCTS - WEIGHTED AVERAGE INTEREST RATE (Details)	Mar. 31, 2023	Mar. 31, 2022
Other annuity
Liability for Future Policy Benefit, Activity [Line Items]
Interest accretion rate	4.76%	4.72%
Current discount rate	5.17%	3.68%
Supplemental health
Liability for Future Policy Benefit, Activity [Line Items]
Interest accretion rate	5.04%	5.09%
Current discount rate	5.14%	3.66%
Medicare supplement
Liability for Future Policy Benefit, Activity [Line Items]
Interest accretion rate	4.26%	4.23%
Current discount rate	4.94%	3.41%
Long-term care
Liability for Future Policy Benefit, Activity [Line Items]
Interest accretion rate	5.67%	5.71%
Current discount rate	5.18%	3.71%
Traditional life
Liability for Future Policy Benefit, Activity [Line Items]
Interest accretion rate	4.77%	4.82%
Current discount rate	5.15%	3.66%

LIABILITIES FOR INSURANCE PR_10

LIABILITIES FOR INSURANCE PRODUCTS - SUMMARY OF CHANGES IN POLICYHOLDER ACCOUNT BALANCES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 01, 2021	Dec. 31, 2020
Policyholder Account Balance [Roll Forward]
Policyholder account balances	$ 15,302.9	$ 14,725.6	$ 15,234.2	$ 12,367.7	$ 12,540.6
Fixed indexed annuities
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	9,490.4	8,681
Issuances	323.3	354.6
Premiums received	0.4	0.1
Policy charges	(4)	(3)
Surrenders and withdrawals	(178.2)	(133.7)
Benefit payments	(59.2)	(67.3)
Interest credited	6.1	65.7
Other	5.5	4.6
Balance, end of period excluding contracts 100% ceded	9,584.3	8,902
Balance, end of period for contracts 100% ceded	154.4	166.6
Policyholder account balances	9,738.7	9,068.6
Balance, end of period, reinsurance ceded	(154.4)	(166.6)
Balance, end of period, net of reinsurance	$ 9,584.3	$ 8,902
Weighted average crediting rate	1.60%	1.40%
Net amount at risk	$ 0	$ 0
Cash surrender value, net of reinsurance	8,932.4	8,295.5
Fixed interest annuities
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	1,663.1	1,806.1
Issuances	45.3	10.5
Premiums received	0.7	1.1
Policy charges	(0.2)	(0.1)
Surrenders and withdrawals	(43.3)	(37.9)
Benefit payments	(27.7)	(39.6)
Interest credited	11.3	11.5
Other	0.1	0.2
Balance, end of period excluding contracts 100% ceded	1,649.3	1,751.8
Balance, end of period for contracts 100% ceded	632.6	658.8
Policyholder account balances	2,281.9	2,410.6
Balance, end of period, reinsurance ceded	(632.6)	(658.8)
Balance, end of period, net of reinsurance	$ 1,649.3	$ 1,751.8
Weighted average crediting rate	2.70%	2.60%
Net amount at risk	$ 0	$ 0
Cash surrender value, net of reinsurance	1,631.5	1,743.3
Other annuities
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	127.1	131.2
Issuances	0	0
Premiums received	7.5	9.1
Policy charges	0	0
Surrenders and withdrawals	(10.5)	(10.2)
Benefit payments	(1.7)	(1.4)
Interest credited	0.6	0.6
Other	(0.2)	0
Balance, end of period excluding contracts 100% ceded	122.8	129.3
Balance, end of period for contracts 100% ceded	26.3	28.2
Policyholder account balances	149.1	157.5
Balance, end of period, reinsurance ceded	(26.3)	(28.2)
Balance, end of period, net of reinsurance	$ 122.8	$ 129.3
Weighted average crediting rate	1.90%	1.80%
Net amount at risk	$ 0	$ 0
Cash surrender value, net of reinsurance	122.8	129.3
Interest-sensitive life
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	1,209.6	1,163.9
Issuances	9.5	10.6
Premiums received	50.3	47.6
Policy charges	(46.1)	(44.5)
Surrenders and withdrawals	(8.2)	(5.7)
Benefit payments	(6)	(7.8)
Interest credited	8.1	15.7
Other	0	0
Balance, end of period excluding contracts 100% ceded	1,217.2	1,179.8
Balance, end of period for contracts 100% ceded	110.7	115.7
Policyholder account balances	1,327.9	1,295.5
Balance, end of period, reinsurance ceded	(130.5)	(136.5)
Balance, end of period, net of reinsurance	$ 1,197.4	$ 1,159
Weighted average crediting rate	3.10%	5.90%
Net amount at risk	$ 26,865.3	$ 26,436.6
Cash surrender value, net of reinsurance	977.1	938.6
Funding agreements
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	1,410.8	502
Issuances	0	899
Premiums received	0	0
Policy charges	0	0
Surrenders and withdrawals	(9.9)	0
Benefit payments	0	0
Interest credited	7.2	7
Other	0	0
Balance, end of period excluding contracts 100% ceded	1,408.1	1,408
Balance, end of period for contracts 100% ceded	0	0
Policyholder account balances	1,408.1	1,408
Balance, end of period, reinsurance ceded	0	0
Balance, end of period, net of reinsurance	$ 1,408.1	$ 1,408
Weighted average crediting rate	2%	2%
Net amount at risk	$ 0	$ 0
Cash surrender value, net of reinsurance	0	0
Other
Policyholder Account Balance [Roll Forward]
Balance, beginning of period excluding contracts 100% ceded	395.5	368
Issuances	0	0
Premiums received	63	61.7
Policy charges	0	0
Surrenders and withdrawals	(72.6)	(56.8)
Benefit payments	0	(0.1)
Interest credited	0.7	0.7
Other	0	0
Balance, end of period excluding contracts 100% ceded	386.6	373.5
Balance, end of period for contracts 100% ceded	10.6	11.9
Policyholder account balances	397.2	385.4
Balance, end of period, reinsurance ceded	(24.8)	(26.7)
Balance, end of period, net of reinsurance	$ 372.4	$ 358.7
Weighted average crediting rate	0.60%	0.70%
Net amount at risk	$ 0	$ 0
Cash surrender value, net of reinsurance	$ 372.4	$ 358.7

LIABILITIES FOR INSURANCE PR_11

LIABILITIES FOR INSURANCE PRODUCTS - RECONCILIATION OF LIABILITY FOR POLICYHOLDER ACCOUNT BALANCES (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Jan. 01, 2021	Dec. 31, 2020
Policyholder Account Balance [Line Items]
Total	$ 15,302.9	$ 15,234.2	$ 14,725.6	$ 12,367.7	$ 12,540.6
Fixed indexed annuities
Policyholder Account Balance [Line Items]
Total	9,738.7		9,068.6
Fixed interest annuities
Policyholder Account Balance [Line Items]
Total	2,281.9		2,410.6
Other annuity
Policyholder Account Balance [Line Items]
Total	149.1		157.5
Interest-sensitive life
Policyholder Account Balance [Line Items]
Total	1,327.9		1,295.5
Funding agreements
Policyholder Account Balance [Line Items]
Total	1,408.1		1,408
Other
Policyholder Account Balance [Line Items]
Total	$ 397.2		$ 385.4

LIABILITIES FOR INSURANCE PR_12

LIABILITIES FOR INSURANCE PRODUCTS - GUARANTEED MINIMUM CREDITING RATES (Details) $ in Millions	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 15,302.9	$ 15,234.2	$ 14,725.6	$ 12,367.7	$ 12,540.6
0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 2,963.9		2,416.8
0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 2,473.5		2,635.3
3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 126.8		604.9
5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 1,680.9		1,658.8
At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	2,122.4		2,230.8
At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 123.3		129.8
1-50 basis points above | Minimum
Policyholder Account Balance [Line Items]
Policyholder account balance, above guaranteed minimum crediting rate	0.0001
1-50 basis points above | Maximum
Policyholder Account Balance [Line Items]
Policyholder account balance, above guaranteed minimum crediting rate	0.0050
1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 902.4		703.6
1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	79.4		80
1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 0.5		0.4
51-150 basis points above | Minimum
Policyholder Account Balance [Line Items]
Policyholder account balance, above guaranteed minimum crediting rate	0.0051
51-150 basis points above | Maximum
Policyholder Account Balance [Line Items]
Policyholder account balance, above guaranteed minimum crediting rate	0.0150
51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 303.7		42.9
51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	146.7		178.1
51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 2.7		0
Greater than 150 basis points above | Minimum
Policyholder Account Balance [Line Items]
Policyholder account balance, above guaranteed minimum crediting rate	0.0150
Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 76.9		11.5
Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	125		146.4
Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0.3		474.7
Contracts Excluding Fixed Index Annuities
Policyholder Account Balance [Line Items]
Policyholder account balances	5,564.2		5,657
Contracts Excluding Fixed Index Annuities | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	3,926.6		4,019.4
Contracts Excluding Fixed Index Annuities | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	982.3		784
Contracts Excluding Fixed Index Annuities | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	453.1		221
Contracts Excluding Fixed Index Annuities | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	202.2		632.6
Fixed interest annuities
Policyholder Account Balance [Line Items]
Policyholder account balances	2,281.9		2,410.6
Fixed interest annuities | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 591.8		558.3
Fixed interest annuities | 0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
Fixed interest annuities | 0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
Fixed interest annuities | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 1,599.8		1,757.9
Fixed interest annuities | 3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
Fixed interest annuities | 3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
Fixed interest annuities | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 90.3		94.4
Fixed interest annuities | 5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
Fixed interest annuities | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 1,807.2		2,000.4
Fixed interest annuities | At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	144.9		171.7
Fixed interest annuities | At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	1,572		1,734.3
Fixed interest annuities | At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	90.3		94.4
Fixed interest annuities | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	319.4		355.7
Fixed interest annuities | 1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	291.7		332.2
Fixed interest annuities | 1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	27.7		23.5
Fixed interest annuities | 1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Fixed interest annuities | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	78.4		43
Fixed interest annuities | 51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	78.3		42.9
Fixed interest annuities | 51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0.1		0.1
Fixed interest annuities | 51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Fixed interest annuities | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	76.9		11.5
Fixed interest annuities | Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	76.9		11.5
Fixed interest annuities | Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Fixed interest annuities | Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity
Policyholder Account Balance [Line Items]
Policyholder account balances	149.1		157.5
Other annuity | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 73.1		83.4
Other annuity | 0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
Other annuity | 0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
Other annuity | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 65.3		62.4
Other annuity | 3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
Other annuity | 3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
Other annuity | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 10.7		11.7
Other annuity | 5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
Other annuity | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 119.6		127.2
Other annuity | At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	43.6		53.1
Other annuity | At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	65.3		62.4
Other annuity | At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	10.7		11.7
Other annuity | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	29.5		30.3
Other annuity | 1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	29.5		30.3
Other annuity | 1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | 1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | 51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | 51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | 51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other annuity | Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Interest-sensitive life
Policyholder Account Balance [Line Items]
Policyholder account balances	1,327.9		1,295.5
Interest-sensitive life | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 517.7		7.5
Interest-sensitive life | 0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
Interest-sensitive life | 0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
Interest-sensitive life | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 784.8		790.2
Interest-sensitive life | 3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
Interest-sensitive life | 3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
Interest-sensitive life | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 25.4		497.8
Interest-sensitive life | 5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
Interest-sensitive life | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 549.9		439.5
Interest-sensitive life | At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	66.5		7.5
Interest-sensitive life | At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	461.5		409.3
Interest-sensitive life | At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	21.9		22.7
Interest-sensitive life | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	278		56.9
Interest-sensitive life | 1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	225.8		0
Interest-sensitive life | 1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	51.7		56.5
Interest-sensitive life | 1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0.5		0.4
Interest-sensitive life | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	374.7		178
Interest-sensitive life | 51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	225.4		0
Interest-sensitive life | 51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	146.6		178
Interest-sensitive life | 51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	2.7		0
Interest-sensitive life | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	125.3		621.1
Interest-sensitive life | Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Interest-sensitive life | Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	125		146.4
Interest-sensitive life | Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0.3		474.7
Funding agreements
Policyholder Account Balance [Line Items]
Policyholder account balances	1,408.1		1,408
Funding agreements | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 1,408.1		1,408
Funding agreements | 0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
Funding agreements | 0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
Funding agreements | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 0		0
Funding agreements | 3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
Funding agreements | 3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
Funding agreements | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 0		0
Funding agreements | 5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
Funding agreements | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 1,408.1		1,408
Funding agreements | At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	1,408.1		1,408
Funding agreements | At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | 51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Funding agreements | Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other
Policyholder Account Balance [Line Items]
Policyholder account balances	397.2		385.4
Other | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 373.2		359.6
Other | 0.00%-2.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	0%
Other | 0.00%-2.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	2.99%
Other | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 23.6		24.8
Other | 3.00%-4.99% | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	3%
Other | 3.00%-4.99% | Maximum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	4.99%
Other | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 0.4		1
Other | 5.00% and greater | Minimum
Policyholder Account Balance [Line Items]
Range of guaranteed minimum crediting rates	5%
Other | At guaranteed minimum
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 41.8		44.3
Other | At guaranteed minimum | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	17.8		18.5
Other | At guaranteed minimum | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	23.6		24.8
Other | At guaranteed minimum | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0.4		1
Other | 1-50 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	355.4		341.1
Other | 1-50 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	355.4		341.1
Other | 1-50 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | 1-50 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | 51-150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | 51-150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | 51-150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | 51-150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | Greater than 150 basis points above
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | Greater than 150 basis points above | 0.00%-2.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | Greater than 150 basis points above | 3.00%-4.99%
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Other | Greater than 150 basis points above | 5.00% and greater
Policyholder Account Balance [Line Items]
Policyholder account balances	0		0
Fixed indexed annuities
Policyholder Account Balance [Line Items]
Policyholder account balances	$ 9,738.7		$ 9,068.6

DEFERRED ACQUISITION COSTS, P_3

DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS - DEFERRED ACQUISITION COSTS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	$ 1,690.4	$ 1,553.3
Capitalizations	84.2	79
Amortization expense	(46.6)	(43)
End of period	1,728	1,589.3
Fixed indexed annuities
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	365.6	313
Capitalizations	21.6	22.5
Amortization expense	(11.1)	(9.7)
End of period	376.1	325.8
Fixed interest annuities
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	19.6	19
Capitalizations	2.5	0.5
Amortization expense	(0.9)	(0.9)
End of period	21.2	18.6
Supplemental health
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	378.8	357.5
Capitalizations	14.4	12
Amortization expense	(7.6)	(7)
End of period	385.6	362.5
Medicare supplement
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	161.2	170.2
Capitalizations	5.8	5.5
Amortization expense	(7.2)	(7.6)
End of period	159.8	168.1
Long-term care
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	137.9	136.4
Capitalizations	3.4	4.8
Amortization expense	(3.8)	(3.9)
End of period	137.5	137.3
Interest-sensitive life
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	212.2	196.3
Capitalizations	8.3	7.8
Amortization expense	(3.5)	(3.4)
End of period	217	200.7
Traditional life
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	409.1	357.6
Capitalizations	28.2	21.7
Amortization expense	(12.2)	(10.2)
End of period	425.1	369.1
Funding agreements
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Beginning of period	6	3.3
Capitalizations	0	4.2
Amortization expense	(0.3)	(0.3)
End of period	$ 5.7	$ 7.2

DEFERRED ACQUISITION COSTS, P_4

DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS - PRESENT VALUE OF FUTURE PROFITS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	$ 203.7	$ 230.1
Amortization expense	(6.1)	(6.9)
End of period	197.6	223.2
Supplemental health
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	154	168.1
Amortization expense	(3.3)	(3.6)
End of period	150.7	164.5
Medicare supplement
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	27.5	36.5
Amortization expense	(1.9)	(2.5)
End of period	25.6	34
Long-term care
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	6.2	7.3
Amortization expense	(0.3)	(0.3)
End of period	5.9	7
Traditional life
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	14.8	16.9
Amortization expense	(0.5)	(0.5)
End of period	14.3	16.4
Fixed indexed annuities
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	0.8	0.9
Amortization expense	(0.1)	0
End of period	0.7	0.9
Fixed interest annuities
Movement in Present Value of Future Insurance Profits [Roll Forward]
Beginning of period	0.4	0.4
Amortization expense	0	0
End of period	$ 0.4	$ 0.4

DEFERRED ACQUISITION COSTS, P_5

DEFERRED ACQUISITION COSTS, PRESENT VALUE OF FUTURE PROFITS AND SALES INDUCEMENTS - SALES INDUCEMENTS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fixed indexed annuities
Movement in Deferred Sales Inducements [Roll Forward]
Beginning of period	$ 76	$ 63
Capitalizations	5.4	4.6
Amortization expense	(2.6)	(2.1)
End of period	78.8	65.5
Fixed interest annuities
Movement in Deferred Sales Inducements [Roll Forward]
Beginning of period	4.5	5
Capitalizations	0.2	0.1
Amortization expense	(0.2)	(0.3)
End of period	4.5	4.8
Annuity
Movement in Deferred Sales Inducements [Roll Forward]
Beginning of period	80.5	68
Capitalizations	5.6	4.7
Amortization expense	(2.8)	(2.4)
End of period	$ 83.3	$ 70.3

EARNINGS PER SHARE - BASIC AND

EARNINGS PER SHARE - BASIC AND DILUTED EARNINGS PER SHARE (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net income (loss) for basic earnings per share	$ (0.8)	$ 183.4
Net income (loss) for diluted earnings per share	$ (0.8)	$ 183.4
Shares:
Weighted average shares outstanding for basic earnings per share (in shares)	114,545	118,622
Effect of dilutive securities on weighted average shares:
Amounts related to employee benefit plans (in shares)	0	2,380
Weighted average shares outstanding for diluted earnings per share (in shares)	114,545	121,002
Common share equivalent excluded from computation of earnings per share (in shares)	2,182

BUSINESS SEGMENTS - NARRATIVE (

BUSINESS SEGMENTS - NARRATIVE (Details)	3 Months Ended
	Mar. 31, 2023 product_line
Segment Reporting [Abstract]
Number of product lines	3

BUSINESS SEGMENTS - SCHEDULE OF

BUSINESS SEGMENTS - SCHEDULE OF SEGMENT REPORTING INFORMATION BY SEGMENT (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Insurance policy income	$ 625.5	$ 625
Fee revenue and other income:	52.1	42.4
Total segment revenues	1,000.5	869.1
Expenses:
Insurance policy benefits	609.7	333.9
Interest expense	54.7	23.8
Impact of annual option forfeitures related to fixed indexed annuity surrenders	0	(1.6)
Other expenses	271.7	218.3
Total segment expenses	924.1	784.6
Operating earnings before taxes	76.4	84.5
Income tax expense on operating income	17.8	20
Net operating income	58.6	64.5
Operating Segments
Revenues:
Total segment revenues	1,000.5	869.1
Expenses:
Total segment expenses	924.1	784.6
Insurance Product Lines
Expenses:
Allocated expenses	157.5	144.8
Total insurance product margin	221.2	207.2
Operating earnings before taxes	63.7	62.4
Investment income not allocated to product lines
Revenues:
Change in market values of the underlying options supporting the fixed indexed annuity and life products (offset by market value changes credited to policyholder balances)	18.6	(71.9)
Investment income not allocated to product lines	67.8	46.6
Expenses:
Interest credited	7.2	6.9
Market value changes of options credited to fixed indexed annuity and life policyholders	18.6	(71.9)
Interest expense	37.4	18.1
Amortization	0.4	0.4
Other expenses	7.3	(4.2)
Total insurance product margin	15.5	27
Fee income
Revenues:
Fee revenue and other income:	51.3	40.3
Expenses:
Commissions and other operating expenses	35.8	30.4
Total insurance product margin	15.5	9.9
Amounts netted in expenses not allocated to product lines
Revenues:
Fee revenue and other income:	1.6	2.8
Expenses:
Expenses not allocated to product lines	19.9	17.6
Total insurance product margin	(18.3)	(14.8)
Annuity: | Insurance Product Lines
Revenues:
Insurance policy income	5.1	5
Net investment income	125.4	117.5
Total insurance product line revenue	130.5	122.5
Expenses:
Insurance policy benefits	8.7	9.5
Interest credited	48.1	42.5
Amortization and non-deferred commissions	16.4	14.6
Total expenses	73.2	66.6
Total insurance product margin	57.3	55.9
Health: | Insurance Product Lines
Revenues:
Insurance policy income	401.4	406.7
Net investment income	74	73.3
Total insurance product line revenue	475.4	480
Expenses:
Insurance policy benefits	318.1	323.1
Amortization and non-deferred commissions	40.8	41.6
Total expenses	358.9	364.7
Total insurance product margin	116.5	115.3
Life: | Insurance Product Lines
Revenues:
Insurance policy income	219	213.3
Net investment income	36.3	35.5
Total insurance product line revenue	255.3	248.8
Expenses:
Insurance policy benefits	147.2	153.1
Interest credited	12.1	12
Amortization and non-deferred commissions	48.6	47.7
Total expenses	207.9	212.8
Total insurance product margin	47.4	36
Allocated expenses | Insurance Product Lines
Expenses:
Total insurance product margin	$ (157.5)	$ (144.8)

BUSINESS SEGMENTS - RECONCILIAT

BUSINESS SEGMENTS - RECONCILIATION OF OPERATING PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total segment revenues	$ 1,000.5	$ 869.1
Total investment losses	(14.6)	18.8
Total revenues	1,006	842.9
Total segment expenses	924.1	784.6
Total benefits and expenses	1,007	602.6
Income (loss) before income taxes	(1)	240.3
Income tax expense (benefit) on period income (loss)	(0.2)	56.9
Net income (loss)	(0.8)	183.4
Operating Segments
Segment Reporting Information [Line Items]
Total segment revenues	1,000.5	869.1
Total segment expenses	924.1	784.6
Segment Reconciling Items
Segment Reporting Information [Line Items]
Total investment losses	(14.6)	(32.7)
Revenues related to earnings attributable to VIEs	20.1	6.5
Insurance policy benefits - changes in fair value of embedded derivative liabilities and market risk benefits	65.1	(165.4)
Expenses attributable to VIEs	17.8	6.1
Fair value changes related to agent deferred compensation plan	$ 0	$ (22.7)

ACCOUNTING FOR DERIVATIVES - FA

ACCOUNTING FOR DERIVATIVES - FAIR VALUE BY BALANCE SHEET LOCATION (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fixed indexed call options
Derivatives, Fair Value [Line Items]
Gross amounts recognized	$ 108.2	$ 56.7
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross amounts recognized	91.8	38.9
Gross derivative liability	1,347.9	1,297
Not Designated as Hedging Instrument | Fixed indexed call options | Other invested assets:
Derivatives, Fair Value [Line Items]
Gross amounts recognized	108.2	56.7
Not Designated as Hedging Instrument | Reinsurance receivables | Reinsurance receivables
Derivatives, Fair Value [Line Items]
Gross amounts recognized	(16.4)	(17.8)
Not Designated as Hedging Instrument | Fixed indexed products | Future policy benefits:
Derivatives, Fair Value [Line Items]
Gross derivative liability	$ 1,347.9	$ 1,297

ACCOUNTING FOR DERIVATIVES - NA

ACCOUNTING FOR DERIVATIVES - NARRATIVE (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Embedded derivative	$ 88
Fixed Index Call Options
Derivative [Line Items]
Notional amount	$ 2,700	$ 2,800

ACCOUNTING FOR DERIVATIVES - SC

ACCOUNTING FOR DERIVATIVES - SCHEDULE PRE-TAX GAINS (LOSSES) RECOGNIZED IN NET INCOME FOR DERIVATIVE INSTRUMENTS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative [Line Items]
Gains (losses) on derivatives not designated as hedging instruments	$ 20	$ (79.4)
Net investment income (loss) from policyholder and other special-purpose portfolios | Fixed indexed call options
Derivative [Line Items]
Gains (losses) on derivatives not designated as hedging instruments	18.6	(72.9)
Net realized gains (losses) | Embedded derivative related to modified coinsurance agreement | Coinsurance agreements
Derivative [Line Items]
Gains (losses) on derivatives not designated as hedging instruments	$ 1.4	$ (6.5)

ACCOUNTING FOR DERIVATIVES - DE

ACCOUNTING FOR DERIVATIVES - DERIVATIVES WITH MASTER NETTING ARRANGEMENTS (Details) - Fixed indexed call options - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Gross amounts recognized	$ 108.2	$ 56.7
Gross amounts offset in the balance sheet	0	0
Net amounts of assets presented in the balance sheet	108.2	56.7
Financial instruments	0	0
Cash collateral received	0	0
Net amount	$ 108.2	$ 56.7

REINSURANCE (Details)

REINSURANCE (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Insurance [Abstract]
Ceded premiums written	$ 48.3	$ 52
Reinsurance recoveries benefits	134.9	93.9
Assumed premiums written	4.1	4.9
Insurance policy benefits related to reinsurance assumed	$ 4.7	$ 6.1

INCOME TAXES - COMPONENTS OF TA

INCOME TAXES - COMPONENTS OF TAX EXPENSE (BENEFIT) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Current tax expense	$ 14	$ 4.4
Deferred tax expense (benefit)	(14.2)	52.5
Total income tax expense (benefit)	$ (0.2)	$ 56.9

INCOME TAXES - RECONCILIATION O

INCOME TAXES - RECONCILIATION OF CORPORATE TAX RATE (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
U.S. statutory corporate rate	21%	21%
Non-taxable income and nondeductible benefits, net	(0.40%)	0%
State taxes	2.70%	2.70%
Effective tax rate	23.30%	23.70%

INCOME TAXES - DEFERRED ASSETS

INCOME TAXES - DEFERRED ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Jan. 01, 2021	Dec. 31, 2020
Deferred tax assets:
Net federal operating loss carryforwards	$ 149.9	$ 166
Net state operating loss carryforwards	2.5	2.5
Insurance liabilities	329.4	298.5
Indirect costs allocable to self-constructed real estate assets	224.4	214.8
Accumulated other comprehensive loss	470.1	552.4
Other	0	7.3
Gross deferred tax assets	1,176.3	1,241.5
Deferred tax liabilities:
Investments	(34.8)	(37.2)
Present value of future profits and deferred acquisition costs	(152.1)	(148.9)
Other	(1.5)	0
Gross deferred tax liabilities	(188.4)	(186.1)
Net deferred tax assets	987.9	1,055.4
Current income taxes prepaid	0.2	8
Income tax assets, net	$ 988.1	$ 1,063.4	$ 806.4	$ 199.4

INCOME TAXES - NARRATIVE (Detai

INCOME TAXES - NARRATIVE (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Deferred tax assets more likely than not to be realized through future taxable earnings	$ 987.9	$ 1,055.4
Loss limitation based on income of life insurance company, percent	35%
Loss limitation based on loss of non-life entities, percent	35%
Federal long-term tax exempt rate	2.92%
Ownership change threshold restricting NOL usage	50%
Net state operating loss carryforwards	$ 2.5	$ 2.5
Federal
Operating Loss Carryforwards [Line Items]
Net federal operating loss carryforwards	$ 700

INCOME TAXES - NET OPERATING LO

INCOME TAXES - NET OPERATING LOSSES (Details) $ in Millions	Mar. 31, 2023 USD ($)
Operating Loss Carryforwards [Line Items]
Total federal non-life NOLs	$ 714
2023
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	127.4
2025
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	85.2
2026
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	149.9
2027
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	10.8
2028
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	80.3
2029
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	213.2
2030
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	0.3
2031
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	0.2
2032
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	44.4
2033
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	0.6
2034
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	0.9
2035
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 0.8

NOTES PAYABLE - DIRECT CORPOR_3

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS - SCHEDULE OF LONG-TERM DEBT INSTRUMENTS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Notes payable – direct corporate obligations	$ 1,139.2	$ 1,138.8
Unamortized debt issue costs	$ (10.8)	(11.2)
Senior Notes | 5.250% Senior Notes due May 2025
Debt Instrument [Line Items]
Interest rate	5.25%
Notes payable – direct corporate obligations	$ 500	500
Senior Notes | 5.250% Senior Notes due May 2029
Debt Instrument [Line Items]
Interest rate	5.25%
Notes payable – direct corporate obligations	$ 500	500
Subordinated Debt | 5.125% Subordinated Debentures due November 2060
Debt Instrument [Line Items]
Interest rate	5.125%
Notes payable – direct corporate obligations	$ 150	150
Revolving Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Notes payable – direct corporate obligations	$ 0	$ 0

NOTES PAYABLE - DIRECT CORPOR_4

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS - NARRATIVE (Details) - USD ($)	Jul. 16, 2021	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Outstanding amount		$ 1,139,200,000	$ 1,138,800,000
Line of Credit | Revolving Credit Agreement
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 250,000,000
Total capitalization percentage	15%
Debt covenant, required minimum debt to total capitalization ratio	35%
Debt covenant, actual debt to total capitalization ratio at period end		20.90%
Debt covenant, minimum required consolidated net worth, component one, amount	$ 2,674,000,000
Debt covenant, minimum required consolidated net worth, component two, as a percent of net equity proceeds received from issuance and sale of equity interests	25%
Debt covenant, actual consolidated net worth at period end		$ 3,696,200,000
Debt covenant, required minimum consolidated net worth, amount		2,696,200,000
Outstanding amount		$ 0	$ 0
Line of Credit | Revolving Credit Agreement | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate	0.10%
Line of Credit | Revolving Credit Agreement | Eurodollar | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.375%
Line of Credit | Revolving Credit Agreement | Eurodollar | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.125%
Line of Credit | Revolving Credit Agreement | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.375%
Line of Credit | Revolving Credit Agreement | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%

INVESTMENT BORROWINGS - NARRATI

INVESTMENT BORROWINGS - NARRATIVE (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) subsidiary	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Number of insurance subsidiaries that are members of the FHLB | subsidiary	3
Investment borrowings	$ 1,839.6		$ 1,639.5
Interest expense on FHLB borrowings	21.7	$ 2.4
Federal Home Loan Bank Advances
Debt Instrument [Line Items]
Federal home loan bank stock	79.6
Investment borrowings	1,839.6
Federal home loan bank advances, collateral pledged	2,400
Aggregate fee to prepay all fixed rate FHLB borrowings	$ 1

INVESTMENT BORROWINGS - TERMS O

INVESTMENT BORROWINGS - TERMS OF THE BORROWINGS FROM THE FHLB (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 1,839.6	$ 1,639.5
Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	1,839.6
Borrowings due April 2024 at 4.973% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	4.973%
Borrowings due May 2024 at 5.202% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 22
Interest rate	5.202%
Borrowings due July 2024 at 1.990% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 15.5
Interest rate	1.99%
Borrowings Due August 2024 at 0.640% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 27
Interest rate	0.64%
Borrowings due September 2024 at 5.439% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 25
Interest rate	5.439%
Borrowings due May 2025 at 5.114% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 21.7
Interest rate	5.114%
Borrowings due June 2025 at 2.940% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 18.4
Interest rate	2.94%
Borrowings due September 2025 at 5.170% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 125
Interest rate	5.17%
Borrowings due October 2025 at 5.246% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.246%
Borrowings due October 2025 at 5.223% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.223%
Borrowings due October 2025 at 5.185% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 57.7
Interest rate	5.185%
Borrowings due November 2025 at 5.226% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.226%
Borrowings due January 2026 at 5.168% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.168%
Borrowings due January 2026 at 5.195% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.195%
Borrowings due January 2026 at 5.064% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.064%
Borrowings Due January 2026 at 5.487% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 15
Interest rate	5.487%
Borrowings due May 2026 at 4.954% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 21.8
Interest rate	4.954%
Borrowings due May 2026 at 5.090% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.09%
Borrowings Due December 2026 at 5.169% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 75
Interest rate	5.169%
Borrowings Due January 2027 at 5.060% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 75
Interest rate	5.06%
Borrowings Due January 2027 at 5.077% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.077%
Borrowings Due January 2027 at 5.204% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.204%
Borrowings Due February 2027 at 5.133% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.133%
Borrowings due April 2027 at 5.135% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.135%
Borrowings due May 2027 at 5.145% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.145%
Borrowings due June 2027 at 5.190% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.19%
Borrowings due June 2027 at 5.413% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 10
Interest rate	5.413%
Borrowings Due January 2028 at 5.174% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 75
Interest rate	5.174%
Borrowings Due January 2028 at 5.382% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.382%
Borrowings Due January 2028 at 5.236% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 50
Interest rate	5.236%
Borrowings Due February 2028 at 5.294% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 34.5
Interest rate	5.294%
Borrowings Due February 2028 at 5.156% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 21
Interest rate	5.156%
Borrowings Due February 2028 at 5.153% | Federal Home Loan Bank Advances
Debt and Equity Securities, FV-NI [Line Items]
Investment borrowings	$ 100
Interest rate	5.153%

CHANGES IN COMMON STOCK (Detail

CHANGES IN COMMON STOCK (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	1 Months Ended	3 Months Ended
	May 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Equity, Class of Treasury Stock [Line Items]
Common stock repurchased		$ 15.1	$ 100
Stock repurchase program, remaining repurchase authorized amount		171.8
Common stock dividends declared		$ 16.4	$ 16
Dividends (in dollars per share)		$ 0.14
Common stock
Equity, Class of Treasury Stock [Line Items]
Stock repurchased and retired during period (in shares)		633	4,057
Dividends (in dollars per share)		$ 0.14
Common stock | Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Additional of share repurchase program remaining authorized amount	$ 500
Dividends (in dollars per share)	$ 0.15

LITIGATION AND OTHER LEGAL PR_2

LITIGATION AND OTHER LEGAL PROCEEDINGS (Details)	Mar. 25, 2022 policyholder	Apr. 09, 2019 trust_agreement
Commitments and Contingencies Disclosure [Abstract]
Number of trust agreements | trust_agreement		4
Number of Policyholders | policyholder	2,000

CONSOLIDATED STATEMENT OF CAS_4

CONSOLIDATED STATEMENT OF CASH FLOWS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ (0.8)	$ 183.4
Adjustments to reconcile net income (loss) to net cash from operating activities:
Amortization and depreciation	65.7	61.1
Income taxes	(6.4)	42.3
Insurance liabilities	173.3	(152.4)
Accrual, amortization and fair value changes included in investment income	(27.9)	52.2
Deferral of policy acquisition costs	(89.8)	(83.7)
Net investment losses	14.6	32.7
Other	(46.8)	(79.2)
Net cash from operating activities	81.9	56.4
Amounts related to employee benefit plans	$ 6.5	$ 7.2

INVESTMENTS IN VARIABLE INTER_3

INVESTMENTS IN VARIABLE INTEREST ENTITIES - BALANCE SHEET ITEMS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Jan. 01, 2021	Dec. 31, 2020
Assets:
Investments held by variable interest entities	$ 1,017.9	$ 1,077.6
Cash and cash equivalents held by variable interest entities	97.1	69.2
Accrued investment income	241.3	235.6
Income tax assets, net	988.1	1,063.4	$ 806.4	$ 199.4
Other assets	669	580.8
Total assets	34,015	33,133.1		35,339.9
Liabilities:
Other liabilities	681.3	693.9
Borrowings related to variable interest entities	1,065.4	1,104.6
Total liabilities	31,983.2	31,364.3		$ 29,855.7
Investments held by variable interest entities - corporate securities
Assets:
Investments held by variable interest entities	1,017.9	1,077.6
Notes receivable of VIEs held by subsidiaries	(113.8)	(113.8)
Cash and cash equivalents held by variable interest entities	97.1	69.2
Accrued investment income	4	3.5
Income tax assets, net	16.6	19.6
Other assets	3.7	1.7
Total assets	1,025.5	1,057.8
Liabilities:
Other liabilities	22.9	26.9
Borrowings related to variable interest entities	1,065.4	1,104.6
Notes payable of VIEs held by subsidiaries	0	0
Total liabilities	1,088.3	1,131.5
Investments held by variable interest entities - corporate securities | VIEs
Assets:
Investments held by variable interest entities	1,017.9	1,077.6
Notes receivable of VIEs held by subsidiaries	0	0
Cash and cash equivalents held by variable interest entities	97.1	69.2
Accrued investment income	4	3.5
Income tax assets, net	16.6	19.6
Other assets	4.5	2.5
Total assets	1,140.1	1,172.4
Liabilities:
Other liabilities	26.8	29.3
Borrowings related to variable interest entities	1,065.4	1,104.6
Notes payable of VIEs held by subsidiaries	126.1	126.1
Total liabilities	1,218.3	1,260
Investments held by variable interest entities - corporate securities | Eliminations
Assets:
Investments held by variable interest entities	0	0
Notes receivable of VIEs held by subsidiaries	(113.8)	(113.8)
Cash and cash equivalents held by variable interest entities	0	0
Accrued investment income	0	0
Income tax assets, net	0	0
Other assets	(0.8)	(0.8)
Total assets	(114.6)	(114.6)
Liabilities:
Other liabilities	(3.9)	(2.4)
Borrowings related to variable interest entities	0	0
Notes payable of VIEs held by subsidiaries	(126.1)	(126.1)
Total liabilities	$ (130)	$ (128.5)

INVESTMENTS IN VARIABLE INTER_4

INVESTMENTS IN VARIABLE INTEREST ENTITIES - NARRATIVE (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) investment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Variable Interest Entity [Line Items]
Total amortized cost	$ 1,060.3
Variable interest entity, gross unrealized gains fixed maturity securities	1.4
Variable interest entity gross unrealized losses fixed maturity securities	40.3
Variable interest entity, allowance for credit losses fixed maturity securities	3.5
Estimated fair value of fixed maturity securities	1,017.9
Variable interest entities net realized gain (losses) on investments	(0.6)	$ (3.2)
Variable interest entities net loss from sale of fixed maturity investments	(2.6)	(0.8)
Variable interest entities, change in allowance for credit losses	2	(2.2)
Variable interest entity, gross investment losses	2.6	0.8
Variable interest entities, investments sold	$ 5.6	11.7
Variable interest entities change in market value of other investments		$ (0.2)
Number of investments held by VIE, in default | investment	0
Fair value of investments in unrealized loss position for less than 12 months	$ 3,088.7		$ 7,636.9
Gross unrealized losses of investments in unrealized loss position for less than 12 months	108.6		835.2
Fair value of investments in unrealized loss position for more than 12 months	6,207.4		1,897.5
Gross unrealized losses of investments in unrealized loss position for more than 12 months	950.9		471.6
Investments held in limited partnerships	578.5
Unfunded commitments to limited partnerships	431
Investments held by variable interest entities - corporate securities
Variable Interest Entity [Line Items]
Fair value of investments in unrealized loss position for less than 12 months	214.9		392.2
Gross unrealized losses of investments in unrealized loss position for less than 12 months	3.3		14.2
Fair value of investments in unrealized loss position for more than 12 months	571.3		477.9
Gross unrealized losses of investments in unrealized loss position for more than 12 months	$ 19.4		$ 17.3

INVESTMENTS IN VARIABLE INTER_5

INVESTMENTS IN VARIABLE INTEREST ENTITIES - CHANGES IN ALLOWANCE (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	$ 56	$ 7.6
Additions for securities for which credit losses were not previously recorded	3	14.4
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.8	15
Reduction for securities sold during the period	(0.7)	(0.4)
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	59.1	36.6
Corporate securities
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	54.4	7.4
Additions for securities for which credit losses were not previously recorded	3	14
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	0.5	14.6
Reduction for securities sold during the period	(0.7)	(0.4)
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	57.2	35.6
Investments held by variable interest entities - corporate securities | Corporate securities
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]
Allowance at the beginning of the period	5.5	3.7
Additions for securities for which credit losses were not previously recorded	0.3	1.5
Additions for purchased securities with deteriorated credit	0	0
Additions (reductions) for securities where an allowance was previously recorded	(0.7)	1.3
Reduction for securities sold during the period	(1.6)	(0.6)
Reduction for securities for which the Company made the decision to sell where an allowance was previously recorded	0	0
Write-offs	0	0
Recoveries of previously written-off amount	0	0
Allowance at the end of the period	$ 3.5	$ 5.9

INVESTMENTS IN VARIABLE INTER_6

INVESTMENTS IN VARIABLE INTEREST ENTITIES - SCHEDULE OF VIEs (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Amortized cost
Due in one year or less	$ 140.1	$ 112
Due after one year through five years	2,209.3	1,913.7
Due after five years through ten years	1,871.8	2,098.9
Amortized cost	23,517.9	23,384.2
Estimated fair value
Due in one year or less	138.7	110.8
Due after one year through five years	2,080	1,790.2
Due after five years through ten years	1,742.8	1,910.4
Estimated fair value	21,107.1	$ 20,353.4
Investments held by variable interest entities - corporate securities
Amortized cost
Due in one year or less	5.4
Due after one year through five years	782.3
Due after five years through ten years	272.6
Amortized cost	1,060.3
Estimated fair value
Due in one year or less	4.7
Due after one year through five years	752.8
Due after five years through ten years	260.4
Estimated fair value	$ 1,017.9

FAIR VALUE MEASUREMENTS - NARRA

FAIR VALUE MEASUREMENTS - NARRATIVE (Details)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair value of level 3 fixed maturity securities and trading securities valued using broker quotes, percentage	86%
Available for sale fixed maturities classified as level 3, investment grade, percent	87%
Available for sale fixed maturities classified as Level 3 and corporate securities	59%

FAIR VALUE MEASUREMENTS - MEASU

FAIR VALUE MEASUREMENTS - MEASUREMENTS BY INPUT LEVEL (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Jan. 01, 2021	Dec. 31, 2020
Assets:
Estimated fair value	$ 21,107.1	$ 20,353.4
Equity securities - corporate securities	106.1	135.3
Total trading securities	208.1	207.9
Investments held by variable interest entities - corporate securities	1,017.9	1,077.6
Total other invested assets	1,097.1	1,034.7
Market risk benefit asset	57.8	65.3	$ 16.9	$ 2.5	$ 0
Assets held in separate accounts	2.8	2.7
Liabilities:
Market risk benefit liability	17.6	11.3	$ 63.8	$ 114.8	$ 0
Corporate securities
Assets:
Estimated fair value	11,976.4	11,712.7
United States Treasury securities and obligations of United States government corporations and agencies
Assets:
Estimated fair value	170.1	158.7
States and political subdivisions
Assets:
Estimated fair value	2,462.6	2,388.5
Foreign governments
Assets:
Estimated fair value	78.6	74.7
Asset-backed securities
Assets:
Estimated fair value	1,340.2	1,287
Agency residential mortgage-backed securities
Assets:
Estimated fair value	215.9	175
Non-agency residential mortgage-backed securities
Assets:
Estimated fair value	1,640.5	1,548.5
Collateralized loan obligations
Assets:
Estimated fair value	918.9	785.9
Commercial mortgage-backed securities
Assets:
Estimated fair value	2,303.9	2,222.4
Significant unobservable inputs  (Level 3)
Assets:
Total assets carried at fair value by category	369	418.7
Fair Value, Measurements, Recurring
Assets:
Total trading securities	208.1	207.9
Investments held by variable interest entities - corporate securities	1,017.9	1,077.6
Derivatives	108.2	56.7
Residual tranches	20.1	18.3
Total other invested assets	128.3	75
Market risk benefit asset	57.8	65.3
Assets held in separate accounts	2.8	2.7
Total assets carried at fair value by category	22,628.1	21,917.2
Liabilities:
Market risk benefit liability	17.6	11.3
Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities)	1,347.9	1,297
Total liabilities carried at fair value by category	1,365.5	1,308.3
Fair Value, Measurements, Recurring | Corporate securities
Assets:
Estimated fair value	11,976.4	11,712.7
Equity securities - corporate securities	106.1	135.3
Fair Value, Measurements, Recurring | United States Treasury securities and obligations of United States government corporations and agencies
Assets:
Estimated fair value	170.1	158.7
Fair Value, Measurements, Recurring | States and political subdivisions
Assets:
Estimated fair value	2,462.6	2,388.5
Fair Value, Measurements, Recurring | Foreign governments
Assets:
Estimated fair value	78.6	74.7
Fair Value, Measurements, Recurring | Asset-backed securities
Assets:
Estimated fair value	1,340.2	1,287
Total trading securities	25.5	15.1
Fair Value, Measurements, Recurring | Agency residential mortgage-backed securities
Assets:
Estimated fair value	215.9	175
Total trading securities	0.3	0.3
Fair Value, Measurements, Recurring | Non-agency residential mortgage-backed securities
Assets:
Estimated fair value	1,640.5	1,548.5
Total trading securities	58.8	60.7
Fair Value, Measurements, Recurring | Collateralized loan obligations
Assets:
Estimated fair value	918.9	785.9
Fair Value, Measurements, Recurring | Commercial mortgage-backed securities
Assets:
Estimated fair value	2,303.9	2,222.4
Total trading securities	123.5	131.8
Fair Value, Measurements, Recurring | Total fixed maturities, available for sale
Assets:
Estimated fair value	21,107.1	20,353.4
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Assets:
Total trading securities	0	0
Investments held by variable interest entities - corporate securities	0	0
Derivatives	0	0
Residual tranches	0	0
Total other invested assets	0	0
Market risk benefit asset	0	0
Assets held in separate accounts	0	0
Total assets carried at fair value by category	31.1	59.6
Liabilities:
Market risk benefit liability	0	0
Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities)	0	0
Total liabilities carried at fair value by category	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Corporate securities
Assets:
Estimated fair value	0	0
Equity securities - corporate securities	31.1	59.6
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | United States Treasury securities and obligations of United States government corporations and agencies
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | States and political subdivisions
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Foreign governments
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Asset-backed securities
Assets:
Estimated fair value	0	0
Total trading securities	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Agency residential mortgage-backed securities
Assets:
Estimated fair value	0	0
Total trading securities	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Non-agency residential mortgage-backed securities
Assets:
Estimated fair value	0	0
Total trading securities	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Collateralized loan obligations
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Commercial mortgage-backed securities
Assets:
Estimated fair value	0	0
Total trading securities	0	0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Total fixed maturities, available for sale
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2)
Assets:
Total trading securities	207.6	207.4
Investments held by variable interest entities - corporate securities	1,017.9	1,077.6
Derivatives	108.2	56.7
Residual tranches	0.9	0
Total other invested assets	109.1	56.7
Market risk benefit asset	0	0
Assets held in separate accounts	2.8	2.7
Total assets carried at fair value by category	22,228	21,438.9
Liabilities:
Market risk benefit liability	0	0
Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities)	0	0
Total liabilities carried at fair value by category	0	0
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Corporate securities
Assets:
Estimated fair value	11,848.6	11,584.9
Equity securities - corporate securities	0	0
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | United States Treasury securities and obligations of United States government corporations and agencies
Assets:
Estimated fair value	170.1	158.7
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | States and political subdivisions
Assets:
Estimated fair value	2,462.6	2,388.5
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Foreign governments
Assets:
Estimated fair value	78.6	74.7
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Asset-backed securities
Assets:
Estimated fair value	1,299.1	1,230
Total trading securities	25.5	15.1
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Agency residential mortgage-backed securities
Assets:
Estimated fair value	215.9	175
Total trading securities	0.3	0.3
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Non-agency residential mortgage-backed securities
Assets:
Estimated fair value	1,606.7	1,492.3
Total trading securities	58.3	60.2
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Collateralized loan obligations
Assets:
Estimated fair value	918.9	782.5
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Commercial mortgage-backed securities
Assets:
Estimated fair value	2,290.1	2,207.9
Total trading securities	123.5	131.8
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Total fixed maturities, available for sale
Assets:
Estimated fair value	20,890.6	20,094.5
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3)
Assets:
Total trading securities	0.5	0.5
Investments held by variable interest entities - corporate securities	0	0
Derivatives	0	0
Residual tranches	19.2	18.3
Total other invested assets	19.2	18.3
Market risk benefit asset	57.8	65.3
Assets held in separate accounts	0	0
Total assets carried at fair value by category	369	418.7
Liabilities:
Market risk benefit liability	17.6	11.3
Embedded derivatives associated with fixed indexed annuity products (classified as policyholder account liabilities)	1,347.9	1,297
Total liabilities carried at fair value by category	1,365.5	1,308.3
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Corporate securities
Assets:
Estimated fair value	127.8	127.8
Equity securities - corporate securities	75	75.7
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | United States Treasury securities and obligations of United States government corporations and agencies
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | States and political subdivisions
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Foreign governments
Assets:
Estimated fair value	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Asset-backed securities
Assets:
Estimated fair value	41.1	57
Total trading securities	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Agency residential mortgage-backed securities
Assets:
Estimated fair value	0	0
Total trading securities	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Non-agency residential mortgage-backed securities
Assets:
Estimated fair value	33.8	56.2
Total trading securities	0.5	0.5
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Collateralized loan obligations
Assets:
Estimated fair value	0	3.4
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Commercial mortgage-backed securities
Assets:
Estimated fair value	13.8	14.5
Total trading securities	0	0
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3) | Total fixed maturities, available for sale
Assets:
Estimated fair value	$ 216.5	$ 258.9

FAIR VALUE MEASUREMENTS - RECUR

FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Cash and cash equivalents:
Held by variable interest entities	$ 97.1	$ 69.2
Fair Value, Measurements, Recurring | Total estimated fair value
Assets:
Mortgage loans	1,557.5	1,273.6
Policy loans	123	121.6
Other invested assets:
Company-owned life insurance	201.3	199.1
Cash and cash equivalents:
Unrestricted	425	575.7
Held by variable interest entities	97.1	69.2
Liabilities:
Policyholder account liabilities	15,302.9	15,234.2
Investment borrowings	1,840.6	1,640.5
Borrowings related to variable interest entities	1,034.8	1,066.3
Notes payable – direct corporate obligations	1,079.5	1,077
Fair Value, Measurements, Recurring | Total carrying amount
Assets:
Mortgage loans	1,676.1	1,411.9
Policy loans	123	121.6
Other invested assets:
Company-owned life insurance	201.3	199.1
Cash and cash equivalents:
Unrestricted	425	575.7
Held by variable interest entities	97.1	69.2
Liabilities:
Policyholder account liabilities	15,302.9	15,234.2
Investment borrowings	1,839.6	1,639.5
Borrowings related to variable interest entities	1,065.4	1,104.6
Notes payable – direct corporate obligations	1,139.2	1,138.8
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Assets:
Mortgage loans	0	0
Policy loans	0	0
Other invested assets:
Company-owned life insurance	0	0
Cash and cash equivalents:
Unrestricted	425	575.7
Held by variable interest entities	97.1	69.2
Liabilities:
Policyholder account liabilities	0	0
Investment borrowings	0	0
Borrowings related to variable interest entities	0	0
Notes payable – direct corporate obligations	0	0
Fair Value, Measurements, Recurring | Significant other observable inputs  (Level 2)
Assets:
Mortgage loans	0	0
Policy loans	0	0
Other invested assets:
Company-owned life insurance	201.3	199.1
Cash and cash equivalents:
Unrestricted	0	0
Held by variable interest entities	0	0
Liabilities:
Policyholder account liabilities	0	0
Investment borrowings	1,840.6	1,640.5
Borrowings related to variable interest entities	1,034.8	1,066.3
Notes payable – direct corporate obligations	1,079.5	1,077
Fair Value, Measurements, Recurring | Significant unobservable inputs  (Level 3)
Assets:
Mortgage loans	1,557.5	1,273.6
Policy loans	123	121.6
Other invested assets:
Company-owned life insurance	0	0
Cash and cash equivalents:
Unrestricted	0	0
Held by variable interest entities	0	0
Liabilities:
Policyholder account liabilities	15,302.9	15,234.2
Investment borrowings	0	0
Borrowings related to variable interest entities	0	0
Notes payable – direct corporate obligations	$ 0	$ 0

FAIR VALUE MEASUREMENTS - BALAN

FAIR VALUE MEASUREMENTS - BALANCE SHEET RECURRING (Details) - Significant unobservable inputs  (Level 3) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Corporate securities
Assets:
Beginning balance	$ 127.8	$ 89.7
Purchases, sales, issuances and settlements, net	(0.5)	0
Total realized and unrealized gains (losses) included in net income	0.1	(1.4)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.9	(6.5)
Transfers into level 3	5.9	36.2
Transfers out of level 3	(6.4)	0
Ending balance	127.8	118
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0.1	(2.1)
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	0.1	(6.5)
Corporate securities | Investments held by variable interest entities - corporate securities
Assets:
Beginning balance		2.2
Purchases, sales, issuances and settlements, net		(2.1)
Total realized and unrealized gains (losses) included in net income		(0.1)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0
Transfers into level 3		0
Transfers out of level 3		0
Ending balance		0
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date		0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date		0
Asset-backed securities
Assets:
Beginning balance	57	26.6
Purchases, sales, issuances and settlements, net	(5.1)	15.9
Total realized and unrealized gains (losses) included in net income	(0.2)	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(0.2)	(1.3)
Transfers into level 3	0	0
Transfers out of level 3	(10.4)	0
Ending balance	41.1	41.2
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0	0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	(0.5)	(1.3)
Non-agency residential mortgage-backed securities
Assets:
Beginning balance	56.2	0
Purchases, sales, issuances and settlements, net	(0.2)	0
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	2.3	(0.6)
Transfers into level 3	0	5
Transfers out of level 3	(24.5)	0
Ending balance	33.8	4.4
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0	0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	2.4	(0.6)
Collateralized loan obligations
Assets:
Beginning balance	3.4	5
Purchases, sales, issuances and settlements, net	0	10
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	(0.2)
Transfers into level 3	0	0
Transfers out of level 3	(3.4)	(5)
Ending balance	0	9.8
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0	0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	0	(0.2)
Commercial mortgage-backed securities
Assets:
Beginning balance	14.5	19
Purchases, sales, issuances and settlements, net	0	0
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(0.7)	(1.5)
Transfers into level 3	0	0
Transfers out of level 3	0	0
Ending balance	13.8	17.5
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0	0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	(0.7)	(1.5)
Total fixed maturities, available for sale
Assets:
Beginning balance	258.9	140.3
Purchases, sales, issuances and settlements, net	(5.8)	25.9
Total realized and unrealized gains (losses) included in net income	(0.1)	(1.4)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	2.3	(10.1)
Transfers into level 3	5.9	41.2
Transfers out of level 3	(44.7)	(5)
Ending balance	216.5	190.9
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0.1	(2.1)
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	1.3	(10.1)
Equity securities - corporate securities
Assets:
Beginning balance	75.7	11.5
Purchases, sales, issuances and settlements, net	0	(2.9)
Total realized and unrealized gains (losses) included in net income	(0.7)	(0.2)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	0
Transfers into level 3	0	0
Transfers out of level 3	0	0
Ending balance	75	8.4
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	(0.7)	(0.2)
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	0	0
Trading securities - non-agency residential mortgage-backed securities
Assets:
Beginning balance	0.5	3.5
Purchases, sales, issuances and settlements, net	0	0
Total realized and unrealized gains (losses) included in net income	0	0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0	0
Transfers into level 3	0	0
Transfers out of level 3	0	(3.5)
Ending balance	0.5	0
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0	0
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	0	0
Trading Securities - Commercial mortgage-backed securities
Assets:
Beginning balance		12.9
Purchases, sales, issuances and settlements, net		0
Total realized and unrealized gains (losses) included in net income		(0.4)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0.2
Transfers into level 3		0
Transfers out of level 3		0
Ending balance		12.7
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date		(0.4)
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date		0
Total trading securities
Assets:
Beginning balance		16.4
Purchases, sales, issuances and settlements, net		0
Total realized and unrealized gains (losses) included in net income		(0.4)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0.2
Transfers into level 3		0
Transfers out of level 3		(3.5)
Ending balance		12.7
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date		(0.4)
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date		$ 0
Other invested assets - residual tranches
Assets:
Beginning balance	18.3
Purchases, sales, issuances and settlements, net	0.5
Total realized and unrealized gains (losses) included in net income	0.4
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0
Transfers into level 3	0
Transfers out of level 3	0
Ending balance	19.2
Amount of total gains (losses) included in our net income relating to assets still held as of the reporting date	0.4
Amount of total gains (losses) included in accumulated other comprehensive income (loss) relating to assets still held as of the reporting date	$ 0

FAIR VALUE MEASUREMENTS - FAIR

FAIR VALUE MEASUREMENTS - FAIR VALUE ACTIVITY (Details) - Significant unobservable inputs  (Level 3) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Corporate securities
Assets:
Purchases	$ 0.9	$ 9.4
Sales	(1.4)	(9.4)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(0.5)	0
Corporate securities | Variable Interest Entities
Assets:
Purchases		0
Sales		(2.1)
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net		(2.1)
Asset-backed securities
Assets:
Purchases	2.3	16
Sales	(7.4)	(0.1)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(5.1)	15.9
Collateralized loan obligations
Assets:
Purchases		10
Sales		0
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net	0	10
Non-agency residential mortgage-backed securities
Assets:
Purchases	0
Sales	(0.2)
Issuances	0
Settlements	0
Purchases, sales, issuances and settlements, net	(0.2)	0
Total fixed maturities, available for sale
Assets:
Purchases	3.2	35.4
Sales	(9)	(9.5)
Issuances	0	0
Settlements	0	0
Purchases, sales, issuances and settlements, net	(5.8)	25.9
Equity securities - corporate securities
Assets:
Purchases		0.3
Sales		(3.2)
Issuances		0
Settlements		0
Purchases, sales, issuances and settlements, net	0	$ (2.9)
Other invested assets - residual tranches
Assets:
Purchases	0.7
Sales	(0.2)
Issuances	0
Settlements	0
Purchases, sales, issuances and settlements, net	$ 0.5

FAIR VALUE MEASUREMENTS-CHANGES

FAIR VALUE MEASUREMENTS-CHANGES IN VALUE OF EMBEDDED DERIVATIVES (Details) - Fair Value, Inputs, Level 3 - Fixed Index Annuity Products - Fair Value, Measurements, Recurring - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Liabilities:
Balance at beginning of the period	$ 1,297	$ 1,724.1
Premiums less benefits	(14)	21.1
Change in fair value, net	64.9	(201.7)
Balance at end of the period	$ 1,347.9	$ 1,543.5

FAIR VALUE MEASUREMENTS - FAI_2

FAIR VALUE MEASUREMENTS - FAIR VALUE INPUTS (Details) $ in Millions	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Equity securities - corporate securities	$ 106.1	$ 135.3
Market risk benefit asset	57.8	65.3	$ 16.9	$ 2.5	$ 0
Market risk benefit liability	17.6	11.3	$ 63.8	$ 114.8	$ 0
Significant unobservable inputs  (Level 3)
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets carried at fair value by category	369	418.7
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Market risk benefit asset	57.8	65.3
Market risk benefit liability	$ 17.6	$ 11.3
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Surrender rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.0128	0.0128
Unobservable inputs, market risk benefit, liability measurement input	0.0128	0.0128
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Surrender rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.1105	0.1105
Unobservable inputs, market risk benefit, liability measurement input	0.1105	0.1105
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Surrender rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.0345	0.0368
Unobservable inputs, market risk benefit, liability measurement input	0.0345	0.0368
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Utilization rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.0592	0.0678
Unobservable inputs, market risk benefit, liability measurement input	0.0592	0.0678
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Utilization rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.4762	0.6316
Unobservable inputs, market risk benefit, liability measurement input	0.4762	0.6316
Significant unobservable inputs  (Level 3) | Discounted cash flow analysis | Utilization rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, market risk benefit, assets measurement input	0.2254	0.2009
Unobservable inputs, market risk benefit, liability measurement input	0.2254	0.2009
Significant unobservable inputs  (Level 3) | Market comparables | EBITDA multiples | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, equity securities	8.8	8.5
Significant unobservable inputs  (Level 3) | Recovery method | Percent of recovery expected | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0	0
Unobservable inputs, equity securities	0	0
Significant unobservable inputs  (Level 3) | Recovery method | Percent of recovery expected | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.3500	0.3500
Unobservable inputs, equity securities	1	1
Significant unobservable inputs  (Level 3) | Recovery method | Percent of recovery expected | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.3500	0.3500
Unobservable inputs, equity securities	1	1
Significant unobservable inputs  (Level 3) | Unadjusted third-party price source
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Other assets	$ 206.1	$ 249
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded derivatives related to fixed indexed annuity products	$ 1,347.9	$ 1,297
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Discount margins/rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0347	0.0377
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Discount margins/rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0533	0.0548
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Discount margins/rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0413	0.0447
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Projected portfolio yields | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0430	0.0430
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Projected portfolio yields | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0463	0.0463
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Projected portfolio yields | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0431	0.0431
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Surrender rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0190	0.0190
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Surrender rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.2770	0.2770
Significant unobservable inputs  (Level 3) | Discounted projected embedded derivatives | Surrender rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, liabilities	0.0920	0.0920
Significant unobservable inputs  (Level 3) | Corporate securities | Discounted cash flow analysis
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fixed maturities, available for sale	$ 2.9	$ 2.9
Significant unobservable inputs  (Level 3) | Corporate securities | Discounted cash flow analysis | Discount margins/rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities		0.0223
Significant unobservable inputs  (Level 3) | Corporate securities | Discounted cash flow analysis | Discount margins/rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities		0.0394
Significant unobservable inputs  (Level 3) | Corporate securities | Discounted cash flow analysis | Discount margins/rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.0241	0.0225
Significant unobservable inputs  (Level 3) | Corporate securities | Unadjusted purchase price
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fixed maturities, available for sale	$ 0.5	$ 0.5
Significant unobservable inputs  (Level 3) | Corporate securities | Recovery method
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fixed maturities, available for sale	3.5	3.5
Significant unobservable inputs  (Level 3) | Asset-backed securities | Discounted cash flow analysis
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fixed maturities, available for sale	$ 23.1	$ 21.8
Significant unobservable inputs  (Level 3) | Asset-backed securities | Discounted cash flow analysis | Discount margins/rates | Minimum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.0199	0.0250
Significant unobservable inputs  (Level 3) | Asset-backed securities | Discounted cash flow analysis | Discount margins/rates | Maximum
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.0402	0.0386
Significant unobservable inputs  (Level 3) | Asset-backed securities | Discounted cash flow analysis | Discount margins/rates | Weighted Average
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unobservable inputs, fixed maturities	0.0320	0.0330
Significant unobservable inputs  (Level 3) | Equity Securities | Unadjusted purchase price
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Equity securities - corporate securities	$ 11.4	$ 11.7
Significant unobservable inputs  (Level 3) | Equity Securities | Market comparables
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Equity securities - corporate securities	63.6	63.9
Significant unobservable inputs  (Level 3) | Equity Securities | Recovery method
Fair Value, Assets on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Equity securities - corporate securities	$ 0.1	$ 0.1